Trinity Biotech PLC 6-K, filed May 15, 2025
Trinity Biotech PLC (TRIB)
6-K
2025-05-15
For: 2025-05-15
View Original
Added on
April 12, 2026
About this 6-K
Trinity Biotech PLC filed this 6-K on May 15, 2025.
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 6-K
REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16
UNDER THE SECURITIES EXCHANGE ACT OF 1934
For the month of May 2025
TRINITY BIOTECH PLC
(Name of Registrant)
IDA Business Park
Bray, Co. Wicklow, Ireland
(Address of Principal Executive Office)
Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.
Form 20-F ☒ Form 40-F ☐
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1):
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7):
Indicate by check mark whether by furnishing the information contained in this Form, the registrant is also thereby furnishing
the information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934.
Yes ☐ No ☒
If “Yes” is marked, indicate below the file number assigned to the registrant in connection with Rule 12g3-2(b): 82-
This Form 6-K is being incorporated by reference into our Registration Statements on Form F-3 (File Nos. 333-286020,
333-267160, 333-280391, 333-283273) and Form S-8 (File Nos. 333-182279, 333-195232 and 333-253070).
EXPLANATORY NOTE
On May 14, 2025, Trinity Biotech plc (the “Company”) and certain of its subsidiaries amended and restated the credit agreement governing
the companies’ term loan facility with Perceptive Credit Holdings III, L.P. On May 15, 2025 the Company issued a press release announcing its fourth quarter and fiscal year 2024 financial results and a business update. Copies of the amended and
restated credit agreement and press release are filed herewith as Exhibits 99.1 and 99.2.
EXHIBIT INDEX
|
Exhibit
|
|
Description
|
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed
on its behalf by the undersigned, thereunto duly authorized.
|
|
TRINITY BIOTECH PLC
|
|
|
|
|
|
Trinity Biotech plc
|
|
|
|
|
(Registrant)
|
|
|
|
|
|
|
|
|
By:
|
/s/ Susan O’Connor
|
|
|
|
|
Susan O’Connor
|
|
|
|
|
Interim Chief Financial Officer
|
|
Date: May 15, 2025
Exhibit 99.1
Execution Version
Fifth Amended and Restated Credit Agreement and Guaranty
dated as of
May 14, 2025
among
Trinity Biotech, Inc.,
Clark Laboratories, Inc. (d/b/a Trinity Biotech (USA)),
Biopool U.S., Inc. (d/b/a Trinity Biotech Distribution),
Primus Corporation,
MarDx Diagnostics, Inc. and
IMMCO Diagnostics, Inc.
TRIB Biosensors Inc.
as the Borrowers,
as the Borrowers,
The Guarantors from Time to Time Party hereto,
as Guarantors
and
Perceptive Credit Holdings III, LP,
as Administrative Agent and as a Lender
Table of Contents
| Section | Heading | Page |
|
2
|
||
|
2
|
||
|
42
|
||
|
42
|
||
|
43
|
||
|
43
|
||
|
43
|
||
|
43
|
||
|
45
|
||
|
46
|
||
|
46
|
||
|
46
|
||
|
46
|
||
|
46
|
||
|
46
|
||
|
50
|
||
|
52
|
||
|
52
|
||
|
53
|
||
|
53
|
||
|
53
|
||
|
54
|
||
|
54
|
||
|
55
|
||
|
55
|
||
|
61
|
||
|
61
|
||
|
61
|
|
62
|
||
|
62
|
||
|
62
|
||
|
63
|
||
|
63
|
||
|
64
|
||
|
66
|
||
|
66
|
||
|
67
|
||
|
67
|
||
|
68
|
||
|
68
|
||
|
68
|
||
|
68
|
||
|
68
|
||
|
69
|
||
|
69
|
||
|
69
|
||
|
70
|
||
|
70
|
||
|
73
|
||
|
73
|
||
|
73
|
||
|
73
|
||
|
73
|
||
|
73
|
||
|
73
|
||
|
74
|
||
|
74
|
||
|
76
|
||
|
79
|
||
|
80
|
||
|
80
|
||
|
80
|
||
|
81
|
||
|
81
|
||
|
81
|
||
|
81
|
||
|
82
|
||
|
83
|
||
|
83
|
||
|
84
|
||
|
84
|
||
|
84
|
||
|
85
|
||
|
85
|
||
|
86
|
||
|
86
|
||
|
86
|
||
|
86
|
||
|
86
|
|
87
|
||
|
87
|
||
|
89
|
||
|
90
|
||
|
91
|
||
|
92
|
||
|
93
|
||
|
94
|
||
|
94
|
||
|
94
|
||
|
95
|
||
|
96
|
||
|
96
|
||
|
97
|
||
|
97
|
||
|
97
|
||
|
97
|
||
|
97
|
||
|
97
|
||
|
97
|
||
|
97
|
||
|
98
|
||
|
98
|
||
|
98
|
||
|
98
|
||
|
101
|
||
|
101
|
||
|
102
|
||
|
102
|
||
|
102
|
||
|
104
|
||
|
104
|
||
|
105
|
||
|
105
|
||
|
105
|
||
|
105
|
||
|
106
|
||
|
106
|
|
107
|
||
|
107
|
||
|
107
|
||
|
107
|
||
|
108
|
||
|
109
|
||
|
109
|
||
|
110
|
||
|
110
|
||
|
111
|
||
|
112
|
||
|
112
|
||
|
112
|
||
|
112
|
||
|
113
|
||
|
114
|
||
|
116
|
||
|
116
|
||
|
116
|
||
|
117
|
||
|
117
|
||
|
118
|
||
|
118
|
||
|
118
|
||
|
118
|
||
|
118
|
||
|
118
|
||
|
119
|
||
|
120
|
||
|
120
|
||
|
121
|
||
|
121
|
||
|
122
|
||
|
124
|
||
|
124
|
Schedules:
|
—
|
||
|
Schedule 2
|
—
|
Notice Addresses
|
|
Schedule 3
|
—
|
Products
|
|
Schedule 4
|
—
|
Commercial Partners
|
|
Schedule 7.01
|
—
|
Power and Authority
|
|
Schedule 7.05(a)
|
—
|
Obligor Owned Real Property
|
|
Schedule 7.05(b)
|
—
|
Obligor Material Intellectual Property
|
|
Schedule 7.06(a)
|
—
|
Litigation
|
|
Schedule 7.13A
|
—
|
Existing Indebtedness
|
|
Schedule 7.13B
|
—
|
Existing Liens
|
|
Schedule 7.14
|
—
|
Material Agreements
|
|
Schedule 7.15
|
—
|
Restrictive Agreements
|
|
Schedule 7.16
|
—
|
Real Property
|
|
Schedule 7.17
|
—
|
Pension Matters
|
|
Schedule 7.19(b)
|
—
|
Regulatory Approvals
|
|
Schedule 7.19(e)
|
—
|
Regulatory Authority Notices
|
|
Schedule 7.20
|
—
|
Capitalization
|
|
Schedule 7.22
|
—
|
Broker’s Fee
|
|
Schedule 7.23
|
—
|
Trade Compliance
|
|
Schedule 7.26
|
—
|
Royalty and Other Payments
|
|
Schedule 9.03
|
—
|
Subsidiaries to be Dissolved
|
|
Schedule 9.05(a)
|
—
|
Existing Investments
|
|
Schedule 9.10
|
—
|
Transactions with Affiliates
|
Exhibits:
|
Exhibit A
|
—
|
Form of Guarantee Assumption Agreement
|
|
Exhibit B
|
—
|
[Reserved]
|
|
Exhibit C
|
—
|
Form of Note
|
|
Exhibit D
|
—
|
Form of U.S. Tax Compliance Certificate
|
|
Exhibit E
|
—
|
Form of Compliance Certificate
|
|
Exhibit F
|
—
|
Form of Assignment Agreement
|
|
Exhibit G-1
|
—
|
Form of U.S. Security Agreement
|
|
Exhibit G-2
|
—
|
Form of Canadian Security Agreement
|
|
Exhibit G-3
|
—
|
Form of Irish Debenture
|
|
Exhibit H-1
|
—
|
Form of Patent and Trademark Security Agreement
|
|
Exhibit H-2
|
—
|
Form of Copyright Security Agreement
|
|
Exhibit I
|
—
|
Form of Collateral Questionnaire
|
|
Exhibit J
|
—
|
[Reserved]
|
|
Exhibit K
|
—
|
Form of Intercompany Subordination Agreement
|
|
Exhibit L
|
—
|
Form of Investor Subordination Agreement
|
|
Exhibit M
|
—
|
Form of Effective Date Term Loan Borrowing Notice
|
|
Exhibit N
|
—
|
Form of Delayed Draw Term Loan Borrowing Notice
|
|
Exhibit O
|
—
|
Form of Third Amendment Term Loan Borrowing Notice
|
|
Exhibit P
|
—
|
Form of Fourth Amendment Term Loan Borrowing Notice
|
|
Exhibit Q
|
—
|
Form of Fifth Amendment Term Loan Borrowing Notice
|
Fifth Amended and Restated Credit Agreement And Guaranty, dated as of May 14, 2025 (this “Agreement”),
among Trinity Biotech, Inc., a Delaware corporation (“U.S. Holdings”), Clark Laboratories, Inc. (d/b/a Trinity
Biotech (USA)), a New York corporation (“U.S. Clark”), Biopool U.S., Inc., a Delaware corporation (d/b/a Trinity Biotech Distribution) (“U.S. Biopool”), Primus Corporation, a Missouri corporation (“U.S. Primus”), MarDx
Diagnostics, Inc., a California corporation (“U.S. MarDx”), IMMCO Diagnostics, Inc., a Delaware corporation (“U.S.
Immco”), TRIB Biosensors Inc., a Delaware corporation (“U.S. TRIB”, and together with U.S. Holdings, U.S. Fitzgerald, U.S. Clark, U.S. Biopool, U.S.
Primus, U.S. MarDx and U.S. Immco, each a “Borrower” and collectively, the “Borrowers”), certain Guarantors from time to time parties hereto, the lenders from time
to time party hereto (each, as a “Lender” and collectively, the “Lenders”), and Perceptive Credit Holdings III, LP, a
Delaware limited partnership (“Perceptive”), as administrative agent for the Lenders (in such capacity, together with its successors and assigns, the “Administrative Agent”).
Witnesseth:
The Borrowers, the Guarantors, the Administrative Agent and the Lenders are party to that certain Amended and Restated Credit Agreement and Guaranty, dated as of February 21,
2023 (as amended by that certain First Amendment to Amended and Restated Credit Agreement and Guaranty, dated as of April 20, 2023, the “Original Credit Agreement”).
The Borrowers, the Guarantors, the Administrative Agent and the Lenders amended and restated the Original Credit Agreement pursuant to that certain Second Amended and Restated
Credit Agreement and Guaranty, dated as of January 30, 2024 (the “Second A&R Credit Agreement”).
The Borrowers, the Guarantors, the Administrative Agent and the Lenders amended and restated the Second A&R Credit Agreement pursuant to that certain Third Amended and
Restated Credit Agreement and Guaranty, dated as of December 23, 2024 (the “Third A&R Credit Agreement”).
The Borrowers, the Guarantors, the Administrative Agent and the Lenders amended and restated the Third A&R Credit Agreement pursuant to that certain Fourth Amended and
Restated Credit Agreement and Guaranty, dated as of February 27, 2025 (the “Fourth A&R Credit Agreement”).
The Borrowers have requested, and the Administrative Agent and the Lenders have agreed (i) to provide a new Fifth Amendment Term Loan and (ii) that certain other terms and
conditions of the Fourth A&R Credit Agreement be amended and, for the sake of clarity and convenience, that the Fourth A&R Credit Agreement be restated in its entirety.
It is the intent of the Obligors to confirm that all Obligations of the Obligors under the Loan Documents (as amended, modified or supplemented through the Fifth Amendment
Restatement Date) shall continue in full force and effect.
It is the intent of the parties hereto that this Agreement does not constitute a novation of the obligations and liabilities of the parties under the Fourth A&R Credit
Agreement and that this Agreement amend and restate in its entirety the Fourth A&R Credit Agreement.
Section 1.01. Certain Defined Terms. As
used herein, the following terms have the following respective meanings:
“510(k)” means (a) any premarket notification and corresponding FDA clearance for a Device pursuant to FDA regulations, (b) all
substantially equivalent or similar notifications, applications and clearances with respect to any other non-United States Regulatory Authority, including the EMA, HPRA, and Health Canada, ANVISA and (iii) all amendments, supplements and other
additions and modifications thereto, and all documents, data and other information concerning any applicable Device which are necessary for, filed with, incorporated by reference in, or otherwise supportive of any of the foregoing.
“Accounting Change” has the meaning set forth in Section 1.02.
“Accounting Change Notice” has the meaning set forth in Section 1.02.
“Acquisition” means any transaction, or any series of related transactions, by which any Person directly or indirectly, by means of a
take‑over bid, tender offer, amalgamation, plan of arrangement, merger, purchase of assets, or similar transaction having the same effect as any of the foregoing, (a) acquires any business or all or substantially all of the assets of any Person
engaged in any business, (b) acquires all or substantially all of a business line or unit or division of any other Person, (c) acquires Control of securities of a Person engaged in a business representing more than 50% of the ordinary voting power
for the election of directors or other governing body if the business affairs of such Person are managed by a Board or other governing body, or (d) acquires Control of more than 50% of the ownership interest in any Person engaged in any business
that is not managed by a Board or other governing body.
“Act” has the meaning set forth in Section 13.16.
“Administrative Agent” has the meaning set forth in the introduction hereto.
“Administrative Borrower” has the meaning set forth in Section 13.21.
“ADSs” means American Depositary Shares.
“ADS Ratio” has the meaning set forth in the Existing Warrant Certificate and Effective Date Warrant Certificate.
- 2 -
“Affected Financial Institution” means (a) any EEA Financial Institution or (b) any U.K. Financial Institution.
“Affiliate” means, with respect to a specified Person, another Person that directly, or indirectly through one or more intermediaries,
Controls or is Controlled by or is under common Control with the Person specified.
“Agreement” has the meaning set forth in the introduction hereto.
“American Depositary Receipts” means the American Depositary Receipts (representing the American Depositary Shares) issued by The Bank of
New York Mellon, as depositary of the American Depositary Shares and issuer of the American Depositary Receipts.
“American Depositary Shares” means the American Depositary Shares (represented by American Depositary Receipts) of Trinity Biotech plc
held by The Bank of New York Mellon, as depositary.
“Anti‑Corruption Laws” means all laws, rules and regulations of any jurisdiction applicable to the Obligors and their Affiliates
concerning or relating to bribery or corruption, including, without limitation, the Foreign Corrupt Practices Act of 1977, as amended, and the Corruption of Foreign Public Officials Act (Canada), as
amended.
“Anti‑Terrorism Laws” means any laws or regulations relating to terrorism or money laundering, including, without limitation the Bank Secrecy Act (31 U.S.C. §§ 5311 et seq.), the Money Laundering Control Act of 1986 (18 U.S.C. §§ 1956 et seq.), USA Patriot Act, the Proceeds of Crime (Money Laundering) and Terrorist Financing Act (Canada), Part II.1 of the Criminal
Code (Canada), regulations promogulated pursuant to the Special Economic Measures Act (Canada), and the United Nations Act (Canada), and any similar law
enacted in any of the United States, Canada, or any other jurisdiction applicable to the Obligors and their Affiliates after the date of this Agreement.
“ANVISA” means Agência Nacional de Vigilância Sanitária of Brazil and any successor thereto.
“Applicable Margin” means (a) from the Original Closing Date until the Effective Date, 11.25% per annum and (b) on and after the
Effective Date, (i) 8.75% per annum on and after the day immediately following the date that the aggregate principal amount of the Term Loans is equal to or greater than $35,000,000 and (ii) 6.25% per annum on and after the day immediately
following the date that the aggregate principal amount of the Term Loans is less than $35,000,0000.
“Approved Fund” means any Person (other than a natural person) that is engaged in making, purchasing, holding or investing in bank loans
and similar extensions of credit in the ordinary course of its business and that is administered or managed by (a) a Lender, (b) an Affiliate of a Lender or (c) an entity or an Affiliate of an entity that administers or manages a Lender.
- 3 -
“Asset Sale” has the meaning set forth in Section 9.09.
“Assignment Agreement” means an assignment and assumption entered into by a Lender and an assignee of such Lender in substantially the
form of Exhibit F.
“Available Tenor” means, as of any date of determination and with respect to the then current Benchmark, as applicable (a) if the then
current Benchmark is a term rate, any tenor for such Benchmark that is or may be used for determining the length of an Interest Period or (b) otherwise, any payment period for interest calculated with reference to such Benchmark, as applicable,
pursuant to this Agreement as of such date; not including, for the avoidance of doubt, any tenor for such Benchmark that is then-removed from the definition of “Interest Period” pursuant to Section 3.02(c)(iv).
“Bail‑In Action” means the exercise of any Write‑Down and Conversion Powers by the applicable Resolution Authority in respect of any
liability of an Affected Financial Institution.
“Bail‑In Legislation” means (a) with respect to any EEA Member Country implementing Article 55 of Directive 2014/59/EU of the European
Parliament and of the Council of the European Union, the implementing law, regulation, rule or requirement for such EEA Member Country from time to time which is described in the EU Bail-In Legislation Schedule and (b) with respect to the United
Kingdom, Part I of the United Kingdom Banking Act 2009 (as amended from time to time) and any other law, regulation, rule or requirement applicable in the United Kingdom relating to the resolution of unsound or failing banks, investment firms or
other financial institutions or their affiliates (other than through liquidation, administration or other Insolvency Proceedings).
“Bankruptcy Code” means Title 11 of the United States Code entitled “Bankruptcy.”
“Benchmark” means, initially, the Term SOFR Reference Rate; provided that if a Benchmark
Transition Event has occurred with respect to the Term SOFR Reference Rate or the then-current Benchmark, then “Benchmark” means the applicable Benchmark Replacement to the extent that such Benchmark Replacement has replaced such prior benchmark
rate pursuant to Section 3.02(c).
“Benchmark Replacement” means the first alternative set forth in the order below that can be determined by the Administrative Agent for
the applicable Benchmark Replacement Date:
(a) Daily Simple SOFR; or
(b) the sum of: (i) the alternate benchmark rate that has been selected by the Administrative Agent and the Administrative Borrower giving due
consideration to (A) any selection or recommendation of a replacement benchmark rate or the mechanism for determining such a rate by the Relevant Governmental Body or (B) any evolving or then-prevailing market convention for determining a benchmark
rate as a replacement to the then-current Benchmark for Dollar-denominated syndicated credit facilities and (ii) the related Benchmark Replacement Adjustment.
- 4 -
If the Benchmark Replacement as determined pursuant to clause (a) or (b) above would be less than the Floor, the Benchmark Replacement will be deemed to be the Floor for the purposes of this
Agreement and the other Loan Documents.
“Benchmark Replacement Adjustment” means, with respect to any replacement of the then-current Benchmark with an Unadjusted Benchmark
Replacement, the spread adjustment, or method for calculating or determining such spread adjustment, (which may be a positive or negative value or zero) that has been selected by the Administrative Agent and the Borrower giving due consideration to
(a) any selection or recommendation of a spread adjustment, or method for calculating or determining such spread adjustment, for the replacement of such Benchmark with the applicable Unadjusted Benchmark Replacement by the Relevant Governmental
Body or (b) any evolving or then-prevailing market convention for determining a spread adjustment, or method for calculating or determining such spread adjustment, for the replacement of such Benchmark with the applicable Unadjusted Benchmark
Replacement for Dollar-denominated syndicated credit facilities at such time.
“Benchmark Replacement Date” means a date and time determined by the Administrative Agent, which date shall be no later than the
earliest to occur of the following events with respect to the then‑current Benchmark:
(a) in the case of clause (a) or (b) of the definition of “Benchmark Transition Event,” the later of (i) the date of the public statement or
publication of information referenced therein and (ii) the date on which the administrator of such Benchmark (or the published component used in the calculation thereof) permanently or indefinitely ceases to provide all Available Tenors of such
Benchmark (or such component thereof); or
(b) in the case of clause (c) of the definition of “Benchmark Transition Event”, the first date on which such Benchmark (or the published component
used in the calculation thereof) has been determined and announced by the regulatory supervisor for the administrator of such Benchmark (or such component thereof) to be non‑representative; provided that
such non‑representativeness will be determined by reference to the most recent statement or publication referenced in such clause (c) and even if any Available Tenor of such Benchmark (or such component thereof) continues to be provided on such
date.
For the avoidance of doubt, the “Benchmark Replacement Date” will be deemed to have occurred in the case of clause (a) or (b) with respect to any Benchmark upon the occurrence of the applicable
event or events set forth therein with respect to all then‑current Available Tenors of such Benchmark (or the published component used in the calculation thereof).
- 5 -
“Benchmark Transition Event” means the occurrence of one or more of the following events with respect to the then‑current Benchmark:
(a) a public statement or publication of information by or on behalf of the administrator of such Benchmark (or the published component used in the
calculation thereof) announcing that such administrator has ceased or will cease to provide all Available Tenors of such Benchmark (or such component thereof), permanently or indefinitely; provided that, at
the time of such statement or publication, there is no successor administrator that will continue to provide any Available Tenor of such Benchmark (or such component thereof);
(b) a public statement or publication of information by the regulatory supervisor for the administrator of such Benchmark (or the published component
used in the calculation thereof), the Federal Reserve Board, the Federal Reserve Bank of New York, an insolvency official with jurisdiction over the administrator for such Benchmark (or such component), a resolution authority with jurisdiction over
the administrator for such Benchmark (or such component) or a court or an entity with similar insolvency or resolution authority over the administrator for such Benchmark (or such component), which states that the administrator of such Benchmark
(or such component) has ceased or will cease to provide all Available Tenors of such Benchmark (or such component thereof) permanently or indefinitely; provided that, at the time of such statement or
publication, there is no successor administrator that will continue to provide any Available Tenor of such Benchmark (or such component thereof); or
(c) a public statement or publication of information by the regulatory supervisor for the administrator of such Benchmark (or the published component used in the
calculation thereof) announcing that all Available Tenors of such Benchmark (or such component thereof) are not, or as of a specified future date will not be, representative.
For the avoidance of doubt, a “Benchmark Transition Event” will be deemed to have occurred with respect to any Benchmark if a public statement or publication of information set forth above has
occurred with respect to each then‑current Available Tenor of such Benchmark (or the published component used in the calculation thereof).
“Benchmark Unavailability Period” means, the period (if any) (a) beginning at the time that a Benchmark Replacement Date has occurred if,
at such time, no Benchmark Replacement has replaced the then‑current Benchmark for all purposes hereunder and under any Loan Document in accordance with Section 3.02(c) and (b) ending at the time that a Benchmark Replacement has replaced the
then‑current Benchmark for all purposes hereunder and under any Loan Document in accordance with Section 3.02(c).
“Beneficial Ownership Regulation” has the meaning set forth in Section 13.16.
“Benefit Plan” means any employee benefit plan as defined in Section 3(3) of ERISA to which any Obligor or Subsidiary thereof incurs or
otherwise has any obligation or liability, contingent or otherwise.
“Board” means, with respect to any Person, the board of directors or managers (as applicable) (or equivalent governing body) of such
Person or any committee thereof.
“Borrower” and “Borrowers” have the meaning set forth in the introduction hereto; provided that upon the completion of the Fitzgerald and Benen Sale, U.S. Fitzgerald shall no longer be a Borrower hereunder.
- 6 -
“Borrowing” means collectively, (i) the Funding Date Term Loan made by the Lenders on the Funding Date, (ii) the Tranche B Term Loan made
by the Lenders on the Tranche B Term Loan Borrowing Date, (iii) the Effective Date Term Loan made by the Lenders on the Effective Date, (iv) the Delayed Draw Term Loan made on the Delayed Draw Term Loan Borrowing Date, (v) the Third Amendment Term
Loan made by the Lenders on the Third Amendment Restatement Date, (vi) the Fourth Amendment Term Loan made by the Lenders on the Fourth Amendment Restatement Date and (vii) the Fifth Amendment Term Loan made by the Lenders on the Fifth Amendment
Restatement Date.
“Bray Leases” means (a) that certain Lease Agreement between Ronan O’Caoimh and Jim Walsh with Trinity Biotech Manufacturing Limited for
the office in Bray, Co. Wicklow Ireland dated November 26, 2004, (b) that certain Indenture between Jim Walsh and Trinity Biotech Manufacturing Limited dated December 20, 2007 and (c) that certain Lease between O’Caoimh, O’Boyle and Trinity Biotech
Manufacturing Limited dated July 2016.
“Brazilian Subsidiary” means Trinity Biotech Do Brasil LTDA.
“Business Day” means a day (other than a Saturday or Sunday) on which commercial banks are not authorized or not required to close in
New York City.
“Canadian Bankruptcy Legislation” means the Bankruptcy and Insolvency Act (Canada), the Companies’ Creditors Arrangement Act (Canada), the Winding-Up and Restructuring Act (Canada), and all other liquidation, winding-up, bankruptcy, assignment for the
benefit of creditors, conservatorship, moratorium, receivership, insolvency, plan of arrangement, reorganization, proposal or similar statutes, laws, rules and regulations of Canada, or any province or territory thereof or any other applicable
jurisdictions, in effect from time to time.
“Canadian Defined Benefit Pension Plan” means a pension plan for the purposes of any applicable pension benefits standards, statute or
regulation in Canada, which contains a “defined benefit provision,” as defined in subsection 147.1(1) of the Income Tax Act (Canada).
“Canadian Intellectual Property Security Agreements” means Trademark security agreements, dated as of the Funding Date, entered into by
U.S. Primus and Phoenix Bio-Tech Corp, in favor of the Administrative Agent for the benefit of the Lenders, each in form and substance satisfactory to the Administrative Agent.
“Canadian Obligor” means an Obligor incorporated or organized under the laws of Canada.
“Canadian Pension Plan” means a “registered pension plan” (as defined in subsection 248(1) of the Income
Tax Act (Canada) sponsored or administrated by one or more of the Obligors or any of their Subsidiaries.
- 7 -
“Canadian Pledge Agreement” means the Canadian Pledge Agreement, dated as of the Funding Date, among Parent, the Lenders and the
Administrative Agent, pledging 100% of the Equity Interests in Phoenix Bio-Tech Corp. in favor of the Administrative Agent for the benefit of the Lenders.
“Canadian Security Agreement” means the Canadian Security Agreement, dated as of the Funding Date, in substantially the form of Exhibit
G-2, among the Obligors organized under the laws of Canada, the Lenders and the Administrative Agent, granting a security interest in the personal Property constituting Collateral thereunder in favor of the Administrative Agent for the benefit of
the Lenders.
“Capital Lease Obligations” means, as to any Person, the obligations of such Person to pay rent or other amounts under a lease of (or
other agreement conveying the right to use) real and/or personal Property which obligations are required to be classified and accounted for as a capital lease on a balance sheet of such Person under IFRS and, for purposes of this Agreement, the
amount of such obligations shall be the capitalized amount thereof, determined substantially in accordance with IFRS; provided that any lease that would have been considered an operating lease under IFRS as
in effect as of December 31, 2018 shall be treated as an operating lease for all purposes under this Agreement and the other Loan Documents, and all obligations in respect thereof shall be excluded from the definition of Indebtedness.
“Casualty Event” means any actual or constructive loss, condemnation, destruction, confiscation, requisition, seizure or forfeiture of
any asset of the Borrowers or any other Obligor, with a fair market value as of the date of such event, individually or in the aggregate, of greater than $1,000,000 in any calendar year.
“Cayman Subsidiary” means Trinity Biotech Investment Limited.
“Change of Control” means and shall be deemed to have occurred if:
(a) any “person” or “group” (within the meaning of Rule 13d-5 of the Exchange Act as in effect on the date hereof) shall own, directly or
indirectly, beneficially or of record, shares representing 40% or more of the aggregate ordinary voting power represented by the issued and outstanding Equity Interests of Parent;
(b) during any period of twelve (12) consecutive calendar months, the occupation of a majority of the seats (other than vacant seats) on the Board
of Parent by Persons who were neither (i) nominated or approved by the Board of Parent, nor (ii) appointed by directors on the Board on the Original Closing Date or so nominated;
(c) Parent shall cease to own directly or indirectly, determined on a fully diluted basis, 100% of the issued and outstanding Equity Interests of
the Obligors; and
(d) each Obligor (other than Parent) shall cease to own directly, beneficially and of record, determined on a fully diluted basis, 100% of the
issued and outstanding Equity Interests of its Subsidiaries (except an Immaterial Foreign Subsidiary).
- 8 -
“Claims” includes claims, litigation, demands, complaints, grievances, actions, applications, suits, causes of action, orders, charges,
indictments, prosecutions, information (brought by a public prosecutor without grand jury indictment) or other similar processes, assessments or reassessments.
“CLIA” means the Clinical Laboratory Improvement Amendments (CLIA) of 1988, as amended from time to time, and the rules, regulations,
guidelines, guidance documents and compliance policy guides issued or promulgated thereunder.
“Code” means the Internal Revenue Code of 1986, as amended from time to time.
“Collateral” means any Property in which a Lien is purported to be granted under any of the Security Documents (or all such Property, as
the context may require).
“Collateral Questionnaire” means that certain Collateral Questionnaire and certification by a Responsible Officer of the Obligors
substantially in the form of attached hereto as Exhibit I and otherwise in form reasonably satisfactory to the Administrative Agent.
“COMI” means center of main interests within the meaning, and for the purposes, of the EU Insolvency Regulation.
“Commercial Partner” means each of the parties set out on Schedule 4 attached hereto.
“Commitment” means with respect to each Lender, such Lender’s Fifth Amendment Term Loan Commitment; and “Commitments” means all such Commitments of all Lenders.
“Commodity Account” has the meaning set forth in the U.C.C.
“Compliance Certificate” has the meaning set forth in Section 8.01(d).
“Conforming Changes” means, with respect to either the use or administration of Term SOFR or the use, administration, adoption or
implementation of any Benchmark Replacement, any technical, administrative or operational changes (including changes to the definition of “Business Day,” the definition of “U.S. Government Securities Business Day,” the definition of “Interest
Period” or any similar or analogous definition (or the addition of a concept of “interest period”), timing and frequency of determining rates and making payments of interest, timing of borrowing requests or prepayment, conversion or continuation
notices, the applicability and length of lookback periods and other technical, administrative or operational matters) that the Administrative Agent decides may be appropriate to reflect the adoption and implementation of any such rate or to permit
the use and administration thereof by the Administrative Agent in a manner substantially consistent with market practice (or, if the Administrative Agent decides that adoption of any portion of such market practice is not administratively feasible
or if the Administrative Agent determines that no market practice for the administration of any such rate exists, in such other manner of administration as the Administrative Agent decides is reasonably necessary in connection with the
administration of this Agreement and the other Loan Documents).
- 9 -
“Connection Income Taxes” means Other Connection Taxes that are imposed on or measured by net income (however denominated) or that are
franchise Taxes or branch profits Taxes.
“Contracts” means any contract, license, instrument, lease, agreement, obligation, promise, undertaking, understanding, arrangement,
document, commitment, entitlement or engagement under which a Person has, or will have, any liability or contingent liability (in each case, whether written or oral, express or implied, and whether in respect of monetary or payment obligations,
performance obligations or otherwise), excluding the Loan Documents.
“Control” means, with respect to any particular Person, the possession by one or more other Persons, directly or indirectly, of the power
to direct or cause the direction of the management or policies of such particular Person, whether through the ability to exercise voting power, by contract or otherwise. “Controlling” and “Controlled” have meanings correlative thereto.
“Controlled Account” has the meaning set forth in Section 8.18(a).
“Convertible Notes” means those certain exchangeable senior notes issued pursuant to the Indenture dated as April 9, 2015, by the Cayman
Subsidiary and guaranteed by Parent.
“Copyrights” means all copyrights, copyright registrations and applications for copyright registrations, including all renewals and
extensions thereof, all rights to recover for past, present or future infringements thereof and all other rights whatsoever accruing thereunder or pertaining thereto.
“Daily Simple SOFR” means, for any day (a “SOFR Rate Day”), a rate per annum equal to the greater of (a) SOFR for the day (such day, a
“SOFR Determination Day”) that is two (2) U.S. Government Securities Business Days prior to (i) if such SOFR Rate Day is a U.S. Government Securities Business Day, such SOFR Rate Day or (ii) if such SOFR Rate Day is not a U.S. Government Securities
Business Day, the U.S. Government Securities Business Day immediately preceding such SOFR Rate Day, in each case, as such SOFR is published by the SOFR Administrator on the SOFR Administrator’s Website, and (b) the Floor. If by 5:00 p.m. (New York
City time) on the second (2nd) U.S. Government Securities Business Day immediately following any SOFR Determination Day, SOFR in respect of such SOFR Determination Day has not been published on the SOFR Administrator’s Website and a Benchmark
Replacement Date with respect to the Daily Simple SOFR has not occurred, then SOFR for such SOFR Determination Day will be SOFR as published in respect of the first preceding U.S. Government Securities Business Day for which such SOFR was published
on the SOFR Administrator’s Website; provided that, any SOFR determined pursuant to this sentence shall be utilized for purposes of calculation of Daily Simple SOFR for no more than three (3) consecutive
SOFR Rate Days; provided further, Daily Simple SOFR shall be rounded upwards to the next 1/100% (if necessary). Any change in Daily Simple SOFR due to a change in SOFR shall be effective from and including
the effective date of such change in SOFR without notice to the Administrative Borrower.
“Default” means any Event of Default and any event that, upon the giving of notice, the lapse of time or both, would constitute an Event
of Default.
- 10 -
“Default Rate” has the meaning set forth in Section 3.02(d).
“Delayed Draw Term Loan” means the loan advanced by a Lender pursuant to Section 2.01(d). For purposes of clarification, any calculation
of the aggregate outstanding principal amount of the Delayed Draw Term Loan on any date of determination shall mean the aggregate principal amount of the Delayed Draw Term Loan made pursuant to Section 2.01(d) that has not yet been repaid as of
such date.
“Delayed Draw Term Loan Borrowing Date” means with respect to the Delayed Draw Term Loan, the Business Day on which a Delayed Draw Term
Loan was made pursuant to Section 2.01(d) of the Second A&R Credit Agreement.
“Delayed Draw Term Loan Borrowing Notice” means a notice requesting a Delayed Draw Term Loan substantially in the form of Exhibit N.
“Deposit Account” has the meaning set forth in the U.C.C. (and includes, for greater certainty, any deposit account maintained with a
bank or other financial institution in any Canadian jurisdiction).
“Designated Person” means a person or entity:
(a) listed in the annex to, or otherwise targeted by the provisions of, the Executive Order (as disclosed by World‑Check or another reputable
commercially available database);
(b) named as a “Specially Designated National and Blocked Person” on the most current list published by OFAC at its official website or any
replacement website or other replacement official publication of such list (as disclosed by World‑Check or another reputable commercially available database); or
(c) with which the Lenders are prohibited from dealing or otherwise engaging in any transaction by any Economic Sanctions Laws or Irish Economic
Sanctions Laws.
“Device” means any product that meets the definition of “device” as set forth in Section 321 of the FD&C Act, including (a) any
medical instrument, apparatus, implement, machine, contrivance, implant, in vitro reagent or other similar or related item, including any component, part or accessory, that (i) is intended for use in the diagnosis of disease, malady or other
conditions or in the cure, mitigation, treatment or prevention of disease or malady, in man or other animals, or is intended to affect the structure or any function of the body of man or other animals, (ii) does not achieve its primary intended
purpose or purposes through chemical action within or on the body of man or other animals and (iii) is not dependent upon being metabolized for the achievement of its primary intended purpose or purposes and (b) any other product that meets the
definition of “device” as set forth in Section 321 of the FD&C Act.
- 11 -
“Device Clearance Application” means (a) any premarket approval application submitted under Section 515 of the FD&C Act (21 U.S.C.
§ 360e) (a “PMA”), (b) any de novo request submitted under Section 513(f) of the FD&C Act (21 U.S.C. § 360c(f)), (c) any 510(k) submitted under Section 510(k) of the FD&C Act (21 U.S.C. § 360(k))
seeking clearance from the FDA for a Device that is substantially equivalent to a legally marketed predicate Device, as defined in the FD&C Act, (d) any corresponding or substantially equivalent notification, application or clearance of a
non‑United States Regulatory Authority including, with respect to the European Union, any equivalent submission to a Standard Body pursuant to an applicable directive of the European Council with respect to CE marking (or, if applicable, a
self‑certification of conformity with respect to any such directive through a “declaration of conformity”) and (e) all amendments, variations, extensions and renewals of any of the foregoing.
“Disqualified Equity Interests” means, with respect to any Person, any Equity Interest of such Person that, by its terms (or by the terms
of any security or other Equity Interest into which it is convertible or for which it is exchangeable upon exercise or otherwise), or upon the happening of any event or condition (a) matures or is mandatorily redeemable (other than solely for
Qualified Equity Interests), including pursuant to a sinking fund obligation or otherwise, (b) is redeemable at the option of the holder thereof (other than solely for Qualified Equity Interests), in whole or in part, (c) provides for the scheduled
payments of dividends or other distributions in cash or other securities that would constitute Disqualified Equity Interests, or (d) is or becomes convertible into or exchangeable for Indebtedness or any other Equity Interests that would constitute
Disqualified Equity Interests, in each case, prior to the date that is one hundred and eighty (180) days after the Stated Maturity Date; provided that, if such Equity Interests are issued pursuant to any
plan for the benefit of directors, officers, employees or consultants of such Person or by any such plan to such directors, officers, employees or consultants, such Equity Interests shall not constitute Disqualified Equity Interests solely because
they may be required to be repurchased by such Person upon the death, disability, retirement or termination of employment or service of such director, officer, employee or consultant.
“Dollars” and “$” means lawful money of the United States.
“Domestic Subsidiary” means any Subsidiary that is organized under the laws of the United States, any state thereof or the District of
Columbia.
“Economic Sanctions Laws” means (a) the Executive Order, the International Emergency Economic Powers Act (50 U.S.C. §§ 1701 et seq.), the
Trading with the Enemy Act (50 U.S.C. App. §§ 1 et seq.), any other law or regulation promulgated thereunder from time to time and administered by OFAC and any similar law enacted in the United States after the date of this Agreement and (b) any
other similar applicable law now or hereafter enacted in any other applicable jurisdiction, including, without limitation, the Special Economic Measures Act (Canada), the United
Nations Act (Canada), the Freezing Assets of Corrupt Foreign Officials Act (Canada), Part II.1 of the Criminal Code (Canada), and the Export and Import Permits Act (Canada), and any regulations thereunder.
- 12 -
“EEA Financial Institution” means (a) any credit institution or investment firm established in any EEA Member Country which is subject
to the supervision of an EEA Resolution Authority, (b) any entity established in an EEA Member Country which is a parent of an institution described in clause (a) of this definition, or (c) any financial institution established in an EEA Member
Country which is a subsidiary of an institution described in clauses (a) or (b) of this definition and is subject to consolidated supervision with its parent.
“EEA Member Country” means any of the member states of the European Union, Iceland, Liechtenstein, and Norway.
“EEA Obligor” means an Obligor which is incorporated or established in, or under the laws of, an EEA Member Country.
“EEA Resolution Authority” means any public administrative authority or any person entrusted with public administrative authority of any
EEA Member Country (including any delegee) having responsibility for the resolution of any EEA Financial Institution.
“Effective Date” means January 30, 2024.
“Effective Date Acquisition” means the acquisition by U.S. TRIB and Konamite of certain assets of WaveForm and WaveForm Holdings
(including, without limitation, the Equity Interests of WaveForm Slovenia to be transferred subsequent to the closing under the Effective Date Acquisition Agreement) pursuant to the terms of the Effective Date Acquisition Agreement and the WaveForm
Slovenia Side Agreement.
“Effective Date Acquisition Agreement” means that certain Asset and Share Purchase Agreement, dated as of January 30, 2024, among U.S.
TRIB, as buyer, WaveForm and WaveForm Holdings, as sellers, and WaveForm Slovenia.
“Effective Date Term Loan” means the loan advanced by a Lender pursuant to Section 2.01(c). For purposes of clarification, any
calculation of the aggregate outstanding principal amount of the Effective Date Term Loan on any date of determination shall mean the aggregate principal amount of the Effective Date Term Loan made pursuant to Section 2.01(c) that has not yet been
repaid as of such date.
“Effective Date Term Loan Borrowing Notice” means a notice substantially in the form attached
hereto as Exhibit M.
“Effective Date Warrant Certificate” means the Warrant, dated as of the Effective Date, as amended by the First Amendment to the
Effective Date Warrant Certificate, that, among other things, grants the holder thereof the right to purchase the number of American Depositary Shares (represented by American Depositary Receipts) of Parent as indicated on the Warrant Shares table
on Schedule 1.
“EMA” means the European Medicines Agency and any successor thereto.
- 13 -
“Environmental Law” means any federal, state, provincial, territorial, or local governmental law, rule, regulation, order, writ,
judgment, injunction or decree relating to pollution or protection of the environment or the treatment, storage, disposal, release, threatened release or handling of Hazardous Materials, and all local laws and regulations related to environmental
matters and any specific agreements entered into with any competent authorities which include commitments related to environmental matters.
“Equity Interest” means, with respect to any Person, any and all shares (including all American Depositary Shares represented by American
Depositary Receipts), interests, participations or other equivalents, including membership interests (however designated, whether voting or nonvoting), of equity of such Person, including, if such Person is a partnership, partnership interests
(whether general or limited) and any other interest or participation that confers on a Person the right to receive a share of the profits and losses of, or distributions of property of, such partnership, but excluding debt securities convertible or
exchangeable into such equity.
“ERISA” means the United States Employee Retirement Income Security Act of 1974, as amended.
“ERISA Affiliate” means, collectively, any Obligor, Subsidiary thereof, and any Person treated as a single employer, with any Obligor or
Subsidiary thereof, within the meaning of Section 414(b), (c), (m) or (o) of the Code.
“ERISA Event” means (a) a reportable event as defined in Section 4043 of ERISA with respect to a Title IV Plan, excluding, however, such
events as to which the PBGC by regulation has waived the requirement of Section 4043(a) of ERISA that it be notified within thirty (30) days of the occurrence of such event; (b) the applicability of the requirements of Section 4043(b) of ERISA with
respect to a contributing sponsor, as defined in Section 4001(a)(13) of ERISA, to any Title IV Plan where an event described in paragraph (9), (10), (11), (12) or (13) of Section 4043(c) of ERISA is reasonably expected to occur with respect to such
plan within the following thirty (30) days; (c) a withdrawal by any Obligor or any ERISA Affiliate thereof from a Title IV Plan or the termination of any Title IV Plan resulting in liability under Sections 4063 or 4064 of ERISA; (d) the withdrawal
of any Obligor or any ERISA Affiliate thereof in a complete or partial withdrawal (within the meaning of Section 4203 and 4205 of ERISA) from any Multiemployer Plan if there is any potential liability therefore, or the receipt by any Obligor or any
ERISA Affiliate thereof of notice from any Multiemployer Plan that it is insolvent or in critical status pursuant to Section 4241 or 4245 of ERISA; (e) the filing of a notice of intent to terminate, the treatment of a plan amendment as a
termination under Section 4041 or 4041A of ERISA, or the commencement of proceedings by the PBGC to terminate a Title IV Plan or Multiemployer Plan; (f) the imposition of liability on any Obligor or any ERISA Affiliate thereof pursuant to
Sections 4062(e) or 4069 of ERISA or by reason of the application of Section 4212(c) of ERISA; (g) the failure by any Obligor or any ERISA Affiliate thereof to make any required contribution to a Title IV Plan, or the failure to meet the minimum
funding standard of Section 412 of the Code with respect to any Title IV Plan (whether or not waived in accordance with Section 412(c) of the Code) or the failure to make by its due date a required installment under Section 430 of the Code with
respect to any Title IV Plan or the failure to make any required contribution to a Multiemployer Plan; (h) the determination that any Title IV Plan is considered an at‑risk plan or a plan in endangered to critical status within the meaning of
Sections 430, 431 and 432 of the Code or Sections 303, 304 and 305 of ERISA; (i) an event or condition which might reasonably be expected to constitute grounds under Section 4042 of ERISA for the termination of, or the appointment of a trustee to
administer, any Title IV Plan or Multiemployer Plan; (j) the imposition of any liability under Title I or Title IV of ERISA, other than PBGC premiums due but not delinquent under Section 4007 of ERISA, upon any Obligor or any ERISA Affiliate
thereof; (k) an application for a funding waiver under Section 303 of ERISA or an extension of any amortization period pursuant to Section 412 of the Code with respect to any Title IV Plan; (l) the occurrence of a non‑exempt prohibited transaction
under Sections 406 or 407 of ERISA for which any Obligor or any Subsidiary thereof may be directly or indirectly liable which may give rise to the imposition of fines or penalties thereon; (m) a violation of the applicable requirements of
Section 404 or 405 of ERISA or the exclusive benefit rule under Section 401(a) of the Code with respect to any Plan by any fiduciary or disqualified person for which any Obligor or any ERISA Affiliate thereof would be directly or indirectly liable;
(n) the occurrence of an act or omission which gives rise to the imposition on any Obligor or any ERISA Affiliate thereof of fines, penalties, Taxes or related charges under Chapter 43 of the Code or under Sections 409, 502(c), (i) or (1) or 4071
of ERISA; (o) the assertion of a material claim (other than routine Claims for benefits) against any Plan or the assets thereof, or against any Obligor or any Subsidiary thereof in connection with any such plan; (p) receipt from the IRS of notice
of the failure of any Qualified Plan to qualify under Section 401(a) of the Code, or the failure of any trust forming part of any Qualified Plan to fail to qualify for exemption from taxation under Section 501(a) of the Code; (q) the imposition of
any Lien (or the fulfillment of the conditions for the imposition of any Lien) on any of the rights, properties or assets of any Obligor or any ERISA Affiliate thereof, in either case pursuant to Title I or IV, including Section 302(f) or 303(k) of
ERISA or to Section 401(a)(29) or 430(k) of the Code; or (r) the establishment or amendment by any Obligor or any Subsidiary thereof of any “welfare plan,” as such term is defined in Section 3(1) of ERISA, that provides post‑employment welfare
benefits in a manner that would increase the liability of any Obligor, other than those benefits required under the Consolidated Omnibus Budget Reconciliation Act.
- 14 -
“ERISA Funding Rules” means the rules regarding minimum required contributions (including any installment payment thereof) to Title IV
Plans, as set forth in Sections 412, 430, 431, 432 and 436 of the Code and Sections 302, 303, 304 and 305 of ERISA.
“EU Bail‑In Legislation Schedule” means the EU Bail‑In Legislation Schedule published by the Loan Market Association (or any successor
Person), as in effect from time to time.
“EU Insolvency Regulation” means Regulation (EU) 2015/848 of the European Parliament and of the Council of 20 May 2015 on insolvency
proceedings (recast).
“Event of Default” has the meaning set forth in Section 10.01.
“Excess Funding Guarantor” has the meaning set forth in Section 11.08.
“Excess Payment” has the meaning set forth in Section 11.08.
“Exchange Act” means the Securities Exchange Act of 1934, as amended, and the rules and regulations promulgated thereunder.
“Excluded Accounts” means (a) Deposit Accounts exclusively used for payroll, payroll Taxes and other employee wage and benefit payments
to or for the benefit of the employees of the Obligors, (b) Deposit Accounts with aggregate balances of $250,000 or less at any time and (c) Deposit Accounts that are Segregated Health Care Accounts.
- 15 -
“Excluded Taxes” means any of the following Taxes imposed on or with respect to a Recipient or required to be withheld or deducted from a
payment to a Recipient: (a) Taxes imposed on or measured by the overall net income (however denominated), franchise Taxes and branch profits Taxes in each case (i) imposed on such Recipient by the jurisdiction (or any political supervision thereof)
under the laws of which such Recipient is organized, or having its principal office or, in the case of a Lender, its applicable lending office located in, the jurisdiction imposing such Tax or (ii) that are Other Connection Taxes, (b) any United
States federal withholding Taxes that are imposed on amounts payable to Lender to the extent that the obligation to withhold amounts existed on the date that (i) Lender became a “Lender” under this Agreement or (ii) Lender changes its lending
office, except in each case to the extent Lender is a direct or indirect assignee of any other Lender that was entitled, at the time the assignment of such other Lender became effective, to receive additional amounts under Section 5.03 or Lender
was entitled to receive additional amounts under Section 5.03 immediately before it changed its lending office, (c) any Taxes imposed in connection with FATCA, and (d) Taxes attributable to such Recipient’s failure to comply with Section 5.03(f).
“Executive Order” means the US Executive Order No. 13224 on Blocking Property and Prohibiting Transactions with Persons who commit,
Threaten to Commit, or Support Terrorism.
“Existing Warrant Certificate” means the Warrant, dated as of the Funding Date, that, among other things, grants the holder thereof the
right to purchase the number of American Depositary Shares (represented by American Depositary Receipts) of Parent as indicated on the Warrant Shares table on Schedule 1, as amended by the Existing Warrant Certificate Amendments and as may be
further amended, replaced or otherwise modified pursuant to the terms thereof.
“Existing Warrant Certificate Amendments” means that First Amendment to Existing Warrant Certificate, that Second Amendment to Warrant
Certificate and that Third Amendment to Warrant Certificate.
“FATCA” means Sections 1471 through 1474 of the Code, as of the date of this Agreement (or any amended or successor version that is
substantively comparable and not materially more onerous to comply with), any current or future regulations or official interpretations thereof, any agreements entered into pursuant to Section 1471(b)(1) of the Code and any fiscal or regulatory
legislation, rules or practices adopted pursuant to any intergovernmental agreement, treaty or convention among Governmental Authorities entered into in connection with the implementation of the foregoing.
“FD&C Act” means the United States Food, Drug and Cosmetic Act of 1938 (or any successor thereto), as amended from time to time, and
the rules, regulations, guidelines, guidance documents and compliance policy guides issued or promulgated thereunder.
“FDA” means the United States Food and Drug Administration and any successor entity.
- 16 -
“FDA Laws” means all applicable statutes, rules, regulations and orders administered or issued by the FDA, including without limitation,
the FD&C Act and its implementing regulations.
“Federal Health Care Program” means (i) a “Federal Health Care Program” as defined in Section 1128B(f) of the Social Security Act, and
includes the programs commonly known as Medicare, Medicaid, TRICARE and CHAMPVA; and (ii) a health care plan pursuant to the provincial plans under the Canada Health Act.
“Fifth Amendment Restatement Date” means May 15, 2025.
“Fifth Amendment Term Loan” means the loan advanced by a Lender pursuant to Section 2.01(g). For purposes of clarification, any
calculation of the aggregate outstanding principal amount of the Fifth Amendment Term Loan on any date of determination shall mean the aggregate principal amount of the Fifth Amendment Term Loan made pursuant to Section 2.01(g) that has not yet
been repaid as of such date.
“Fifth Amendment Term Loan Borrowing Notice” means a notice substantially in the form attached
hereto as Exhibit Q.
“Fifth Amendment Term Loan Commitment” means the commitment of a Lender to make or otherwise fund the Fifth Amendment Term Loan and “Fifth Amendment Term Loan Commitments” means such commitments of all Lenders in the aggregate. The amount of each Lender’s Fifth Amendment Term Loan Commitment is set forth on Schedule 1. The aggregate amount
of the Fifth Amendment Term Loan Commitments as of the Fifth Amendment Restatement Date is $2,000,000.
“Financial Plan” has the meaning set forth in Section 8.01(i).
“First Amendment to Effective Date Warrant Certificate” means that certain First Amendment to Warrant Certificate, dated as of the Third
Amendment Restatement Date, by and among Parent and Perceptive.
“First Amendment to Existing Warrant Certificate” means that certain First Amendment to Warrant Certificate, dated as of February 21,
2023, by and among Parent and Perceptive.
“Fitzgerald and Benen Sale” means the sale by (a) U.S. Holdings of all of the Equity Interests of U.S. Fitzgerald to Biosynth
International Inc. and (b) Parent and Trinity Biotech Manufacturing Limited of all of the Equity Interests of Benen Trading Limited to Aalto Bio Holdings Limited, for an aggregate purchase price of approximately $30,000,000, subject to adjustment.
“Flash Financial Report” means a financial report prepared by management based on the Obligors’ books and records, prepared without the
review necessary to make all adjustments necessary for presentation of the financial statements to be delivered with the Officer’s Certificate to be delivered pursuant to Section 8.01(b)(i) or the Audit Report to be delivered pursuant to Section
8.01(c).
- 17 -
“Floor” means a rate of interest equal to 4.00%.
“Foreign Lender” means a Lender that is not a U.S. Person.
“Foreign Subsidiary” means any Subsidiary that is not a Domestic Subsidiary.
“Fourth A&R Credit Agreement” has the meaning set forth in the recitals hereto.
“Fourth Amendment Restatement Date” means February 27, 2025.
“Fourth Amendment Term Loan” means the loan advanced by a Lender pursuant to Section 2.01(f). For purposes of clarification, any
calculation of the aggregate outstanding principal amount of the Fourth Amendment Term Loan on any date of determination shall mean the aggregate principal amount of the Fourth Amendment Term Loan made pursuant to Section 2.01(f) that has not yet
been repaid as of such date.
“Fourth Amendment Term Loan Borrowing Notice” means a notice substantially in the form attached
hereto as Exhibit P.
“Funding Date” means January 27, 2022.
“Funding Date Term Loan” means the loan made by a Lender pursuant to Section 2.01(a).
“Governmental Approval” means any consent, authorization, approval, order, license, franchise, permit, certification, accreditation,
registration, clearance, exemption, filing or notice, that is issued or granted by or from (or pursuant to any act of) any Governmental Authority, including any application or submission related to any of the foregoing.
“Governmental Authority” means any nation, government, branch of power (whether executive, legislative or judicial), state, province,
territory, municipality or other political subdivision thereof and any entity exercising executive, legislative, judicial, monetary, regulatory or administrative functions of or pertaining to government, including without limitation Regulatory
Authorities, governmental departments, agencies, commissions, bureaus, officials, ministers, courts, bodies, boards, tribunals and dispute settlement panels, and other law‑, rule‑ or regulation‑making organizations or entities of any State,
province, territory, county, city or other political subdivision of the United States, Ireland, Canada, or any foreign country.
- 18 -
“Guarantee” of or by any Person (the “guarantor”) means any obligation, contingent or
otherwise, of the guarantor guaranteeing or having the economic effect of guaranteeing any Indebtedness or other obligation of any other Person (the “primary obligor”) in any manner, whether directly or
indirectly, and including any obligation of the guarantor, direct or indirect, (a) to purchase or pay (or advance or supply funds for the purchase or payment of) such Indebtedness or other obligation or to purchase (or to advance or supply funds
for the purchase of) any security for the payment thereof, (b) to purchase or lease property, securities or services for the purpose of assuring the owner of such Indebtedness or other obligation of the payment thereof, (c) to maintain working
capital, equity capital or any other financial statement condition or liquidity of the primary obligor so as to enable the primary obligor to pay such Indebtedness or other obligation or (d) as an account party in respect of any letter of credit or
letter of guaranty issued to support such Indebtedness or obligation; provided that the term Guarantee shall not include endorsements for collection or deposit in the Ordinary Course of Business.
“Guarantee Assumption Agreement” means a Guarantee Assumption Agreement substantially in the form of Exhibit A by an entity that,
pursuant to Section 8.11(a), is required to become a “Guarantor”.
“Guaranteed Obligations” has the meaning set forth in Section 11.01.
“Guarantor” means (a) initially, Parent and each Subsidiary of Parent listed as a Guarantor on the signature pages hereto and (b) any
other Subsidiary of Parent joined as a Guarantor from time to time pursuant to Section 8.11; provided that upon the completion of the Fitzgerald and Benen Sale, Benen Trading Limited shall no longer be a
Guarantor hereunder.
“Hazardous Material” means any substance, element, chemical, compound, product, solid, gas, liquid, waste, by‑product, pollutant,
contaminant or material which is hazardous or toxic, and includes, without limitation, (a) asbestos, polychlorinated biphenyls and petroleum (including crude oil or any fraction thereof) and (b) any material classified or regulated as “hazardous”
or “toxic” or words of like import pursuant to an Environmental Law.
“Health Canada” means Health Canada, including all of the respective divisions, departments, bureaus, directorates, and agencies thereof
(including, without limitation, the Medical Services Bureau and the Therapeutic Products Directorate), and any successors thereto.
“Health Canada Laws” means all applicable statues, rules, regulations and orders administered or issued by Health Canada, including
without limitation, the Food and Drugs Act (Canada) and the regulations thereunder (including, without limitation, the Medical Devices Regulations thereunder).
“Health Care Compliance Program” has the meaning set forth in Section 7.07(d).
- 19 -
“Healthcare Laws” means, collectively, all Laws applicable to the business of the Borrowers, any other Obligor regulating the
manufacturing, sale, distribution, labeling, marketing, or promotion, the export, or the provision of and payment for, health care products (including diagnostic products), items and services, including but not limited to (a) all applicable laws in
any jurisdiction relating to the privacy or security of consumer information, including but not limited to the Health Insurance Portability and Accountability Act of 1996 (Pub. L. No. 104‑191) (“HIPAA”) and
any similar state laws; (b) all applicable federal and state fraud and abuse laws, and equivalent laws in any other jurisdiction, including but not limited to the federal Anti‑Kickback Statute (42 U.S.C. §1320a‑7b(b) and any similar state laws),
the federal Physician Self‑Referral Prohibition (commonly referred to as the “Stark Law”) (42 U.S.C. § 1395nn and any similar state laws), the Civil Monetary Penalties Act (42 U.S.C. §1320a‑7a), and the
civil False Claims Act (31 U.S.C. §3729 et seq. and any similar state laws); (c) all applicable FDA Laws and equivalent laws under in other jurisdiction; (d) CLIA; (e) all applicable laws regarding the
provision of health care supplies, items or services to Federal Health Care Program beneficiaries or the billing of the Federal Health Care Programs, and equivalent laws in any other jurisdiction; (f) all applicable Health Canada Laws; and (g) all
rules and regulations promulgated under or pursuant to any of the foregoing.
“Hedging Agreement” means any interest rate exchange agreement, foreign currency exchange agreement, commodity price protection agreement
or other interest or currency exchange rate or commodity price hedging arrangement.
“HPRA” means the Health Products Regulatory Authority of Ireland and any successor thereto.
“IDE” means an application, including an application filed with any Regulatory Authority, for authorization to commence human clinical
studies with respect to any Device, including (a) an Investigational Device Exemption as defined in the FD&C Act or any successor application or procedure filed with the FDA, (b) an abbreviated Investigational Device Exemption as specified in
FDA regulations in 21 C.F.R. § 812.2(b), (c) any equivalent of any of the foregoing pursuant to or under any non‑United States country or regulatory jurisdiction, (d) all amendments, variations, extensions and renewals of any of the foregoing that
may be filed with respect thereto, and (e) all documents and correspondence with Institutional Review Boards, whether United States or non‑United States, or equivalent.
“IFRS” means international accounting standards within the meaning of IAS Regulation 1606/2002 to the extent applicable to the relevant
financial statements delivered under or referred to herein. Subject to Section 1.02, all references to “IFRS” shall be to IFRS applied consistently with the principles used in the preparation of the financial statements described in
Section 7.04(a).
“imaware Convertible Note Investment’ means that certain investment by Trinity Biotech Manufacturing Limited in up to $1,500,000 of
convertible promissory notes issued by imaware, Inc., a Delaware corporation.
- 20 -
“Immaterial Foreign Subsidiary” means, as of any date, any Foreign Subsidiary for which (a) the consolidated total assets of such Foreign
Subsidiary and its Subsidiaries is not in excess of 5.0% of the consolidated total assets of Parent and its Subsidiaries, (b) the aggregate amount of the Net Revenue of such Foreign Subsidiary and its Subsidiaries on a consolidated basis is not in
excess of 5.0% of Net Revenue of Parent and its Subsidiaries, (c) the consolidated total assets of such Foreign Subsidiary and its Subsidiaries, when taken together with the consolidated total assets of all other Immaterial Foreign Subsidiaries and
their Subsidiaries, is not in excess of 10.0% of the consolidated total assets of Parent and its Subsidiaries and (d) the aggregate amount of the Net Revenue of such Foreign Subsidiary and its Subsidiaries on a consolidated basis, when taken
together with the contribution to Net Revenue of all other Immaterial Foreign Subsidiaries and their Subsidiaries on a consolidated basis, is not in excess of 10.0% of Net Revenue of Parent and its Subsidiaries in each case as of the last day of
any four quarter period; provided that notwithstanding the foregoing, at no time shall any Guarantor existing on the Original Closing Date or joined hereto pursuant to Section 8.11 subsequently be deemed an
Immaterial Foreign Subsidiary; provided further, that as of the Original Closing Date, the Brazilian Subsidiary, Swedish Subsidiaries, Cayman Subsidiary and U.K. Subsidiary are Immaterial Foreign
Subsidiaries; provided further, that the Luxembourg Subsidiary is not an Immaterial Foreign Subsidiary.
“Indebtedness” of any Person means, without duplication, (a) all obligations of such Person for borrowed money, (b) all obligations of
such Person evidenced by bonds, debentures, notes, loan agreements or similar instruments, (c) all obligations of such Person under conditional sale or other title retention agreements relating to Property acquired by such Person (excluding amounts
related to inventory which are incurred in the Ordinary Course of Business), (d) all obligations of such Person (i) in respect of the deferred purchase price of Property or services or (ii) upon which interest charges are customarily paid
(excluding, in each case of (i) and (ii), current accounts payable which are incurred in the Ordinary Course of Business and except if subject to bona fide dispute contested in good faith by appropriate proceedings and for which such Obligor has
set aside on its books adequate reserves with respect thereto substantially in accordance with IFRS, not overdue by more than one hundred twenty (120) days), (e) all Indebtedness of others secured by (or for which the holder of such Indebtedness
has an existing right, contingent or otherwise, to be secured by) any Lien on Property owned or acquired by such Person, whether or not the Indebtedness secured thereby has been assumed, (f) all Guarantees by such Person of Indebtedness of others,
(g) all Capital Lease Obligations of such Person, (h) all obligations, contingent or otherwise, of such Person as an account party in respect of letters of credit and letters of guaranty, (i) obligations under any Hedging Agreement, currency swaps,
forwards, futures or derivatives transactions, (j) all obligations, contingent or otherwise, of such Person in respect of bankers’ acceptances, (k) all obligations of such Person under license or other agreements containing a guaranteed minimum
payment or purchase by such Person, (l) any Disqualified Equity Interests of such Person, (m) any earnout obligation at the time such obligation is both required to be reflected as a liability on the balance sheet of such Person in accordance with
IFRS and not paid after becoming due and payable and (n) all other obligations required to be classified as indebtedness of such Person under IFRS. The Indebtedness of any Person shall include, without duplication, the Indebtedness of any other
entity (including any partnership in which such Person is a general partner) to the extent such Person is liable therefor as a result of such Person’s ownership interest in or other relationship with such entity, except to the extent the terms of
such Indebtedness provide that such Person is not liable therefor.
“Indemnified Party” has the meaning set forth in Section 13.03(b).
“Indemnified Taxes” means (a) Taxes, other than Excluded Taxes, imposed on or with respect to any payment made by or on account of any
Obligation and (b) to the extent not otherwise described in clause (a), Other Taxes.
“Industrial Designs” means all rights, title and interests arising under any Laws in or relating to all industrial designs, intangibles
of like nature, and any work subject to the design laws of the United States, Canada, Ireland or any other country or any political subdivision thereof.
“Ineligible Assignee” means (a) a natural person or (b) the Obligors or any of their respective Subsidiaries and Affiliates.
- 21 -
“Information” has the meaning set forth in Section 13.17.
“Insolvency Proceeding” means (a) any case, action or proceeding before any court or other Governmental Authority relating to bankruptcy,
reorganization, examinership (in the case of an Irish Obligor, or an Obligor with a COMI in Ireland), insolvency, liquidation, receivership, dissolution, winding‑up or relief of debtors, or (b) any general assignment for the benefit of creditors,
composition, marshaling of assets for creditors, or other similar arrangement in respect of any Person’s creditors generally or any substantial portion of such Person’s creditors, in each case undertaken under any of United States federal, state or
foreign law, or the laws of any other jurisdiction applicable to the Obligors, including, without limitation, the Bankruptcy Code or any Canadian Bankruptcy Legislation.
“Intellectual Property” means, with respect to any Person, all of such Person’s rights, title and interest in and to all Patents,
Trademarks, Copyrights, Industrial Designs, Technical Information, whether registered or not and whether existing under United States or non-United States Law or jurisdiction, including, without limitation, all:
(a) applications, registrations, amendments and extensions relating to such Intellectual Property;
(b) rights and privileges arising under any applicable Laws with respect to any Intellectual Property;
(c) rights to sue for or collect any damages from any past, present or future infringements of any Intellectual Property; and
(d) rights under Product Agreements related to such Intellectual Property.
“Intercompany Subordination Agreement” means that certain Intercompany Subordination Agreement, dated as of the Funding Date, among the
Obligors, the Immaterial Foreign Subsidiaries and the Administrative Agent.
“Interest Period” means, (a) initially, the period beginning on (and including) the Funding Date and ending on (and including) the last
day of the calendar month in which the Funding Date occurs, and (b) thereafter, the period beginning on (and including) the first day of each succeeding calendar month and ending on the earlier of (and including) (i) the last day of such calendar
month and (ii) the Maturity Date.
“Invention” means any novel, inventive or useful art, apparatus, method, process, machine (including any article or Device), manufacture
or composition of matter, or any novel, inventive and useful improvement in any art, method, process, machine (including any article or Device), manufacture or composition of matter.
- 22 -
“Investment” means, for any Person: (a) the acquisition (whether for cash, Property, services or securities or otherwise) of Equity
Interests, bonds, notes, debentures, partnership or other ownership interests or other securities of any other Person or any agreement to make any such acquisition (including any “short sale” or any sale of any securities at a time when such
securities are not owned by the Person entering into such sale); (b) the making of any deposit with, or advance, loan, assumption of debt, other extension of credit to, any other Person (including the purchase of Property from another Person
subject to an understanding or agreement, contingent or otherwise, to resell such Property to such Person), but excluding any such advance, loan or extension of credit in the nature of an ordinary course trade receivable having a term not exceeding
one hundred twenty (120) days arising in connection with the sale of services, inventory or supplies by such Person in the Ordinary Course of Business; (c) the entering into of any Guarantee of, or other contingent obligation with respect to,
Indebtedness or other liability of any other Person and (without duplication) any amount committed to be advanced, lent or extended to such Person; (d) the entering into any joint venture; or (e) the entering into of any Hedging Agreement. The
amount of an Investment will be determined at the time the Investment is made without giving effect to any subsequent changes in value.
“Investor” means MiCo IVD Holdings, LLC, a Delaware limited liability company.
“Investor Convertible Note” means that certain junior convertible note, in favor of Investor, in form and substance satisfactory to the
Administrative Agent.
“Investor Subordination Agreement” means that certain Subordination Agreement, in substantially the form of Exhibit L, among the Investor
and the Administrative Agent and acknowledged by the Obligors.
“Ireland” means Ireland, excluding Northern Ireland (and “Irish” shall be construed accordingly).
“Irish Anti-Corruption Laws” means the Criminal Justice (Corruption Offences) Act 2018 of Ireland.
“Irish Anti-Terrorism Laws” means the Criminal Justice (Money Laundering and Terrorist Financing) Act 2010.
“Irish Debenture” means the Irish law debenture, dated as of the Funding Date, in substantially the form of Exhibit G-3, among the Irish
Obligors, the Lenders and the Administrative Agent, granting a security interest in the personal Property constituting Collateral thereunder in favor of the Administrative Agent for the benefit of the Lenders.
“Irish Economic Sanctions Laws” means the Financial Transfers Act 1992 and all Irish laws and regulations which implement EU and UN
trade and/or financial sanctions.
“Irish Obligor” means an Obligor incorporated or organized under the laws of Ireland; provided that
upon the completion of the Fitzgerald and Benen Sale, Benen Trading Limited shall no longer be an Irish Obligor hereunder.
“IRS” means the United States Internal Revenue Service or any successor agency, and to the extent relevant, the United States Department
of the Treasury.
- 23 -
“Judgment Currency” has the meaning set forth in Section 13.20.
“Judgment Currency Conversion Date” has the meaning set forth in Section 13.20.
“Key Employee” means an employee engaged in product development or another function with access to significant Obligor Intellectual
Property.
“Konamite” means Konamite Limited, a company organized under the laws of Ireland.
“Laws” means, collectively, all international, foreign, federal, state, provincial, territorial, municipal and local statutes, treaties,
rules, regulations, ordinances, codes and administrative or judicial precedents or authorities, including the interpretation or administration thereof by any Governmental Authority charged with the enforcement, interpretation or administration
thereof, and all applicable administrative orders, directed duties, requests, licenses, authorizations and Permits of, and agreements with, any Governmental Authority, in each case whether or not having the force of law.
“Lenders” has the meaning set forth in the introduction hereto.
“Lien” means any mortgage, lien, pledge, charge or other security interest, or any lease, title retention agreement, mortgage,
restriction, easement, right‑of‑way, option or adverse Claim (of ownership or possession) or other encumbrance of any kind or character whatsoever or any preferential arrangement that has the practical effect of creating a security interest.
“Loan Documents” means, collectively, this Agreement, the Security Documents, any Guarantee Assumption Agreement, the Warrant
Certificates, the Existing Warrant Certificate Amendments, the First Amendment to the Effective Date Warrant Certificate, any intercompany notes and any subordination agreement, intercreditor agreement or other present or future document,
instrument, agreement or certificate delivered to any Lender in connection with this Agreement or any of the other Loan Documents, in each case, as amended, restated, supplemented or otherwise modified.
“Loan Exposure” means, with respect to any Lender, as of any date of determination, the outstanding principal amount of such Lender’s
portion of the Term Loans; provided, at any time prior to the making of the Term Loans, the Loan Exposure of any Lender shall be equal to such Lender’s Commitment.
“Loss” means judgments, debts, liabilities, expenses, costs, damages or losses, contingent or otherwise, whether liquidated or
unliquidated, matured or unmatured, disputed or undisputed, contractual, legal or equitable, including loss of value, reasonable professional fees, including fees and disbursements of legal counsel on a full indemnity basis, and all reasonable
costs incurred in investigating or pursuing any Claim or any proceeding relating to any Claim.
“Luxembourg Subsidiary” means Trinity Biotech Luxembourg SARL.
- 24 -
“Luxembourg Subsidiary Intercompany Subordination Agreement” means that certain Luxembourg Intercompany Subordination Agreement, dated as
of Funding Date, among the Obligors, the Luxembourg Subsidiary and the Administrative Agent on terms and provisions satisfactory to the Administrative Agent.
“Majority Lenders” means, at any time, one or more Lenders having or holding Loan Exposure and representing more than 50% of the
aggregate Loan Exposure of all Lenders.
“Margin Stock” means “margin stock” within the meaning of Regulations U and X.
“Material Adverse Change” and “Material Adverse Effect” mean a material adverse change in or
effect on (a) the business, financial condition, operations, performance or Property of the Obligors taken as a whole, (b) the ability of any Obligor to perform its obligations under any Loan Document as and when they become due, (c) the value of
the Property comprising Collateral (taken as a whole), or (d) the legality, validity, binding effect or enforceability of the Loan Documents or the rights and remedies of any Lender under any of the Loan Documents.
“Material Agreement” means (a) any Contract which is listed in Schedule 7.14, (b) any other Contract to which any Obligor is a party or a
beneficiary from time to time, or to which any assets or properties of any Obligor is bound, the loss or termination of which would reasonably be expected to result in a Material Adverse Effect, (c) the Investor Convertible Note, (d) the Investor
Subordination Agreement and (e) any other Contract to which any Obligor is a party or a guarantor (or equivalent) whether existing as of the Original Closing Date or in the future that during any period of twelve (12) consecutive months is
reasonably expected to (1) result in payments or receipts (including royalty, licensing or similar payments) made to any Obligor in an aggregate amount in excess of $2,500,000 or (2) require payments or expenditures (including royalty, licensing or
similar payments) made by any Obligor in an aggregate amount in excess of $2,500,000; provided that for the avoidance of doubt routine purchase orders entered into in the Ordinary Course of Business shall
not be deemed to be Material Agreements.
“Material Indebtedness” means, at any time, any Indebtedness of any Obligor, the outstanding principal amount of which exceeds $500,000.
“Material Intellectual Property” means all Obligor Intellectual Property, including the Obligor Intellectual Property described in
Schedule 7.05(b) (as such schedule shall be updated by the Obligors from time to time, pursuant to Section 8.01(d)), whether currently owned or licensed, or acquired, developed or otherwise licensed or obtained after the Original Closing Date, (a)
necessary for the operation of the business of any Obligor as currently conducted or as currently contemplated to be conducted, (b) the loss of which would reasonably be expected to have or result in a Material Adverse Effect or (c) that has a fair
market value in excess of $2,500,000 (as such fair market value is determined in the reasonable judgment of the Obligors) but excluding, in each case, WaveForm IP.
- 25 -
“Material WaveForm IP” means all WaveForm IP (a) necessary for the operation of the business of any Obligor as currently conducted or as
currently contemplated to be conducted, (b) the loss of which would reasonably be expected to have or result in a Material Adverse Effect or (c) that has a fair market value in excess of $2,500,000 (as such fair market value is determined in the
reasonable judgment of the Obligors).
“Maturity Date” means the earlier to occur of (a) the Stated Maturity Date and (b) the date on which the Term Loans are accelerated
pursuant to Section 10.02.
“Multiemployer Plan” means any multiemployer plan, as defined in Section 400l(a)(3) of ERISA, to which any ERISA Affiliate incurs or
otherwise has any obligation or liability, contingent or otherwise.
“Net Cash Proceeds” means,
(a) with respect to the incurrence or issuance of any Indebtedness incurred by a Person and not permitted under Section 9.01, the excess, if any, of
(i) the sum of the cash received in connection with such incurrence or issuance over (ii) the investment banking fees, underwriting discounts, commissions, costs and other reasonable expenses and other customary expenses (including reasonable
attorney’s, accountant’s and other similar professional advisor’s fees), incurred by such Person in connection with such incurrence or issuance to third parties (other than any other Obligor or any of their respective Affiliates);
(b) with respect to any Casualty Event, the amount of cash proceeds actually received from time to time by or on behalf of such Obligor after
deducting therefrom only (i) actual costs and expenses related thereto incurred by such Obligor and (ii) Taxes paid or payable in each case, in connection therewith or as a result thereof; and
(c) with respect to any Asset Sale, the excess, if any, of (i) cash proceeds received in respect of such Asset Sale (including cash proceeds
subsequently received (as and when received)) over (ii) the sum of (A) the direct costs of such Asset Sale then payable by the recipient of such proceeds excluding amounts payable to any Obligor or any of its Subsidiaries, (B) Taxes paid or payable
by such recipient in connection therewith or as a result thereof, (C) amounts required to be applied to repay principal, interest and prepayment premiums and penalties on Indebtedness secured by a Permitted Lien on the properties subject to such
Asset Sale and (D) amounts reserved or deposited in escrow with respect to indemnity payments or price adjustments until such amounts are released to the applicable Obligor or any of its Subsidiaries.
“Net Partnership Agreement Proceeds” means the Net Cash Proceeds received from Asset Sales pursuant to Section 9.09(l) net of any
payments of “Contingent Consideration” that are required to be paid by an Obligor pursuant to the Effective Date Acquisition Agreement.
“Net Revenue” means, with respect to any Person, all amounts paid to and received by such Person in the Ordinary Course of Business that,
in accordance with IFRS, would be classified as net revenue.
“Non-EEA Obligor” means an Obligor which is not an EEA Obligor.
- 26 -
“Note” means a promissory note executed and delivered by the Borrowers to any Lender in the form attached hereto as Exhibit C.
“Obligations” means, with respect to any Obligor, all amounts, obligations (including, without limitation, all Warrant Obligations),
liabilities, covenants and duties of every type and description owing by such Obligor to any Lender or any other Indemnified Party hereunder, arising out of, under, or in connection with, any Loan Document, whether direct or indirect (regardless of
whether acquired by assignment), absolute or contingent, due or to become due, whether liquidated or not, now existing or hereafter arising and however acquired, and whether or not evidenced by any instrument for the payment of money, including,
without duplication, (a) the principal amount of the Term Loans, (b) all interest on the Term Loans (including accrued but uncapitalized PIK Interest and interest accruing at the Default Rate), whether or not accruing after the filing of any
petition in bankruptcy or after the commencement of any insolvency, reorganization or similar proceeding, and whether or not a Claim for post‑filing or post‑petition interest is allowed in any such proceeding, (c) any Prepayment Premium and (d)
all other fees, expenses, interest, commissions, charges, costs, disbursements, indemnities and reimbursement of amounts paid and other sums chargeable to such Obligor under any Loan Document (including, without limitation, all unpaid fees and
expenses payable under Section 13.03); provided that with respect to each EEA Obligor the term Obligations shall exclude the Relevant Warrant Obligations; provided further that (and for avoidance of doubt) with respect to each non-EEA Obligor the term Obligations does include, without limitation, the Relevant Warrant Obligations.
“Obligor Intellectual Property” means Intellectual Property owned by or licensed to any of the Obligors.
“Obligors” means, collectively, the Borrowers, each Guarantor and each of their respective successors and permitted assigns.
“OFAC” means the Office of Foreign Assets Control of the United States Department of the Treasury (or any successor thereto).
“Ordinary Course of Business” means, with respect to any Person, the ordinary course of business generally consistent with the Person’s
market or custom and practice (including with respect to nature, scope, magnitude, quantity and frequency).
- 27 -
“Organizational Documents” means (a) with respect to any corporation (other than a corporation organized under the laws of Canada or any
province or territory thereof), its certificate of or articles of incorporation or organization, or memorandum and articles of association, as amended, or constitution, as amended, and its by‑laws, as amended, (b) with respect to any corporation,
company, unlimited liability company, or unlimited liability corporation organized under the laws of Canada or any province or territory thereof, its certificate of incorporation, amalgamation, or continuance, its articles of incorporation,
amalgamation, or continuance, its notice of articles, its articles, and/or any shareholders’ agreement or declaration with respect to it, in each case as amended, as applicable, (c) with respect to any limited partnership, its certificate of
limited partnership, as amended, and its partnership agreement, as amended, (d) with respect to any general partnership, its partnership agreement, as amended, and (e) with respect to any limited liability company, its certificate of formation or
articles of organization, as amended, or its constitution, as amended, and its operating agreement, as amended. In the event any term or condition of this Agreement or any other Loan Document requires any Organizational Document to be certified by
a secretary of state or similar government official, the reference to any such “Organizational Document” shall only be to a document of a type customarily certified by such government official.
“Original Closing Date” means December 15, 2021.
“Original Credit Agreement” has the meaning set forth in the recitals hereto.
“Other Connection Taxes” means, with respect to any Recipient, Taxes imposed as a result of a present or former connection between such
Recipient and the jurisdiction imposing such Tax (other than connections arising solely from such Recipient having executed, delivered, become a party to, performed its obligations under, received payments under, received or perfected a security
interest under, engaged in any other transaction pursuant to or enforced any Loan Document, or sold or assigned an interest in the Term Loans or any Loan Document).
“Other Taxes” means all present or future stamp, court or documentary, intangible, recording, filing or similar Taxes that arise from any
payment made under, from the execution, delivery, performance, enforcement or registration of, from the receipt or perfection of a security interest under, or otherwise with respect to, any Loan Document, except any such Taxes that are Other
Connection Taxes imposed with respect to an assignment (other than an assignment made pursuant to Section 5.03(h)).
“Outstanding Convertible Notes” means those Convertible Notes that remain outstanding after the Funding Date in an aggregate principal
amount not to exceed $275,000 plus accrued and unpaid interest.
“Parent” means Trinity Biotech plc, a company organized under the laws of Ireland (company registration number: 183476).
“Participant” has the meaning set forth in Section 13.05(e).
“Participant Register” has the meaning set forth in Section 13.05(f).
“Partner Agreement” means a written agreement with a Commercial Partner to enter into commercial activities involving any continuous
glucose management product.
“Patents” means all patents and patent applications, including the inventions and improvements described and claimed therein together
with the reissues, divisions, continuations, renewals, extensions and continuations in part thereof, all income, royalties, damages and payments now or hereafter due and/or payable with respect thereto, all damages and payments for past or future
infringements thereof and rights to sue therefor, and all rights corresponding thereto throughout the world, in each case, relating to a Product.
- 28 -
“Payment Date” means the last day of each Interest Period; provided that if such last day of
such Interest Period is not a Business Day, then the Payment Date for such Interest Period will be the next succeeding Business Day.
“PBGC” means the United States Pension Benefit Guaranty Corporation referred to and defined in ERISA and any successor entity performing
similar functions.
“Perceptive” has the meaning set forth in the introduction hereto.
“Periodic Term SOFR Determination Day” has the meaning specified in the definition of “Term SOFR.”
“Permits” means all permits, licenses, registrations, certificates, orders, approvals, authorizations, consents, waivers, franchises,
variances and similar rights issued by or obtained from any Governmental Authority or any other Person, including, without limitation, those relating to Environmental Laws.
“Permitted Acquisition” means any Acquisition by any Obligor or any of their wholly-owned Subsidiaries, by (a) purchase, merger,
amalgamation, plan of arrangement, license or otherwise, of all or substantially all of the assets of, all of the Equity Interests of, or a business line or unit or a division of, any Person or (b) license arrangement for the rights to use,
develop, market or otherwise commercialize any Patents, Trademarks, Copyrights or other Intellectual Property (other than ordinary course, over the counter software license arrangements), including, for the avoidance of doubt, any Partner
Agreement; provided that:
(i) immediately prior to, and immediately after giving effect thereto, no Default or Event of Default shall have occurred and be continuing or
would result therefrom;
(ii) all transactions in connection therewith shall be consummated, in all material respects, in accordance with all applicable Laws and in
conformity in all material respects with all applicable Governmental Approvals;
(iii) in the case of the Acquisition of all of the Equity Interests of such Person, all of the Equity Interests (except for any such securities in
the nature of directors’ qualifying shares required pursuant to applicable Law) acquired, or otherwise issued by such Person or any newly formed Subsidiary of such Obligor in connection with such Acquisition, shall be owned 100% by an Obligor, and
the Obligor shall have taken, or caused to be taken, as of the date such Person becomes a Subsidiary of an Obligor, each of the actions set forth in Section 8.11, if applicable;
- 29 -
(iv) such Person (in the case of an Acquisition of Equity Interests) or assets (in the case of an Acquisition of assets or a division) (A) shall be
engaged or used, as the case may be, in the same business or lines of business in which the Obligors and/or their Subsidiaries are engaged or a business reasonably and substantially related thereto or (B) shall have a similar customer base as the
Borrowers and/or their Subsidiaries;
(v) the Administrative Borrower shall have provided the Administrative Agent with at least ten (10) Business Days’ prior written notice of any such
Acquisition, together with summaries, prepared in reasonable detail, of all due diligence conducted by or on behalf of an Obligor, or the applicable Subsidiary, prior to such Acquisition;
(vi) the Acquisition shall have been approved by the Board or other governing body or controlling Person of the Person acquired or the Person from
whom such assets or division is acquired; and
(vii) on a pro forma basis after giving effect to such Acquisition, the Obligors and their Subsidiaries
shall be in compliance with Section 8.15.
“Permitted Cash Equivalent Investments” means (a) marketable direct obligations issued or unconditionally guaranteed by the United States
or any agency or any State thereof having maturities of not more than two (2) years from the date of acquisition, (b) commercial paper with an average maturity of no more than one (1) year and having the highest rating from either Standard &
Poor’s Ratings Group or Moody’s Investors Service, Inc., (c) any money market funds or other investment vehicles whose principal investments are in investments described in clauses (a) or (b) and (d) certificates of deposit maturing no more than
one (1) year after issue.
“Permitted Indebtedness” means any Indebtedness existing as of the Original Closing Date.
“Permitted Licenses” are (a) licenses of over‑the‑counter software that is commercially available to the public, (b) inbound licenses for
the use of any Patents, Trademarks, Copyrights, Industrial Designs and Technical Information of any third party and (c) non‑exclusive licenses for the use of Obligor Intellectual Property, in each case, entered into in the Ordinary Course of
Business or as otherwise may be approved by the applicable Obligor’s Board and so long as (i) no Event of Default has occurred and is continuing at the time such license is entered into and (ii) such license does not materially impair the Lenders
from exercising their rights under any of the Loan Documents.
“Permitted Liens” means any Liens permitted under Section 9.02.
- 30 -
“Permitted Refinancing” means, with respect to any Indebtedness permitted to be refinanced, extended, renewed or replaced hereunder, any
refinancing, extensions, renewals and replacements of such Indebtedness; provided that such refinancing, extension, renewal or replacement shall not (a) increase the outstanding principal amount of the
Indebtedness, being refinanced, extended, renewed or replaced, (b) contain terms relating to outstanding principal amount, amortization, interest rate or equivalent yield, maturity, collateral security (if any), subordination (if any), or other
material terms that, taken as a whole are less favorable in any material respect to any Obligor and its Subsidiaries or any Lender than the terms of any agreement or instrument governing the Indebtedness being refinanced, and (c) contain any new
requirement to grant any Lien or to give any Guarantee that was not an existing requirement of such Indebtedness.
“Person” means any individual, corporation, company, voluntary association, partnership, limited liability company, unlimited liability
company, unlimited liability corporation, joint venture, trust, unincorporated organization or Governmental Authority or other entity of whatever nature.
“PFIC” has the meaning set forth in Section 8.01(j).
“PIK Interest” shall mean payment‑in‑kind of interest in respect of the Term Loans by increasing the outstanding principal amount of
each Term Loan to which such interest relates by an amount equal to such portion of interest, rather than paying such portion of interest in cash.
“Plan” means any employee pension benefit plan (other than a Multiemployer Plan) subject to the provisions of Title IV of ERISA or
Section 412 of the Code or Section 302 of ERISA, and in respect of which the Borrowers or any ERISA Affiliate is (or, if such plan were terminated, would under Section 4069 of ERISA be deemed to be) an “employer” as defined in Section 3(5) of
ERISA.
“Pledge Agreements” means the U.S. Pledge Agreement and the Canadian Pledge Agreement.
“PPSA” means the Personal Property Security Act (Ontario) and the regulations thereunder, as
from time to time in effect; provided, however, that if by reason of mandatory provisions of law, any or all of the attachment, perfection or priority of the Administrative Agent and/or any Lender’s
security interests in any item or portion of the Collateral are governed by the personal property security laws as in effect in any jurisdiction in Canada other than the laws of the Province of Ontario, then “PPSA”
means those personal property security laws (including the Civil Code of Québec) as in effect in such other jurisdiction in Canada for the purposes of the provisions hereof relating thereto.
“Prepayment Premium” has the meaning set forth in Section 3.03(a).
“Pro Rata Share” has the meaning set forth in Section 11.08.
“Product” means (a) those Devices set forth (and described in reasonable detail) on Schedule 3 attached hereto, and (b) any current or
additional Device subject, as of the date of determination, to any Product Development and Commercialization Activities by any Obligor, including any such Device currently in development. For the avoidance of doubt, separate stock keeping units
(SKUs) by reference to package size or country of sale constitute one Product.
- 31 -
“Product Agreement” means, with respect to any Product, any Contract, license, document, instrument, interest (equity or otherwise) or
the like under which one or more Persons grants or receives (a) any right, title or interest with respect to any Product Development and Commercialization Activities of such Product, or (b) any right to exclude any other Person from engaging in, or
otherwise restricting any right, title or interest as to, any Product Development and Commercialization Activities with respect to such Product, including any Contract with suppliers, manufacturers, distributors, clinical research organizations,
hospitals, group purchasing organizations, wholesalers, pharmacies or any other Person related to such entity.
“Product Assets” means, with respect to any Product, (a) any and all rights, title and interest of the Obligors in any assets relating to
such Product or any Product Development and Commercialization Activities with respect to such Product, (b) all Product Related Information with respect to such Product or any related Product Development and Commercialization Activities, (c) any
Product Agreement related to such Product or any such Product Development and Commercialization Activities, (d) any Intellectual Property, Regulatory Approvals and similar assets with respect to such Product or any such Product Development and
Commercialization Activities, and (e) all rights, title and interests in any other property, tangible or intangible, manifesting or otherwise in respect of such Product or any such Product Development and Commercialization Activities, including,
without limitation, inventory, accounts receivable or similar rights to receive money or payment pertaining thereto and all proceeds of the foregoing.
“Product Authorizations” means any and all Regulatory Approvals (including all applicable IDEs, Device Clearance Applications,
supplements, amendments, governmental price and reimbursement approvals and approvals of applications for regulatory exclusivity), clearances, licenses, notifications, registrations, safety or quality specifications and standards, or any other
authorizations of any applicable Regulatory Authority in each case necessary for the manufacturing, development, distribution, ownership, use, storage, import, export, transport, promotion, marketing, sale or other commercialization of any Product
or for any Product Development and Commercialization Activities with respect thereto in any country or jurisdiction, whether United States or non‑United States.
“Product Development and Commercialization Activities” means, with respect to any Product, any combination of research, development,
manufacture, import, use, sale, licensing, importation, storage, design, labeling, marketing, promotion, supply, distribution, testing, packaging, purchasing or other commercialization activities, receipt of payment in respect of any of the
foregoing (including, without limitation, in respect of licensing, royalty or similar payments), or any similar or other activities the purpose of which is to commercially exploit such Product.
- 32 -
“Product Related Information” means, with respect to any Product, all books, records, lists, ledgers, files, manuals, Contracts,
correspondence, reports, plans, drawings and data (in any form or medium), and all techniques and other know‑how, owned or possessed by the Obligors that are necessary or required for any Product Development and Commercialization Activities
relating to such Product, including (a) brand materials, packaging and other trade dress, customer targeting and other marketing, promotion and sales materials and information, referral, customer, supplier and other contact lists and information,
product, business, marketing and sales plans, research, studies and reports, sales, maintenance and production records, training materials and other marketing, sales and promotional information, (b) clinical data, information included or supporting
any Product Authorization or other Regulatory Approval, any regulatory filings, updates, notices and correspondence (including adverse event and other pharmacovigilance and other post‑marketing reports and information, etc.), technical information,
product development and operational data and records, and all other documents, records, files, data and other information relating to product development, manufacture and use, (c) litigation and dispute records, and accounting records, (d) all
documents, records and files relating to Intellectual Property, including all correspondence from and to third parties (including Intellectual Property counsel and patent, trademark and other Intellectual Property registries, including the United
States Patent and Trademark Office and the Canadian Intellectual Property Office), and (e) all other information, techniques and know‑how necessary or required in connection with the Product Development and Commercialization Activities for any
Product.
“Prohibited Payment” means any bribe, rebate, payoff, influence payment, kickback or other payment or gift of money or anything of value
(including meals or entertainment) made by any Person to any officer, employee or ceremonial office holder of any government or instrumentality thereof, political party or supra‑national organization (such as the United Nations), any political
candidate, any royal family member or any other person who is connected or associated personally with any of the foregoing that is prohibited under any Requirement of Law.
“Projections” means the Confidential - Group EBITDA TO 2025 with Bal Sheet December 2021.
“Property” of any Person means any property or assets, or interest therein, of such Person.
“Proportionate Share” means, with respect to any Lender, the percentage obtained by dividing (a) the Loan Exposure of such Lender then in
effect by (b) the aggregate Loan Exposure of all Lenders then in effect.
“Publicly Reporting Company” means an issuer generally subject to the public reporting requirements of the Exchange Act.
“Qualified Equity Interest” means, with respect to any Person, any Equity Interest of such Person that is not a Disqualified Equity
Interest.
“Qualified Plan” means an employee benefit plan (as defined in Section 3(3) of ERISA) other than a Multiemployer Plan (a) that is or was
at any time maintained or sponsored by any Obligor or any ERISA Affiliate thereof or to which any Obligor or any ERISA Affiliate thereof has ever made, or was ever obligated to make, contributions, and (b) that is intended to be Tax qualified under
Section 401(a) of the Code.
“Recipient” means any Lender or the Administrative Agent or, in the case of the Warrant Indemnified Taxes, the Warrant Holder.
“Redemption Date” has the meaning set forth in Section 3.03(a)(i).
“Redemption Price” has the meaning set forth in Section 3.03(a)(i).
- 33 -
“Referral Source” has the meaning set forth in Section 7.07(b)(i).
“Register” has the meaning set forth in Section 13.05(d).
“Regulation T” means Regulation T of the Board of Governors of the Federal Reserve System, as amended.
“Regulation U” means Regulation U of the Board of Governors of the Federal Reserve System, as amended.
“Regulation X” means Regulation X of the Board of Governors of the Federal Reserve System, as amended.
“Regulatory Approvals” means any Governmental Approval relating to any Product or any Product Development and Commercialization
Activities related to such Product, including any Product Authorizations with respect thereto.
“Regulatory Authority” means any Governmental Authority that is concerned with or has regulatory or supervisory oversight with respect to
any Product or any Product Development and Commercialization Activities relating to any Product, including the FDA, EMA, HPRA, Health Canada, ANVISA, and all equivalent Governmental Authorities, whether United States or non‑United States.
“Relevant ADSs” has the meaning set forth in Section 8.21.
“Relevant Governmental Body” means the Federal Reserve Board and/or the Federal Reserve Bank of New York, or a committee officially
endorsed or convened by the Federal Reserve Board and/or the Federal Reserve Bank of New York or any successor thereto.
“Relevant Warrant Obligations” means the obligations under Section 8.21 (Cashless Exercise of Warrant Certificate and Par Value) and Article 11 (Guarantee) to the extent such obligations relate, directly or indirectly, to a Warrant
Certificate.
“Representatives” has the meaning set forth in Section 13.17.
“Requirement of Law” means, as to any Person, any Law applicable to or binding upon such Person or any of its Properties or revenue.
“Resignation Effective Date” has the meaning set forth in Section 12.06(a).
“Responsible Officer” of any Person means each of the president, chief executive officer, chief financial officer or titles equivalent to
the foregoing.
- 34 -
“Restricted Payment” means any dividend or other distribution (which shall include any management fees) (whether in cash, securities or
other Property) with respect to any Equity Interest of an Obligor or any of its Subsidiaries, or any payment (whether in cash, securities or other Property), including any sinking fund or similar deposit, on account of the purchase, redemption,
retirement, acquisition, cancellation or termination of any Equity Interests of an Obligor or any of its Subsidiaries or any option, warrant or other right to acquire any Equity Interests of an Obligor or any of its Subsidiaries.
“Restrictive Agreement” means any indenture, agreement, instrument or other binding arrangement that prohibits, restricts or imposes any
condition upon (a) the ability of an Obligor or any Subsidiary to create, incur or permit to exist any Lien upon any of its Property (other than (i) customary provisions in Contracts (including without limitation leases and in‑bound licenses of
Intellectual Property) restricting the assignment thereof, (ii) restrictions or conditions imposed by any agreement governing secured Permitted Indebtedness permitted under Section 9.01(h), to the extent that such restrictions or conditions apply
only to the Property securing such Indebtedness and (iii) software and other Intellectual Property licenses pursuant to which an Obligor or a Subsidiary thereof is the licensee of the relevant software or Intellectual Property, as the case may be
(in which case, any prohibition or limitation shall relate only to the assets or rights subject to the applicable license and/or the license itself)), or (b) the ability of any Subsidiary to pay dividends or other distributions with respect to any
shares of its Equity Interests or to make or repay loans or advances to an Obligor or any other Subsidiary or to Guarantee Indebtedness of an Obligor or any other Subsidiary.
“Resolution Authority” means an EEA Resolution Authority or, with respect to any U.K. Financial Institution, a U.K. Resolution Authority.
“Revenue Claim” has the meaning set forth in Section 5.03(i).
“Sanctions” means economic or financial sanctions, requirements or trade embargoes imposed, administered or enforced from time to time by
Governmental Authorities (including, but not limited to, OFAC, the United States Department of State, the United States Department of Commerce, and the government of Canada and respective departments and agencies thereof, including Foreign Affairs,
Trade and Development Canada, and Public Safety Canada).
“Sanctions Laws” means all laws, rules, regulations and requirements of any jurisdiction applicable to the Obligors or any party to the
Loan Documents concerning or relating to Sanctions, terrorism or money laundering.
“SEC” means United States Securities and Exchange Commission.
“Second A&R Credit Agreement” has the meaning set forth in the recitals hereto.
“Second Amendment to Warrant Certificate” means that certain Second Amendment to Warrant Certificate, dated as of the Effective Date, by
and among Parent and Perceptive.
“Securities Account” has the meaning set forth in the U.C.C. and the PPSA, as applicable.
“Security Agreements” means the U.S. Security Agreement, the Canadian Security Agreement and the Irish Debenture.
- 35 -
“Security Documents” means, collectively, the Security Agreements, each Short‑Form IP Security Agreement, the Canadian Intellectual
Property Security Agreements, the Pledge Agreements and each other security document, control agreement or financing statement executed to perfect Liens in favor of the Administrative Agent for the benefit of the Lenders.
“Segregated Health Care Account” means, a Deposit Account of an Obligor in the name of such Obligor and under the sole dominion and
control of such Obligor maintained in accordance with the requirements of Section 8.18(c) hereof, the only funds on deposit in which constitute the direct proceeds of payments made by Federal Health Care Programs.
“Short‑Form IP Security Agreements” means short‑form Copyright, Patent or Trademark (as the case may be) security agreements, dated as of
the Funding Date, in substantially the form of Exhibits H-1 and H-2, entered into by one or more Obligors in favor of the Administrative Agent for the benefit of the Lenders, each in form and substance satisfactory to the Administrative Agent.
“SOFR” means a rate equal to the secured overnight financing rate as administered by the SOFR Administrator.
“SOFR Administrator” means the Federal Reserve Bank of New York (or a successor administrator of the secured overnight financing rate).
“Solvent” means, with respect to any Person at any time, that (a) the present fair saleable value of the Property of such Person is
greater than the total amount of liabilities (including contingent liabilities) of such Person, (b) the present fair saleable value of the Property of such Person is not less than the amount that will be required to pay the probable liability of
such Person on its debts as they become absolute and matured, and (c) such Person: (i) (where such is not an Irish Obligor) has not incurred and does not intend to, and does not believe that it will, incur debts or liabilities beyond such Person’s
ability to pay as such debts and liabilities mature; and (ii) (where such Person is an Irish Obligor) is not “unable to pay its debts” (within the meaning of Section 570 of the Companies Act 2014 of Ireland (as amended)).
“Standard Body” means any of the organizations that create, sponsor or maintain safety, quality or other standards, including ISO, ANSI,
CEN and SCC and the like.
“State” means any state or territory of the United States.
“Stated Maturity Date” means July 27, 2026; provided that if any such date shall occur on a day
that is not a Business Day, then the Stated Maturity Date shall be the immediately succeeding Business Day.
“Subsidiary” means, with respect to any Person (the “parent”) at any time of determination, any
other Person of which more than 50% of the outstanding capital stock of such other Person having ordinary voting powers, determined on a fully diluted basis, is at the time directly or indirectly owned or Controlled by the parent. Unless the
context otherwise specifically requires, the term “Subsidiary” shall be a reference to a Subsidiary of an Obligor.
- 36 -
“Swedish Subsidiaries” means Fiomi Diagnostics Holding AB and Fiomi Diagnostics AB.
“Sweep Agreement” means an agreement, in form and substance reasonably satisfactory to Agent, between the Obligor maintaining a
Segregated Health Care Account, Administrative Agent and applicable bank or other financial institution at which such Segregated Health Care Account is maintained, pursuant to which such bank or financial institution (i) agrees to automatically
sweep amounts deposited in such Segregated Health Care Account to another account of an Obligor subject to a tri-party account control agreement in favor of Administrative Agent satisfying the requirements set forth in Section 8.18(c) hereof, as
and when funds clear and become available in accordance with such bank’s or financial institution’s standard practices and procedures, and (ii) agrees not to change such standing sweep instructions until the date at least five (5) days (or such
lesser period as Administrative Agent may agree in its sole discretion or as may be required by applicable Federal Health Care Program laws or policies after receipt of notice from such Obligor maintaining such Segregated Health Care Account by
Administrative Agent and such bank or financial institution of the termination of such standing sweep instruction).
“Taxes” means all present or future taxes, levies, imposts, duties, (including stamp duties), deductions, withholdings (including backup
withholding), assessments, fees or other charges imposed by any Governmental Authority, including any interest, additions to tax or penalties applicable thereto.
“Technical Information” means all trade secrets and other proprietary or confidential information, which may include any proprietary
information of a scientific, technical, or business nature in any form or medium, standards and specifications, conceptions, ideas, innovations, discoveries, Invention disclosures, all documented research, developmental, demonstration or
engineering work, data, plans, specifications, reports, summaries, experimental data, manuals, models, samples, know‑how, technical information, systems, methodologies, computer programs or information technology.
“Term Loans” means collectively, the Funding Date Term Loan, the Tranche B Term Loan, the Effective Date Term Loan, the Delayed Draw Term
Loan, the Third Amendment Term Loan, the Fourth Amendment Term Loan and the Fifth Amendment Term Loan.
“Term SOFR” means the Term SOFR Reference Rate for a tenor comparable to the applicable Interest Period on the day (such day, the
“Periodic Term SOFR Determination Day”) that is two (2) U.S. Government Securities Business Days prior to the first day of such Interest Period, as such rate is published by the Term SOFR Administrator; provided,
however, that if as of 5:00 p.m. (New York City time) on any Periodic Term SOFR Determination Day the Term SOFR Reference Rate for the applicable tenor has not been published by the Term SOFR Administrator
and a Benchmark Replacement Date with respect to the Term SOFR Reference Rate has not occurred, then Term SOFR will be the Term SOFR Reference Rate for such tenor as published by the Term SOFR Administrator on the first preceding U.S. Government
Securities Business Day for which such Term SOFR Reference Rate for such tenor was published by the Term SOFR Administrator so long as such first preceding U.S. Government Securities Business Day is not more than three (3) U.S. Government
Securities Business Days prior to such Periodic Term SOFR Determination Day; provided, further, Term SOFR shall be rounded upwards to the next 1/100% (if
necessary), provided, further, however; if Term SOFR as so determined shall ever be less than the Floor, then Term SOFR shall be deemed to be the Floor.
- 37 -
“Term SOFR Administrator” means CME Group Benchmark Administration Limited (CBA) (or a successor administrator of the Term SOFR Reference
Rate selected by the Administrative Agent in its reasonable discretion).
“Term SOFR Reference Rate” means the forward-looking term rate based on SOFR.
“Third A&R Credit Agreement” has the meaning set forth in the recitals hereto.
“Third Amendment Restatement Date” means December 23, 2024.
“Third Amendment Term Loan” means the loan advanced by a Lender pursuant to Section 2.01(e). For purposes of clarification, any
calculation of the aggregate outstanding principal amount of the Third Amendment Term Loan on any date of determination shall mean the aggregate principal amount of the Third Amendment Term Loan made pursuant to Section 2.01(e) that has not yet
been repaid as of such date.
“Third Amendment Term Loan Borrowing Notice” means a notice substantially in the form attached
hereto as Exhibit O.
“Third Amendment Warrant Certificate” means the Warrant, dated as of the Third Amendment Restatement Date, that, among other things,
grants the holder thereof the right to purchase the number of American Depositary Shares (represented by American Depositary Receipts) of Parent as indicated on the Warrant Shares table on Schedule 1.
“Third Amendment to Warrant Certificate” means that certain Third Amendment to Warrant Certificate, dated as of the Third Amendment
Restatement Date, by and among Parent and Perceptive.
“Title IV Plan” means an employee benefit plan (as defined in Section 3(3) of ERISA) other than a Multiemployer Plan (a) that is or was
at any time during the six year period ending on the Funding Date maintained or sponsored by any Obligor or any ERISA Affiliate thereof or to which any Obligor or any ERISA Affiliate thereof has ever made, or was obligated to make, contributions,
and (b) that is or was subject to Section 412 of the Code, Section 302 of ERISA or Title IV of ERISA.
“Trademarks” means all trade names, trademarks and service marks, logos, trademark and service mark registrations, and applications for
trademark and service mark registrations, including all renewals of trademark and service mark registrations, all rights to recover for all past, present and future infringements thereof and all rights to sue therefor, and all rights corresponding
thereto throughout the world, together, in each case, with the product lines and goodwill of the business connected with the use thereof (excluding any application for registration of a trademark filed on an intent to use basis solely to the extent
that the grant of a security interest in any such trademark application would materially adversely affect the validity or enforceability of the resulting trademark registration or result in cancellation of such trademark application).
- 38 -
“Tranche B Term Loan” means the loan advanced by a Lender pursuant to Section 2.01(b). For purposes of clarification, any calculation of
the aggregate outstanding principal amount of the Tranche B Term Loan on any date of determination shall mean the aggregate principal amount of the Tranche B Term Loan made pursuant to Section 2.01(b) that has not yet been repaid as of such date.
“Tranche B Term Loan Borrowing Date” means February 21, 2023.
“Transactions” means the execution, delivery and performance by each Obligor of this Agreement and the other Loan Documents to which such
Obligor is a party, the consummation of the Effective Date Acquisition and the other transactions contemplated hereby and thereby, including disbursement and application of the proceeds of the Term Loans.
“U.C.C.” means the Uniform Commercial Code as in effect in the State of New York; provided, however,
that if by reason of mandatory provisions of law, any or all of the attachment, perfection or priority of the Administrative Agent’s security interest in any item or portion of the Collateral is governed by the Uniform Commercial Code as in effect
in a jurisdiction other than the State of New York, the term “U.C.C.” means the Uniform Commercial Code as in effect in such other jurisdiction for purposes of the provisions hereof relating to such
attachment, perfection or priority and for purposes of definitions relating to such provisions.
“U.K. Financial Institution” means any BRRD Undertaking (as such term is defined under the PRA Rulebook (as amended from time to time)
promulgated by the United Kingdom Prudential Regulation Authority) or any person falling within IFPRU 11.6 of the FCA Handbook (as amended from time to time) promulgated by the United Kingdom Financial Conduct Authority, which includes certain
credit institutions and investment firms, and certain affiliates of such credit institutions or investment firms.
“U.K. Resolution Authority” means the Bank of England or any other public administrative authority having responsibility for the
resolution of any U.K. Financial Institution.
“U.K. Subsidiary” means Trinity Biotech (UK) Limited.
“Unadjusted Benchmark Replacement” means the applicable Benchmark Replacement excluding the related Benchmark Replacement Adjustment.
“Unrestricted Cash” means the balance of unencumbered cash (other than cash encumbered by the Liens granted to the Lenders pursuant to
the Loan Documents) and Permitted Cash Equivalent Investments (which for greater certainty shall not include any undrawn credit lines), in each case, to the extent held in a Controlled Account.
“U.S.” means the United States of America.
- 39 -
“U.S. Biopool” has the meaning set forth in the introduction hereto.
“U.S. Clark” has the meaning set forth in the introduction hereto.
“U.S. Fitzgerald” means Fitzgerald Industries International, Inc., a Delaware corporation.
“U.S. Government Securities Business Day” means any day except for (a) a Saturday, (b) a Sunday or (c) a day on which the Securities
Industry and Financial Markets Association recommends that the fixed income departments of its members be closed for the entire day for purposes of trading in United States government securities.
“U.S. Holdings” has the meaning set forth in the introduction hereto.
“U.S. Immco” has the meaning set forth in the introduction hereto.
“U.S. MarDx” has the meaning set forth in the introduction hereto.
“U.S. Person” means a “United States person” within the meaning of Section 7701(a)(30) of the Code.
“U.S. Primus” has the meaning set forth in the introduction hereto.
“U.S. Pledge Agreement” means the U.S. Pledge Agreement, dated as of the Funding Date, among Parent, the Lenders and the Administrative
Agent, pledging 100% of the Equity Interests in U.S. Holdings in favor of the Administrative Agent for the benefit of the Lenders.
“U.S. Security Agreement” means the U.S. Security Agreement, dated as of the Funding Date, in substantially the form of Exhibit G-1 among
the Borrowers, the Lenders and the Administrative Agent, granting a security interest in the personal Property constituting Collateral thereunder in favor of the Administrative Agent for the benefit of the Lenders.
“U.S. Tax Compliance Certificate” has the meaning set forth in Section 5.03(f)(ii)(B)(3).
“U.S. TRIB” has the meaning set forth in the introduction hereto.
“Warrant Certificates” means the Effective Date Warrant Certificate, the Third Amendment Warrant Certificate and the Existing Warrant
Certificate.
“Warrant Indemnified Taxes” means any Indemnified Taxes payable or paid by the Warrant Holder or required to be withheld or deducted from
a payment to Warrant Holder and/or any reasonable costs and expenses arising therefrom or with respect thereto (including, but not limited to, any costs arising from a dispute with the relevant Government Authority in respect of such Indemnified
Taxes) in each case to the extent it relates to the grant of a Warrant Certificate to the Warrant Holder and/or the exercise of a Warrant Certificate by a Warrant Holder and/or the issue of the American Depositary Receipts and/or American
Depositary Shares to any Warrant Holder in accordance with a Warrant Certificate.
- 40 -
“Warrant Holder” means the person or entity to whom a Warrant Certificate is issued, or any transferee or assignee thereof (to the extent
such transfer is permitted by the applicable Warrant Certificate).
“Warrant Obligations” means, with respect to Parent, all of its Obligations arising out of, under or in connection with, the Warrant
Certificates.
“Warrant Stamp Amount” means an amount denominated in EUR (€) credited to the client account of Irish counsel to the Administrative Agent
on the date of execution of the Third Amendment Warrant Certificate by any one or more of the Non-EEA Obligors out of its (or their) existing cash resources (being cash other than cash borrowed pursuant to the terms of this Agreement), which amount
(the source of which shall not require verification, assessment or confirmation by or from the Administrative Agent) shall be sufficient to discharge the Irish stamp duty liability due upon execution of the Third Amendment Warrant Certificate (as
such liability is agreed between the Administrative Agent and the Administrative Borrower on such dates).
“WaveForm” means WaveForm Technologies, Inc., a Delaware corporation.
“WaveForm Holdings” means WaveForm Holdings, LLC, a Delaware limited liability company.
"WaveForm IP” means Intellectual Property acquired pursuant to the Effective Date Acquisition.
"Waveform Slovenia Side Agreement” means that certain WaveForm Side Agreement, dated as of the date hereof, among WaveForm, WaveForm
Slovenia and U.S. TRIB.
“WaveForm Slovenia” means Waveform EU d.o.o., a Slovenian company.
“WHO” means the World Health Organization and any successor thereto.
“Withdrawal Liability” means, at any time, any liability incurred (whether or not assessed) by any ERISA Affiliate and not yet satisfied
or paid in full at such time with respect to any Multiemployer Plan pursuant to Section 4201 of ERISA.
“Write‑Down and Conversion Powers” means, (a) with respect to any EEA Resolution Authority, the write‑down and conversion powers of such
EEA Resolution Authority from time to time under the Bail‑In Legislation for the applicable EEA Member Country, which write‑down and conversion powers are described in the EU Bail‑In Legislation Schedule and (b) with respect to the United Kingdom,
any powers of the applicable Resolution Authority under the Bail-In Legislation to cancel, reduce, modify or change the form of a liability of any U.K. Financial Institution or any contract or instrument under which that liability arises, to
convert all or part of that liability into shares, securities or obligations of that person or any other person, to provide that any such Contract or instrument is to have effect as if a right had been exercised under it or to suspend any
obligation in respect of that liability or any of the powers under that Bail-In Legislation that are related to or ancillary to any of those powers.
- 41 -
Section 1.02. Accounting Terms and Principles.
All accounting determinations required to be made pursuant hereto shall, unless expressly otherwise provided herein, be made substantially in accordance with IFRS. If, after the date hereof, any change occurs in IFRS or in the application thereof
(an “Accounting Change”) and such change would cause any amount required to be determined for the purposes of the covenants to be maintained or calculated pursuant
to Article 8 or 9 to be materially different than the amount that would be determined prior to such change, then the Administrative Borrower will provide a detailed notice of such change (an “Accounting Change
Notice”) to the Administrative Agent in conjunction with the next required delivery of financial statements pursuant to Section 8.01. If the Administrative Borrower requests an amendment to any provision hereof to eliminate the effect of
any Accounting Change occurring after the Fifth Amendment Restatement Date or in the application thereof on the operation of such provision, regardless of whether any Accounting Change Notice is given before or after such Accounting Change or in
the application thereof, then the Administrative Agent and the Administrative Borrower agree that they will negotiate in good faith amendments to the provisions of this Agreement that are directly affected by such Accounting Change with the intent
of having the respective positions of the Administrative Agent and the Administrative Borrower after such Accounting Change conform as nearly as possible to their respective positions as of the date of this Agreement and, until any such amendments
have been agreed upon, (i) the provisions in this Agreement shall be calculated as if no such Accounting Change had occurred and (ii) the Administrative Borrower shall provide to the Administrative Agent a written reconciliation in form and
substance reasonably satisfactory to the Administrative Agent, between calculations of any baskets and other requirements hereunder before and after giving effect to such Accounting Change.
All components of financial calculations made to determine compliance with this Agreement shall be adjusted to include or exclude, as the case may be, without duplication, such
components of such calculations attributable to any Acquisition or disposition of assets consummated after the first day of the applicable period of determination and prior to the end of such period, as determined in good faith by the
Administrative Borrower based on assumptions expressed therein and that were reasonable based on the information available to the Administrative Borrower at the time of preparation of the Compliance Certificate setting forth such calculations.
Section 1.03. Interpretation. For all
purposes of this Agreement, except as otherwise expressly provided herein or unless the context otherwise requires, (a) the terms defined in this Agreement include the plural as well as the singular and vice versa; (b) words importing gender
include all genders; (c) any reference to a Section, Article, Annex, Schedule or Exhibit refers to a Section or Article of, or Annex, Schedule or Exhibit to, this Agreement; (d) any reference to “this Agreement” refers to this Agreement, including
all Annexes, Schedules and Exhibits hereto, and the words herein, hereof, hereto and hereunder and words of similar import refer to this Agreement and its Annexes, Schedules and Exhibits as a whole and not to any particular Section, Article, Annex,
Schedule, Exhibit or any other subdivision; (e) references to days, months and years refer to calendar days, months and years, respectively; (f) all references herein to “include” or “including” shall be deemed to be followed by the words “without
limitation”; (g) the word “from” when used in connection with a period of time means “from and including” and the word “until” means “to but not including”; and (h) accounting terms not specifically defined herein shall be construed substantially
in accordance with IFRS (except for the term “property,” which shall be interpreted as broadly as possible, including, in any case, cash, securities, other assets, rights under contractual obligations and Permits and any right or interest in any
property, except where otherwise noted). Unless otherwise expressly provided herein, references to Organizational Documents, agreements (including the Loan Documents) and other contractual instruments shall be deemed to include all subsequent
amendments, restatements, extensions, supplements and other modifications thereto permitted by the Loan Documents.
- 42 -
Section 1.04. Divisions. For all
purposes under the Loan Documents, in connection with any division or plan of division under Delaware law (or any comparable event under a different jurisdiction’s laws): (a) if any asset, right, obligation or liability of any Person becomes the
asset, right, obligation or liability of a different Person, then it shall be deemed to have been transferred from the original Person to the subsequent Person and (b) if any new Person comes into existence, such new Person shall be deemed to have
been organized on the first date of its existence by the holders of its Equity Interests at such time.
Section 1.05. Interest Rates. The
Administrative Agent does not warrant or accept responsibility for, and shall not have any liability with respect to (a) the continuation of, administration of, submission of, calculation of or any other matter related to the Term SOFR Reference
Rate, Term SOFR, or any component definition thereof or rates referred to in the definition thereof, or any alternative, successor or replacement rate thereto (including any Benchmark Replacement), including whether the composition or
characteristics of any such alternative, successor or replacement rate (including any Benchmark Replacement) will be similar to, or produce the same value or economic equivalence of, or have the same volume or liquidity as, the Term SOFR Reference
Rate, Term SOFR or any other Benchmark prior to its discontinuance or unavailability, or (b) the effect, implementation or composition of any Conforming Changes. The Administrative Agent and its affiliates or other related entities may engage in
transactions that affect the calculation of the Term SOFR Reference Rate, Term SOFR, any alternative, successor or replacement rate (including any Benchmark Replacement) or any relevant adjustments thereto, in each case, in a manner adverse to the
Borrowers. The Administrative Agent may select information sources or services in its reasonable discretion to ascertain the Term SOFR Reference Rate, Term SOFR or any other Benchmark, in each case pursuant to the terms of this Agreement, and
shall have no liability to the Borrowers, any Lender or any other person or entity for damages of any kind, including direct or indirect, special, punitive, incidental or consequential damages, costs, losses or expenses (whether in tort, contract
or otherwise and whether at law or in equity), for any error or calculation of any such rate (or component thereof) provided by any such information source or service.
(a) Funding Date Term Loan.
(i) On the Funding Date, the Funding Date Term Loan was made to the Borrowers pursuant to Section 2.01(a) of the Original Credit Agreement.
- 43 -
(ii) Subject to Section 3.03, all amounts owed hereunder with respect to the Funding Date Term Loan shall be paid in full no later than the
Maturity Date.
(b) Tranche B Term Loan.
(i) On the Tranche B Term Loan Borrowing Date, the Tranche B Term Loan was made to the Borrowers pursuant to Section 2.01(b) of the Original
Credit Agreement.
(ii) Subject to Section 3.03, all amounts owed hereunder with respect to the Tranche B Term Loan shall be paid in full no later than the Maturity
Date.
(c) Effective Date Term Loan.
(i) On the Effective Date, the Effective Date Term Loan was made to the Borrowers pursuant to Section 2.01(c) of the Second A&R Credit
Agreement.
(ii) Subject to Section 3.03, all amounts owed hereunder with respect to the Effective Date Term Loan shall be paid in full no later than the
Maturity Date.
(d) Delayed Draw Term Loan.
(i) On the Delayed Draw Term Loan Borrowing Date, the Delayed Draw Term Loan was made to the Borrowers pursuant to Section 2.01(d) of the Second
A&R Credit Agreement.
(ii) Subject to Section 3.03, all amounts owed hereunder with respect to the Delayed Draw Term Loan shall be paid in full no later than the
Maturity Date.
(e) Third Amendment Term Loan.
(i) On the Third Amendment Restatement Date, the Third Amendment Term Loan was made to the Borrowers pursuant to Section 2.01(e) of the Third
A&R Credit Agreement.
(ii) Subject to Section 3.03, all amounts owed hereunder with respect to the Third Amendment Term Loan shall be paid in full no later than the
Maturity Date.
(f) Fourth Amendment Term Loan.
(iii) On the Fourth Amendment Restatement Date, the Fourth Amendment Term Loan was made to the Borrowers pursuant to Section 2.01(f) of the Fourth
A&R Credit Agreement.
- 44 -
(iv) Subject to Section 3.03, all amounts owed hereunder with respect to the Fourth Amendment Term Loan shall be paid in full no later than the
Maturity Date.
(g) Fifth Amendment Term Loan.
(i) Subject to the terms and conditions of this Agreement and relying on the representations and warranties set forth herein, each Lender,
severally and not jointly, agrees to provide its share of the Fifth Amendment Term Loan to the Borrowers on the Fifth Amendment Restatement Date in Dollars in a principal amount equal to such Lender’s Fifth Amendment Term Loan Commitment. No
Lender shall have an obligation to make a Fifth Amendment Term Loan in excess of such Lender’s Fifth Amendment Term Loan Commitment.
(ii) The Borrowers may make one Borrowing under the Fifth Amendment Term Loan Commitment which shall be on the Fifth Amendment Restatement Date.
Subject to Section 3.03, all amounts owed hereunder with respect to the Fifth Amendment Term Loan shall be paid in full no later than the Maturity Date. Each Lender’s Fifth Amendment Term Loan Commitment shall terminate immediately and without
further action on the Fifth Amendment Restatement Date after giving effect to the funding of such Lender’s Fifth Amendment Term Loan Commitment.
(iii) Subject to the terms and conditions of this Agreement (including Section 6.01), the Administrative Borrower shall deliver to the
Administrative Agent a fully executed Fifth Amendment Term Loan Borrowing Notice no later than 5 p.m. (New York City time) at least one (1) Business Day in advance of the Fifth Amendment Restatement Date.
(h) Certain Acknowledgements. Each Obligor acknowledges that as of May 12, 2025, the aggregate
outstanding principal amount of the Term Loans prior to giving effect to the Fifth Amendment Term Loan, but including all accrued and capitalized PIK Interest on such date was equal to $83,290,457.45. The amounts in this clause (h) do not include
fees, expenses and other amounts that are chargeable or otherwise reimbursable under the Loan Documents.
Any principal amount of the Term Loans borrowed under Section 2.01(a), Section 2.01(b), Section 2.01(c), Section 2.01(d), Section 2.01(e), Section 2.01(f) and Section 2.01(g) hereof and
subsequently repaid or prepaid may not be reborrowed.
Section 2.02. Proportionate Shares.
Each Term Loan shall be made, and all participations purchased, by the Lenders simultaneously and proportionately to their respective Proportionate Shares, it being understood that no Lender shall be responsible for any default by any other Lender
in such other Lender’s obligation to make a Term Loan hereunder or purchase a participation required hereby nor shall the Commitment of any Lender be increased or decreased as a result of a default by any other Lender in such other Lender’s
obligation to make a Term Loan requested hereunder or purchase a participation required hereby.
- 45 -
Section 2.04. Notes. Upon the request
of any Lender, the Borrowers shall prepare, execute and deliver to such Lender one or more Notes evidencing the portion of the Term Loans payable to such Lender (or if requested by it, to it and its registered assigns).
Section 2.05. Use of Proceeds. The
Borrowers shall use the proceeds of the Effective Date Term Loan, (a) to fund the Effective Date Acquisition, (b) to pay, in accordance with the funds flow attached to the Effective Date Term Loan Borrowing Notice, fees, costs and expenses incurred
in connection with this Agreement and (c) for general corporate purposes permitted herein. The Borrowers shall use the proceeds of the Delayed Draw Term Loan, (a) for general corporate purposes permitted herein and (b) to pay, in accordance with
the funds flow attached to the Delayed Draw Term Loan Borrowing Notice, fees, costs and expenses incurred in connection with the applicable Borrowing. The Borrowers shall use the proceeds of the Third Amendment Term Loan for general corporate
purposes permitted herein. The Borrowers shall use the proceeds of the Fifth Amendment Term Loan for general corporate purposes permitted herein.
Section 3.01. Repayment. There will be
no scheduled repayments of principal on the Term Loans prior to the Maturity Date. The entire outstanding principal amount of the Term Loans (including accrued and uncapitalized PIK Interest on the Term Loans), together with all accrued and unpaid
interest thereon, will be due and payable on the Maturity Date.
(a) Interest Generally. The Borrowers agree to pay to the Lenders interest in cash on the outstanding
principal amount of the Term Loans for each Interest Period at a rate per annum equal to the sum of (i) Term SOFR plus (ii) the Applicable Margin provided that interest payable on the Term Loans for the
Interest Periods of September 2024, October 2024, November 2024, December 2024, January 2025, February 2025, March 2025, April 2025, May 2025 and June 2025 shall be paid on the applicable Payment Date as PIK Interest.
(b) Term SOFR Conforming Changes. In connection with the use or administration of Term SOFR, the
Administrative Agent will have the right to make Conforming Changes from time to time and, notwithstanding anything to the contrary herein or in any other Loan Document, any amendments implementing such Conforming Changes will become effective
without any further action or consent of any other party to this Agreement or any other Loan Document. The Administrative Agent will promptly notify the Administrative Borrower and the Lenders of the effectiveness of any Conforming Changes in
connection with the use or administration of Term SOFR.
- 46 -
(c) Effect of Benchmark Transition Event.
(i) Benchmark Replacement. Notwithstanding anything to the contrary herein or in any other Loan
Document, if a Benchmark Transition Event and its related Benchmark Replacement Date have occurred prior to any setting of the then‑current Benchmark, then (x) if a Benchmark Replacement is determined in accordance with clause (a) of the definition
of “Benchmark Replacement” for such Benchmark Replacement Date, such Benchmark Replacement will replace such Benchmark for all purposes hereunder and under any Loan Document in respect of such Benchmark setting and subsequent Benchmark settings
without any amendment to, or further action or consent of any other party to, this Agreement or any other Loan Document and (y) if a Benchmark Replacement is determined in accordance with clause (b) of the definition of “Benchmark Replacement” for
such Benchmark Replacement Date, such Benchmark Replacement will replace such Benchmark for all purposes hereunder and under any Loan Document in respect of any Benchmark setting at or after 5:00 p.m. (New York City time) on the fifth (5th)
Business Day after the date notice of such Benchmark Replacement is provided to the Lenders without any amendment to, or further action or consent of any other party to, this Agreement or any other Loan Document so long as the Administrative Agent
has not received, by such time, written notice of objection to such Benchmark Replacement from Lenders comprising the Majority Lenders.
(ii) Benchmark Replacement Conforming Changes. In connection with the implementation of a Benchmark
Replacement, the Administrative Agent will have the right to make Benchmark Replacement Conforming Changes from time to time and, notwithstanding anything to the contrary herein or in any other Loan Document, any amendments implementing such
Benchmark Replacement Conforming Changes will become effective without any further action or consent of any other party to the Loan Documents.
(iii) Notices; Standards for Decisions and Determinations. The Administrative Agent will promptly notify
the Administrative Borrower and the Lenders of (x) the implementation of any Benchmark Replacement and (y) the effectiveness of any Benchmark Replacement Conforming Changes in connection with the use, administration, adoption or implementation of a
Benchmark Replacement. Any determination, decision or election that may be made by the Administrative Agent or the Lenders pursuant to this Section 3.02(c) including any determination with respect to a tenor, rate or adjustment or of the
occurrence or non‑occurrence of an event, circumstance or date and any decision to take or refrain from taking any action, will be conclusive and binding absent manifest error and may be made in its or their sole discretion and without consent from
any other party hereto, except, in each case, as expressly required pursuant to this Section 3.02(c).
- 47 -
(iv) Unavailability of Tenor of Benchmark. Notwithstanding anything to the contrary herein or in any
other Loan Document, at any time (including in connection with the implementation of a Benchmark Replacement), (x) if the then‑current Benchmark is a term rate (including the Term SOFR Reference Rate) and either (A) any tenor for such Benchmark is
not displayed on a screen or other information service that publishes such rate from time to time as selected by the Administrative Agent in its reasonable discretion or (B) the regulatory supervisor for the administrator of such Benchmark has
provided a public statement or publication of information announcing that any tenor for such Benchmark is not or will not be representative, then the Administrative Agent may modify the definition of “Interest Period” (or any similar or analogous
definition) for any Benchmark settings at or after such time to remove such unavailable or non‑representative tenor and (y) if a tenor that was removed pursuant to clause (x) above either (A) is subsequently displayed on a screen or information
service for a Benchmark (including a Benchmark Replacement) or (B) is not, or is no longer, subject to an announcement that it is not or will not be representative for a Benchmark (including a Benchmark Replacement), then the Administrative Agent
may modify the definition of “Interest Period” (or any similar or analogous definition) for all Benchmark settings at or after such time to reinstate such previously removed tenor
(d) Default Interest. Notwithstanding the foregoing, upon the occurrence and during the continuance of
any Event of Default, the Applicable Margin shall increase automatically by 3.00% per annum (the interest rate, as increased pursuant to this Section 3.02(c), being the, the “Default Rate”).
Notwithstanding any other provision herein, if interest is required to be paid at the Default Rate, it shall also be paid entirely in cash. If any Obligation is not paid when due (giving effect to any applicable grace period) under the applicable
Loan Document, the amount thereof shall accrue interest at a rate equal to 3.00% per annum (without duplication of interest payable at the Default Rate). Payment or acceptance of the increased rates of interest provided for in this Section 3.02(c)
is not a permitted alternative to timely payment and shall not constitute a waiver of any Default or otherwise prejudice or limit any rights or remedies of the Administrative Agent or any Lender.
(e) Payment Dates. Accrued interest on the Term Loans shall be payable in arrears on each Payment Date
with respect to the most recently completed Interest Period in cash (other than PIK Interest), and upon the payment or prepayment of the Term Loans (on the principal amount being so paid or prepaid); provided
that interest payable at the Default Rate shall be payable from time to time on demand by the Majority Lenders. PIK Interest on the Term Loans shall be capitalized and added to the outstanding principal amount of the Term Loans by increasing the
outstanding principal amount of each Term Loan to which such interest relates on each Payment Date with respect to the most recently completed Interest Period.
- 48 -
(f) Maximum Rate; Interest at a Criminal Rate. Notwithstanding any other provision of this Agreement, in
no event will any interest or rates referred to herein exceed the maximum interest rate permitted by applicable Law. If such maximum interest rate would be exceeded by the terms hereof, the rates of interest payable hereunder will be reduced to
the extent necessary so that such rates (together with any fees or other amounts which are construed by a court of competent jurisdiction to be interest or in the nature of interest) equal the maximum interest rate permitted by applicable Law and
any overpayment of interest received by the Lenders before such rates are so construed will be applied, forthwith after determination of such overpayment, to pay all then outstanding interest, and thereafter to pay outstanding principal. Without
limiting the generality of the foregoing, in the event that any provision of this Agreement or any other Loan Document would oblige any Obligor to make any payment of interest or any other payment which is
construed by a court of competent jurisdiction to be interest in an amount or calculated at a rate which would result in a receipt by any of the Administrative Agent or any Lender of interest at a criminal rate (as such terms are construed under
the Criminal Code (Canada)), then notwithstanding such provision, such amount or rate shall be deemed to have been adjusted nunc pro tunc to the maximum amount or
rate of interest, as the case may be, as would not so result in a receipt by the Lender of interest at a criminal rate, such adjustment to be effected, to the extent necessary as follows:
(i) first, by reducing the amount or rate of interest required to be paid under this Agreement or such other Loan Document; and
(ii) thereafter, by reducing any fees, commissions, premiums or other amounts required to be paid which would constitute interest for the purposes
of Section 347 of the Criminal Code (Canada).
If, notwithstanding the provisions immediately above and after giving effect to all adjustments contemplated thereby, any of the Administrative Agent or any Lender shall have
received an amount in excess of the maximum permitted by Law, then such excess shall be applied to the reduction of the balance of outstanding principal and not to the payment of interest, or if such excessive interest exceeds such principal
balance, such excess shall be refunded to the Obligor, as applicable.
(g) Interest Act (Canada). For the purposes of the Interest Act (Canada) and
disclosure under such Act only:
(i) wherever interest to be paid under this Agreement is to be calculated on the basis of any period of time that is less than a calendar year (a
"deemed year"), such rate of interest shall be expressed as a yearly rate by multiplying such rate of interest for the deemed year by the actual number of days in the calendar year in which the rate is to be
ascertained and dividing it by the number of days in the deemed year; and
- 49 -
(ii) each Obligor confirms that it fully understands and is able to calculate the rate of interest applicable to each of the credit facilities
made available hereunder based on the methodology for calculating per annum rates provided for in this Agreement. The Administrative Agent agrees that, if requested in writing by the Administrative Borrower, it shall calculate the nominal and
effective per annum rate of interest on any advance outstanding hereunder at any time and provide such information to the Administrative Borrower promptly following such request; provided that any error in
any such calculation, or any failure to provide such information on request, shall not relieve any Obligor of any of its obligations under this Agreement or any other Loan Document, nor result in any liability to the Administrative Agent. Each
Obligor hereby irrevocably agrees not to plead or assert, whether by way of defense or otherwise, in any proceeding relating to the Loan Documents, that the interest payable under the Loan Documents and the calculation thereof has not been
adequately disclosed to the Obligors, whether pursuant to Section 4 of the Interest Act (Canada) or any other applicable law or legal principle.
(a) Optional Prepayments.
(i) The Borrowers shall have the right to optionally prepay in whole or in part (in a minimum amount of $500,000 and integral multiples of
$100,000 in excess of that amount for each partial prepayment, or, if less, the entire outstanding principal amount of the Term Loans) the outstanding principal amount of the Term Loans on any Business Day (a “Redemption
Date”) for an amount equal to the sum of (x) the aggregate principal amount of the Term Loans being prepaid, (y) the applicable Prepayment Premium in respect of the aggregate principal amount of the Term Loans being prepaid and (z) any
accrued but unpaid interest in respect of the aggregate principal amount of the Term Loans being prepaid (such aggregate amount, the “Redemption Price”). The applicable “Prepayment
Premium” shall be an amount calculated pursuant to Section 3.03(a)(ii).
(ii) If the Redemption Date occurs:
(A) after the first anniversary of the Funding Date and on or prior to the second anniversary of the Funding Date, the Prepayment Premium shall be an
amount equal to four and one-half percent (4.5%) of the aggregate outstanding principal amount of the Term Loans being prepaid on such Redemption Date;
(B) after the second anniversary of the Funding Date and on or prior to the third anniversary of the Funding Date, the Prepayment Premium shall be an
amount equal to four percent (4%) of the aggregate outstanding principal amount of the Term Loans being prepaid on such Redemption Date; and
(C) after the third anniversary of the Funding Date and prior to the Stated Maturity Date, the Prepayment Premium shall be an amount equal to three
and one-half percent (3.5%) of the aggregate outstanding principal amount of the Term Loans being prepaid on such Redemption Date.
(b) Mandatory Prepayments. The Borrowers shall prepay the Term Loans in amounts as provided below, it
being agreed that the relevant payment date shall be deemed to be the “Redemption Date” for purposes of such calculation), as follows:
- 50 -
(i) In the event of any Casualty Event, an amount, inclusive of any Prepayment Premium, any accrued but unpaid interest (including interest on the
amount of the principal being prepaid) and fees then due and owing, equal to 100% of the Net Cash Proceeds received by any Obligor or any of its Subsidiaries with respect thereto; provided, however, so long
as no Default or Event of Default has occurred and is continuing, within one hundred eighty (180) days after receipt of such Net Cash Proceeds, the Obligors may apply the Net Cash Proceeds of any casualty policy up to, but not exceeding $4,000,000
for all losses in the aggregate during the term of this Agreement toward the replacement or repair of destroyed or damaged property; provided, further, that any such replaced or repaired property shall be
Collateral in which the Administrative Agent for the benefit of the Lenders has been granted a security interest under the Security Documents.
(ii) In the event any Obligor or any of its Subsidiaries incurs Indebtedness other than Indebtedness that is permitted by Section 9.01 hereof, an
amount, inclusive of any Prepayment Premium, any accrued but unpaid interest (including interest on the amount of the principal being prepaid) and fees then due and owing, equal to 100% of the Net Cash Proceeds thereof received by such Person. For
the avoidance of doubt, any prepayment made pursuant to this Section 3.03(b)(ii) shall not be deemed to be a consent to any such incurrence of Indebtedness or a cure or waiver of any Event of Default which occurs in connection therewith, it being
understood that any such Event of Default may only be waived with the express consent of the Majority Lenders.
(iii) In the event any Obligor or any of its Subsidiaries consummates an Asset Sale other than an Asset Sale that is permitted by Section 9.09
hereof (other than Section 9.09(j)), an amount, inclusive of any Prepayment Premium, any accrued but unpaid interest (including interest on the amount of the principal being prepaid) and fees then due and owing, equal to 100% of the Net Cash
Proceeds received by such Obligor in connection with such Asset Sale. For the avoidance of doubt, any prepayment made pursuant to this Section 3.03(b)(iii) shall not be deemed to be a consent to any Asset Sale or a cure or waiver of any Event of
Default which occurs in connection therewith, it being understood that any such Event of Default may only be waived with the express consent of the Majority Lenders.
(iv) In the event any Obligor or any of its Subsidiaries consummates an Asset Sale pursuant to Section 9.09(l), an amount (not subject to any
Prepayment Premium) equal to 75% of the Net Partnership Agreement Proceeds received by such Obligor in connection with such Asset Sale.
- 51 -
(c) Prepayment Premium. Payment of any Prepayment Premium under this Section 3.03 constitutes liquidated
damages, not unmatured interest or a penalty, as the actual amount of damages to the Lenders as a result of the relevant triggering event, prepayment or repayment would be impracticable and extremely difficult to ascertain. Accordingly, any
Prepayment Premium hereunder is provided by mutual agreement of the Obligors and the Lenders as a reasonable estimation and calculation of such actual lost profits and other actual damages of the Lenders. Without limiting the generality of the
foregoing, it is understood and agreed that upon the occurrence of any prepayment event, any Prepayment Premium shall be automatically and immediately due and payable as though any prepaid or repaid portion of the Term Loans was voluntarily prepaid
as of such date and shall constitute part of the Obligations secured by the Collateral. Any Prepayment Premium shall also be automatically and immediately due and payable if the Term Loans are satisfied or released by foreclosure (whether by power
of judicial proceeding or otherwise), deed in lieu of foreclosure or by any other means. EACH OBLIGOR HEREBY EXPRESSLY WAIVES (TO THE FULLEST EXTENT IT MAY LAWFULLY DO SO) THE PROVISIONS OF ANY PRESENT OR FUTURE STATUTE OR OTHER LAW THAT PROHIBITS
OR MAY PROHIBIT THE COLLECTION OF THE FOREGOING PREPAYMENT PREMIUM IN CONNECTION WITH ANY SUCH EVENTS. The Obligors expressly agree (to the fullest extent it and they may lawfully do so) that with respect to any Prepayment Premium payable under
the terms of this Agreement: (i) such Prepayment Premium is reasonable and is the product of an arm’s length transaction between sophisticated business parties, ably represented by counsel; (ii) such Prepayment Premium shall be payable
notwithstanding the then-prevailing market rates at the time payment is made; (iii) there has been a course of conduct between the Lenders and the Obligors giving specific consideration in this transaction for such agreement to pay such Prepayment
Premium; and (iv) the Obligors shall be estopped hereafter from claiming differently than as agreed to in this paragraph. The Obligors expressly acknowledge that their agreement to pay such Prepayment Premium as herein described is a material
inducement to the Lenders to provide the Commitments and to make the Term Loans.
(a) Payments Generally. Each payment of principal, interest and other amounts to be made by the Obligors
under this Agreement or any other Loan Document shall be made in Dollars, in immediately available funds, without deduction, set off or counterclaim, to an account of the Administrative Agent specified to the Administrative Borrower from time to
time, not later than 2:00 p.m. (Eastern time) on the date on which such payment shall become due (each such payment made after such time on such due date to be deemed to have been made on the next succeeding Business Day).
(b) Application of Payments. Each payment under this Agreement or any other Loan Document (other than any
payment made pursuant to Section 3.01, which shall be applied to the principal amount of the Term Loans on a ratable basis and any applicable Prepayment Premium) shall be applied in the following order of priority, with proceeds being applied to a
succeeding level of priority only if amounts owing pursuant to the immediately preceding level of priority have been paid in full in cash:
(i) first, to the payment of any unpaid costs and expenses referred to in Section 13.03(a) then due and
owing;
- 52 -
(ii) second, in reduction of the Borrowers’ obligation to pay any unpaid interest and any fees then due
and owing including, without limitation, (x) interest payable pursuant to Section 3.02(c) and (y) any Prepayment Premium;
(iii) third, in reduction of the Borrowers’ obligations to pay any Claims or Losses referred to in
Section 13.03(b) then due and owing;
(iv) fourth, to the payment of unpaid principal of the Term Loans on a pro rata basis;
(v) fifth, in reduction of any other Obligation then due and owing; and
(vi) sixth, to the Borrowers or such other Persons as may lawfully be entitled to or directed by the
Borrowers to receive the remainder.
Unless otherwise directed by the Majority Lenders, all payments of principal, interest and fees under this Agreement and the other Loan Documents shall be made by the Obligors to
the Lenders in accordance with the Lenders’ respective Proportionate Shares of such payments.
(c)Non‑Business Days. If the due date of any payment under this Agreement (whether in respect of principal,
interest, fees, costs or otherwise) would otherwise fall on a day that is not a Business Day, such date shall be extended to the next succeeding Business Day, and, in the case of any payment accruing interest, interest thereon shall be payable for
the period of such extension.
Section 4.02. Computations. All
computations of interest and fees hereunder shall be computed on the basis of a year of 360 days and actual days elapsed during the period for which payable.
Section 4.03. Notices. Each notice of
optional prepayment shall be effective only if received by the Lenders not later than 2:00 p.m. (Eastern time) on the date three (3) Business Days prior to the date of prepayment. Each notice of optional prepayment shall specify the amount to be
prepaid and the date of prepayment.
(a) Set‑Off Generally. Upon the occurrence and during the continuance of any Event of Default, the
Administrative Agent, the Lenders and each of their respective Affiliates are hereby authorized at any time and from time to time, to the fullest extent permitted by Law, to set off and apply any and all deposits (general or special, time or
demand, provisional or final) at any time held and other Indebtedness at any time owing by the Lenders or such Affiliates to or for the credit or the account of any Obligor against any and all of the Obligations, whether or not the Lenders shall
have made any demand and although such Obligations may be unmatured. The Lenders agree promptly to notify the Administrative Borrower after any such set‑off and application, provided that the failure to
give such notice shall not affect the validity of such set‑off and application. The rights of the Lenders and their respective Affiliates under this Section 4.04 are in addition to other rights and remedies (including other rights of set‑off) that
the Lenders and their respective Affiliates may have.
- 53 -
(b) Exercise of Rights Not Required. Nothing contained herein shall require the Administrative Agent, the
Lenders or any of their respective Affiliates to exercise any such right or shall affect the right of such Persons to exercise, and retain the benefits of exercising, any such right with respect to any other Indebtedness or obligation of any
Obligor.
(a) Change in Requirements of Law Generally. If, on or after the Original Closing Date, the adoption of
any Requirement of Law, or any change in any Requirement of Law, or any change in the interpretation or administration thereof by any court or other Governmental Authority charged with the interpretation or administration thereof, or compliance by
any Lender (or its lending office) with any request or directive (whether or not having the force of law) of any such Governmental Authority, shall impose, modify or deem applicable any reserve (including any such requirement imposed by the Board
of Governors of the Federal Reserve System), special deposit, contribution, insurance assessment or similar requirement, in each case that becomes effective after the Original Closing Date, against assets of, deposits with or for the account of, or
credit extended by, a Lender (or its lending office) or shall impose on a Lender (or its lending office) any other condition affecting the Term Loans or the Commitment, not as a result of any action or inaction on the part of such Lender, and the
result of any of the foregoing is to increase the cost to any Lender of making or maintaining its portion of the Term Loans, or to reduce the amount of any sum received or receivable by any Lender under this Agreement or any other Loan Document, by
an amount reasonably deemed by such Lender in good faith to be material (other than (i) Indemnified Taxes, (ii) Taxes described in clauses (b) through (d) of the definition of “Excluded Taxes” and
(iii) Connection Income Taxes), then the Borrowers shall promptly pay to such Lender on demand such additional amount or amounts as will compensate such Lender for such increased cost or reduction. Notwithstanding anything herein to the contrary,
(x) the Dodd‑Frank Wall Street Reform and Consumer Protection Act and all requests, rules, guidelines or directives thereunder or issued in connection therewith and (y) all requests, rules, guidelines or directives promulgated by the Bank for
International Settlements, the Basel Committee on Banking Supervision (or any successor or similar authority) or the United States or foreign regulatory authorities, in each case pursuant to Basel III, shall in each case be deemed to constitute a
change in Requirements of Law for all purposes of this Section 5.01, regardless of the date enacted, adopted or issued.
(b) Change in Capital Requirements. If a Lender shall have determined that, on or after the Original
Closing Date, the adoption of any Requirement of Law regarding capital adequacy, or any change therein, or any change in the interpretation or administration thereof by any Governmental Authority charged with the interpretation or administration
thereof, or any request or directive regarding capital adequacy (whether or not having the force of law) of any such Governmental Authority, in each case that becomes effective after the Original Closing Date, has or would have the effect of
reducing the rate of return on capital of a Lender (or its parent) as a consequence of a Lender’s obligations hereunder or the Term Loans to a level below that which a Lender (or its parent) could have achieved but for such adoption, change,
request or directive by an amount reasonably deemed by it to be material, then the Borrowers shall pay to such Lender on demand such additional amount or amounts as will compensate such Lender (or its parent) for such reduction.
- 54 -
(c) Notification by Lender. The Lenders will promptly notify the Administrative Borrower of any event of
which it has knowledge, occurring after the Original Closing Date which will entitle a Lender to compensation pursuant to this Section 5.01. Before giving any such notice pursuant to this Section 5.01(c) such Lender shall designate a different
lending office if such designation (x) will, in the reasonable judgment of such Lender, avoid the need for, or reduce the amount of, such compensation and (y) will not, in the reasonable judgment of such Lender, be materially disadvantageous to
such Lender. A certificate of the Lender claiming compensation under this Section 5.01, setting forth the amount or amounts to be paid to it hereunder, shall be conclusive and binding on the Borrowers in the absence of manifest error.
Section 5.02. Illegality.
Notwithstanding any other provision of this Agreement, in the event that on or after the Original Closing Date, the adoption of or any change in any Requirement of Law or in the interpretation or application thereof by any competent Governmental
Authority shall make it unlawful for a Lender or its lending office to make or maintain the Term Loans (and, in the opinion of such Lender, the designation of a different lending office would either not avoid such unlawfulness or would be
disadvantageous to such Lender), then such Lender shall promptly notify the Administrative Borrower thereof following which, if such Requirement of Law shall so mandate, the Term Loans shall be prepaid by the Borrowers on or before such date as
shall be mandated by such Requirement of Law in an amount equal to the Redemption Price applicable on the date of such prepayment in accordance with Section 3.03(a).
(a) Payments Free of Taxes. Any and all payments by or on account of any Obligation shall be made without
deduction or withholding for any Taxes, except as required by applicable Law. If any applicable Law requires the deduction or withholding of any Tax from any such payment by an Obligor, then such Obligor shall be entitled to make such deduction or
withholding, and shall timely pay the full amount deducted or withheld to the relevant Governmental Authority in accordance with applicable Law and, if such Tax is an Indemnified Tax, then the sum payable by such Obligor shall be increased as
necessary so that after such deduction or withholding for Indemnified Taxes has been made (including such deductions and withholdings for Indemnified Taxes applicable to additional sums payable under this Section 5.03) the applicable Recipient
receives an amount equal to the sum it would have received had no such deduction or withholding for Indemnified Taxes been made. For purposes of this Section 5.03, the term “applicable Law” includes FATCA.
- 55 -
(b) Payment of Other Taxes by the Borrowers. The Borrowers shall
timely pay to the relevant Governmental Authority in accordance with applicable Law, or at the option of the Administrative Agent, timely reimburse it for, Other Taxes.
(c) Evidence of Payments. As soon as practicable after any payment of Taxes by the Borrowers to a
Governmental Authority, as a withholding Tax pursuant to this Section 5.03, the Borrowers shall deliver to the Administrative Agent the original or a certified copy of a receipt issued by such Governmental Authority evidencing such payment, or a
copy of the return reporting such payment or other evidence of such payment reasonably satisfactory to the Administrative Agent.
(d) Indemnification. The Borrowers shall reimburse and indemnify each Recipient, within ten (10) days
after demand therefor, for the full amount of any Indemnified Taxes and Warrant Indemnified Taxes (including Indemnified Taxes imposed or asserted on or attributable to amounts payable under this Section 5.03) payable or paid by such Recipient or
required to be withheld or deducted from a payment to such Recipient and/or any reasonable costs and expenses arising therefrom or with respect thereto (including, but not limited to, any costs arising from a dispute with the relevant Government
Authority in respect of such Indemnified Taxes or Warrant Indemnified Taxes), whether or not such Indemnified Taxes (or Warrant Indemnified Taxes) were correctly or legally imposed or asserted by the relevant Governmental Authority; provided that, notwithstanding any other provision of this Agreement or any other Loan Document, no EEA Obligor shall be liable (whether as principal or surety or otherwise) for any Warrant Indemnified Taxes. A
certificate as to the amount of such payment or liability delivered to the Administrative Borrower by a Lender (with a copy to the Administrative Agent), or by the Administrative Agent on its own behalf or on behalf of a Lender shall be conclusive
absent manifest error.
(e) Indemnification by the Lenders. Each Lender shall severally indemnify the Administrative Agent,
within ten (10) days after demand therefor, for (i) any Indemnified Taxes attributable to such Lender (but only to the extent that the Borrowers have not already indemnified the Administrative Agent for such Indemnified Taxes and without limiting
the obligation of any Borrower to do so), and (ii) any Taxes attributable to such Lender, in each case, that are payable or paid by the Administrative Agent in connection with any Loan Document, and any reasonable expenses arising therefrom or with
respect thereto, whether or not such Taxes were correctly or legally imposed or asserted by the relevant Governmental Authority. A certificate as to the amount of such payment or liability delivered to any Lender by the Administrative Agent shall
be conclusive absent manifest error. Each Lender hereby authorizes the Administrative Agent to set off and apply any and all amounts at any time owing to such Lender under any Loan Document or otherwise payable by the Administrative Agent to such
Lender from any other source against any amount due to the Administrative Agent under this paragraph (e).
- 56 -
(f) Status of Lenders.
(i) Any Lender that is entitled to an exemption from, or reduction of withholding Tax with respect to payments made under any Loan Document shall
deliver to the Administrative Borrower and the Administrative Agent, at the time or times reasonably requested by the Administrative Borrower or the Administrative Agent, such properly completed and executed documentation reasonably requested by
the Administrative Borrower or the Administrative Agent as will permit such payments to be made without withholding or at a reduced rate of withholding. In addition, any Lender, if reasonably requested by the Administrative Borrower or the
Administrative Agent, shall deliver such other documentation prescribed by applicable Law or as reasonably requested by the Administrative Borrower or the Administrative Agent as will enable the Administrative Agent Borrower or the Administrative
Agent to determine whether or not such Lender is subject to backup withholding or information reporting requirements. Notwithstanding anything to the contrary in the preceding two sentences, the completion, execution and submission of such
documentation (other than such documentation set forth in Section 5.03(f)(ii)(A), (B) or (D)) shall not be required if in the Lender’s reasonable judgment such completion, execution or submission would subject such Lender to any material
unreimbursed cost or expense or would materially prejudice the legal or commercial position of such Lender.
(ii) Without limiting the generality of the foregoing:
(A) any Lender that is a U.S. Person shall deliver to the Administrative Borrower and the Administrative Agent on or prior to the date on which such
Lender becomes a Lender under this Agreement (and from time to time thereafter upon the reasonable request of the Administrative Borrower or the Administrative Agent), duly completed, valid, executed copies of IRS Form W‑9 (or successor form)
certifying that such Lender is exempt from United States federal backup withholding Tax;
(B) any Foreign Lender shall, to the extent it is legally entitled to do so, deliver to the Administrative Borrower and the Administrative Agent (in
such number of copies as shall be requested by the Recipient) on or prior to the date on which such Foreign Lender becomes a Lender under this Agreement (and from time to time thereafter upon the reasonable request of the Administrative Borrower or
the Administrative Agent), whichever of the following is applicable:
(1) in the case of a Foreign Lender claiming the benefits of an income Tax treaty to which the United States is a party (x) with respect to payments
of interest under any Loan Document, duly completed, valid executed copies of IRS Form W‑8BEN (or successor form) or IRS Form W‑8BEN‑E (or successor form) establishing an exemption from, or reduction of, United States federal withholding Tax
pursuant to the “interest” article of such Tax treaty and (y) with respect to any other applicable payments under any Loan Document, duly completed, valid, executed originals of IRS Form W‑8BEN (or successor form) or IRS Form W‑8BEN‑E (or successor
form) establishing an exemption from, or reduction of, United States federal withholding Tax pursuant to the “business profits” or “other income” article of such Tax treaty;
- 57 -
(2) duly completed, valid, executed copies of IRS Form W‑8ECI (or successor form);
(3) in the case of a Foreign Lender claiming the benefits of the exemption for portfolio interest under Section 881(c) of the Code, (x) a
certificate substantially in the form of Exhibit D to the effect that such Foreign Lender is not a “bank” within the meaning of Section 881(c)(3)(A) of the Code, a “10 percent shareholder” of the applicable Borrower within the meaning of
Section 881(c)(3)(B) of the Code, or a “controlled foreign corporation” described in Section 881(c)(3)(C) of the Code (a “U.S. Tax Compliance Certificate”) and (y) executed copies of IRS Form W‑8BEN (or
successor form) or IRS Form W‑8BEN‑E (or successor form); or
(4) to the extent a Foreign Lender is not the beneficial owner, duly completed, valid, executed copies of IRS Form W‑8IMY (or successor form),
accompanied by IRS Form W‑8ECI (or successor form), IRS Form W‑8BEN (or successor form), IRS Form W‑8BEN‑E (or successor form), a U.S. Tax Compliance Certificate, IRS Form W‑9 (or successor form), and/or other certification documents from each
beneficial owner, as applicable; provided that if the Foreign Lender is a partnership and one or more direct or indirect partners of such Foreign Lender are claiming the portfolio interest exemption, such
Foreign Lender may provide a U.S. Tax Compliance Certificate on behalf of each such direct and indirect partner;
(iii) any Foreign Lender shall, to the extent it is legally entitled to do so, deliver to the Administrative Borrower and the Administrative Agent
(in such number of copies as shall be requested by the Recipient) on or prior to the date on which such Foreign Lender becomes a Lender under this Agreement (and from time to time thereafter upon the reasonable request of the Administrative
Borrower or the Administrative Agent), executed copies of any other form prescribed by applicable Law as a basis for claiming exemption from or a reduction in United States federal withholding Tax, duly completed, together with such supplementary
documentation as may be prescribed by applicable Law to permit the Administrative Borrower or the Administrative Agent to determine the withholding or deduction required to be made; and
- 58 -
(iv) if a payment made to a Lender under any Loan Document would be subject to United States federal withholding Tax imposed by FATCA if such
Lender were to fail to comply with the applicable reporting requirements of FATCA (including those contained in Section 1471(b) or 1472(b) of the Code, as applicable), such Lender shall deliver to the Administrative Borrower and the Administrative
Agent at the time or times prescribed by Law and at such time or times reasonably requested by the Administrative Borrower or the Administrative Agent such documentation prescribed by applicable Law (including as prescribed by
Section 1471(b)(3)(C)(i) of the Code) and such additional documentation reasonably requested by the Administrative Borrower or the Administrative Agent as may be necessary for the Administrative Borrower or the Administrative Agent to comply with
its obligations under FATCA and to determine that such Lender has complied with such Lender’s obligations under FATCA or to determine the amount, if any, to deduct and withhold from such payment. Solely for purposes of this clause (D), “FATCA”
shall include any amendments made to FATCA after the date of this Agreement.
Each Recipient agrees that if any form or certification it previously delivered expires or becomes obsolete or inaccurate in any respect, it shall promptly update such form or
certification or promptly notify the Administrative Borrower and the Administrative Agent in writing of its legal inability to do so.
(g) Treatment of Certain Refunds. If any party to this Agreement determines, in its sole discretion
exercised in good faith, that it has received a refund of any Taxes as to which it has been indemnified pursuant to this Section 5.03 (including by the payment of additional amounts pursuant to this Section 5.03), it shall pay to the indemnifying
party an amount equal to such refund (but only to the extent of indemnity payments made under this Section 5.03 with respect to the Taxes giving rise to such refund), net of all out‑of‑pocket expenses (including Taxes) of such indemnified party and
without interest (other than any interest paid by the relevant Governmental Authority with respect to such refund). Such indemnifying party, upon the written request of such indemnified party, shall repay to such indemnified party the amount paid
over pursuant to this paragraph (plus any penalties, interest or other charges imposed by the relevant Governmental Authority) in the event that such indemnified party is required to repay such refund to such Governmental Authority.
Notwithstanding anything to the contrary in this Section 5.03(g), in no event will the indemnified party be required to pay any amount to an indemnifying party pursuant to this Section 5.03(g) the payment of which would place the indemnified party
in a less favorable net after‑Tax position than the indemnified party would have been in if the Tax subject to indemnification and giving rise to such refund had not been deducted, withheld or otherwise imposed and the indemnification payments or
additional amounts giving rise to such refund had never been paid. This Section 5.03(g) shall not be construed to require any indemnified party to make available its Tax returns (or any other information relating to its Taxes that it deems
confidential) to the indemnifying party or any other Person.
- 59 -
(h) Mitigation Obligations. If the Borrowers are required to pay any Indemnified Taxes or additional
amounts to any Lender or to any Governmental Authority for the account of any Lender pursuant to Section 5.01 or this Section 5.03, then such Lender shall (at the request of the Administrative Borrower) use commercially reasonable efforts to
designate a different lending office for funding or booking the Term Loans hereunder or to assign and delegate its rights and obligations hereunder to another of its offices, branches or Affiliates if, in the sole reasonable judgment of such
Lender, such designation or assignment and delegation would (i) eliminate or reduce amounts payable pursuant to Section 5.01 or this Section 5.03, as the case may be, in the future, (ii) not subject such Lender to any unreimbursed cost or expense
and (iii) not otherwise be disadvantageous to such Lender. The Borrowers hereby agree to pay all reasonable costs and expenses incurred by any Lender in connection with any such designation or assignment and delegation.
(i) Revenue Challenge to Warrant Stamp Amount. In the event of any written communication issued by the
Irish Revenue Commissioners to a Recipient concerning the amount of Irish stamp duty liability due upon the execution of a Warrant Certificate (a “Revenue Claim”), the Recipients shall (if the total amount
of stamp duty due on such Warrant Certificate is likely to exceed $50,000):
(i) promptly provide a copy of such written communication from the Irish Revenue Commissioners to the Parent;
(ii) if requested by the Parent, provide to the Parent (at the Parent’s expense) copies of any material correspondence to and from the Irish
Revenue Commissioners relating to the Revenue Claim (subject to legal professional privilege and any obligations of confidence that are binding on the Recipients);
(iii) keep the Parent reasonably informed of the progress of the Revenue Claim and of any material developments in relation to the Revenue Claim;
and
(iv) use reasonable endeavors to consult with the Obligors regarding the conduct of the Revenue Claim.
If the total amount of stamp duty due on a Warrant Certificate would exceed $50,000, no Recipient shall agree any compromise or settlement, or make any payment in relation to, a Revenue Claim
without the prior written consent of the Obligors. Notwithstanding any other provision of this Agreement, any failure by a Recipient to comply with its obligations under this Section 5.03(i) shall reduce the amount of any claim under Section
5.03(d) with respect to a Revenue Claim to the extent that such failure to comply increased or gave rise to the Taxes to which such claim relates.
(j) Survival. Each party’s obligations under this Article 5 shall survive the resignation or replacement
of the Administrative Agent or any assignment of rights by, or the replacement of, a Lender, the termination of the Commitments and the repayment, satisfaction or discharge of all Obligations under any Loan Document.
- 60 -
Section 5.04. Delay in Requests.
Failure or delay on the part of any Lender to demand compensation pursuant to this Article 5 shall not constitute a waiver of such Lender’s right to demand such compensation; provided that the Borrowers
shall not be required to compensate a Lender pursuant to this Article 5 for any increased costs incurred or reductions suffered more than nine (9) months prior to the date that such Lender notifies the Administrative Borrower of the change in Law
giving rise to such increased costs or reductions, and of such Lender’s intention to claim compensation therefor (except that, if the change in Law giving rise to such increased costs or reductions is retroactive, then the nine (9) month period
referred to above shall be extended to include the period of retroactive effect thereof).
Section 6.01. Conditions to Fifth Amendment Term Loan;
Fifth Amendment Restatement Date. The obligation of each Lender to make the Fifth Amendment Term Loan on the Fifth Amendment Restatement Date shall not become effective until the following conditions precedent shall have been reasonably
satisfied or waived in writing by the Administrative Agent (which satisfaction or waiver may be made simultaneously with the making of the Fifth Amendment Term Loan hereunder):
(a) Fifth Amendment Term Loan Borrowing Notice. The Administrative Agent shall have received a Fifth
Amendment Term Loan Borrowing Notice in accordance with Section 2.01(g)(iii) requesting the Borrowing of the Fifth Amendment Term Loan duly executed by a Responsible Officer of the Administrative Borrower, in form and substance reasonably
satisfactory to the Administrative Agent.
(b) Representations and Warranties. The representations and warranties of the Obligors contained in Article
7 or any other Loan Document shall be true and correct in all material respects on and as of the Fifth Amendment Restatement Date; provided that to the extent that such representations and warranties
specifically refer to an earlier date, they shall be true and correct in all material respects as of such earlier date; provided further that any representation and warranty that is qualified as to
“materiality”, “Material Adverse Effect” or similar language shall be true and correct (after giving effect to any qualification therein) in all respects.
(c) No Default. No Default shall have occurred and be continuing, or would result from such proposed
Borrowing or from the application of the proceeds therefrom.
(d) Organizational Documents. The Administrative Agent shall have received (a) certified copies of the
Organizational Documents of each Irish Obligor (or, with respect to any Irish Obligor, to the extent that such Organizational Documents have not been amended, restated or otherwise modified since the Original Closing Date, a certification by a
Responsible Officer to that effect), (b) resolutions of the Board of each Irish Obligor approving and authorizing the execution, delivery and performance of this Agreement, certified as of the Fifth Amendment Restatement Date by the secretary or a
Responsible Officer of such Irish Obligor as being in full force and effect without modification or amendment, (c) a good standing certificate and/or compliance certificate from the applicable Governmental Authority of each Obligor’s jurisdiction
of incorporation, each dated a recent date prior to Fifth Amendment Restatement Date and (d) a certificate of each Irish Obligor as to the authority, incumbency and specimen signatures of the Persons who have executed this Agreement and any other
documents in connection herewith on behalf of the Irish Obligors.
- 61 -
(e) Documentary Deliveries. The Administrative Agent shall have received the following documents, each of
which shall be in form and substance satisfactory to the Administrative Agent:
(i) Agreement. This Agreement duly executed and delivered by the Borrowers and each of the other parties
hereto.
(ii) [Reserved].
(iii) Reaffirmation. Reaffirmation confirming the security interest granted in the Irish Debenture.
The Borrowing shall constitute a certification by the Administrative Borrower to the effect that the conditions set forth in Section 6.01 have been fulfilled as of the Fifth
Amendment Restatement Date.
In order to induce the Lenders to enter into this Agreement and to extend the Term Loans hereunder, each Obligor represents and warrants to the Lenders and the Administrative
Agent, on the Fifth Amendment Restatement Date that the following statements are true and correct:
Section 7.01. Power and Authority.
Except as described in Schedule 7.01, each Obligor (a) is duly organized, validly existing and in good standing (to the extent such concept exists in the relevant jurisdiction) under the Laws of its jurisdiction of organization, (b) has all
requisite corporate (or equivalent) power, and has all material governmental licenses, authorizations, consents and approvals necessary to own its assets and carry on its business as now being or as proposed to be conducted except to the extent
that failure to have the same would not reasonably be expected to have a Material Adverse Effect, (c) is qualified to do business and is in good standing in all jurisdictions in which the nature of the business conducted by it makes such
qualification necessary except where failure to so qualify would not (either individually or in the aggregate) reasonably be expected to have a Material Adverse Effect, and (d) has full power, authority and legal right to make and perform its
obligations under each of the Loan Documents to which it is a party and, in the case of the Borrowers, to borrow the Term Loans hereunder.
Section 7.02. Authorization; Enforceability.
The Transactions are within each Obligor’s corporate (or equivalent) powers and have been duly authorized by all necessary corporate (or equivalent) action and, if required, by all necessary shareholder or other equity holder action. The Loan
Documents have been duly executed and delivered by each Obligor party thereto and constitutes, and each of the other Loan Documents to which it is a party when executed and delivered by such Obligor will constitute, a legal, valid and binding
obligation of such Obligor, enforceable against each Obligor in accordance with its terms, except as such enforceability may be limited by (a) bankruptcy, insolvency, reorganization, moratorium or similar Laws of general applicability affecting the
enforcement of creditors’ rights and (b) the application of general principles of equity (regardless of whether such enforceability is considered in a proceeding in equity or at law).
- 62 -
Section 7.03. Governmental and Other Approvals;
No Conflicts. Except for the FDI Clearance (as defined in the WaveForm Slovenia Side Agreement), and the obligations set out in the WaveForm Slovenia Side Agreement, the Transactions (a) do not require any consent or approval of,
registration or filing with, or any other action by, any Governmental Authority or any other Person, except for (i) such as have been obtained or made and are in full force and effect and (ii) filings and recordings in respect of perfecting or
recording the Liens created pursuant to the Security Documents, (b) will not violate any applicable Requirement of Law or the Organizational Documents of any Obligor or any applicable order of any Governmental Authority, in each case, other than
any such violations that, individually or in the aggregate, would not reasonably be expected to have a Material Adverse Effect, (c) will not violate or result in a default under any Material Agreement, or give rise to a right thereunder to require
any payment to be made by any such Person, and (d) will not result in the creation or imposition of any Lien (other than Permitted Liens) on any asset of any Obligor
(a) Financial Statements. The Obligors have heretofore furnished to the Administrative Agent consolidated
financial statements for the Parent and its consolidated Subsidiaries for the period ended June 30, 2021. Such financial statements present fairly, in all material respects, the financial position and results of operations and cash flows of the
Obligors as of such dates and for such periods substantially in accordance with IFRS, subject to quarterly or year‑end adjustments and the absence of footnotes. As of June 30, 2021, no Obligor has any material contingent liabilities or liabilities
for taxes, long‑term lease or unusual forward or long‑term commitments not disclosed in the aforementioned financial statements.
(b) Projections. On and as of the Original Closing Date, the Projections were based on good faith
estimates and assumptions made by the management of the Obligors; provided, the Projections are not to be viewed as facts and that actual results during the period or periods covered by the Projections may
differ from such Projections and that the differences may be material; provided, further, as of the Original Closing Date, the management of the Obligors believed that the Projections are reasonable and
attainable.
(c) No Material Adverse Change. Since December 31, 2020, no event, circumstance or change has occurred
that has caused or evidences, either in individually or in the aggregate, a Material Adverse Change.
- 63 -
(a) Property Generally. Each Obligor has good and marketable fee simple title to, or valid leasehold
interests in, all its real and personal Property material to its business, including all Product Assets, subject only to Permitted Liens and except as would not reasonably be expected to materially interfere with its ability to conduct its business
as currently conducted or to utilize such properties for their intended purposes. Schedule 7.05(a) lists, with respect to each Obligor, owned real property as of the Original Closing Date.
(b) Intellectual Property.
(i) Schedule 7.05(b) lists, with respect to each Obligor, all United States and foreign registrations of and applications for Patents, Trademarks,
Copyrights, and Industrial Designs that are Obligor Intellectual Property as of the Original Closing Date, including the applicable jurisdiction, registration or application number and date, as applicable thereto, a designation as to whether such
Obligor Intellectual Property is Material Intellectual Property, and a designation as to whether it is licensed or owned by such Obligor.
(ii) Each Obligor (A) owns or possesses all legal equitable rights, title and interest in and to the Material Intellectual Property designated on
Schedule 7.05(b) as being owned by such Obligor (excluding, for the avoidance of doubt, Material Intellectual Property transferred pursuant to the Fitzgerald and Benen Sale) and (B) has the right to use the Material Intellectual Property licensed
to such Obligor, in each case with good and marketable title, free and clear or any Liens or Claims of any kind other than Permitted Liens, in each case, except as described in Schedule 7.05(b).
(iii) To each Obligor’s knowledge, the Material Intellectual Property does not violate any license or infringe any valid and enforceable
Intellectual Property right of another.
(iv) Other than with respect to the Material Agreements, or as permitted by this Agreement, the Obligors have not assigned or otherwise
transferred ownership of, or agreed to assign or otherwise transfer ownership of, any Material Intellectual Property, in whole or in part, to any Person who is not an Obligor.
(v) Other than as set forth on Schedule 7.05(b), the Obligors have not received any written communications, nor is there any pending or, to each
Obligor’s knowledge, threatened action in writing, suit, proceeding or Claim in writing by another, alleging that any of the Obligors has violated, infringed, diluted or misappropriated any Intellectual Property of another.
- 64 -
(vi) There is no pending or, to any Obligor’s knowledge, threatened action in writing, suit, proceeding or Claim in writing by another:
(A) challenging an Obligor’s rights in or to any Material Intellectual Property owned by such Obligor; or (B) challenging the validity, enforceability or scope of any Material Intellectual Property owned by an Obligor.
(vii) Each Obligor has taken commercially reasonable precautions to protect the secrecy, confidentiality and value of the Material Intellectual
Property (including without limitation, by requiring that all current and former Key Employees of that Obligor or its Subsidiaries and all consultants engaged by that Obligor or its Subsidiaries with access to Material Intellectual Property execute
written confidentiality and Invention assignment Contracts).
(viii) Each current Key Employee has signed a written agreement assigning to the applicable Obligor all Intellectual Property rights that are
related to such Obligor’s business as now conducted and as presently proposed to be conducted and confidentiality provisions protecting trade secrets and confidentiality information of the Obligors.
(ix) Each Obligor has complied in all material respects with the terms of each Material Agreement pursuant to which Intellectual Property has been
licensed to the Obligors (which terms shall include, but not be limited to, pricing and duration of the agreement).
(x) All maintenance fees, annuities, and the like due or payable on the Patents included in the Material Intellectual Property have been timely
paid or the failure to so pay was the result of an unintentional failure to pay by the applicable Obligor, which would not reasonably be expected to result in a Material Adverse Change. All documents and instruments necessary to register or apply
for or renew registration of all Material Intellectual Property have been validly executed, delivered and filed in a timely manner with the United States Patent and Trademark Office, the United States Copyright Office, the Canadian Intellectual
Property Office, or the equivalent office in any other applicable jurisdiction, as applicable.
(xi) To each Obligor’s knowledge, (A) there are no material defects in any of the Patents included in the Material Intellectual Property and (B)
no such Patents have ever been finally adjudicated to be invalid, unpatentable or unenforceable for any reason in any administrative, arbitration, judicial or other proceeding.
(xii) To each Obligor’s knowledge, no Obligor has received any written notice asserting that any Patent included in the Material Intellectual
Property is invalid, unpatentable or unenforceable and, to each Obligor’s knowledge, no Obligor has engaged in any conduct, or omitted to perform any necessary act, the result of which would invalidate or render unpatentable or unenforceable any
such Patent, except as described in Schedule 7.05(b).
- 65 -
(xiii) To the knowledge of each Obligor, no third party is materially infringing upon or misappropriating any Material Intellectual Property, and
no counterparty is materially violating any license or agreement with such Obligor relating to any Material Intellectual Property.
(a) Litigation. Except as described in Schedule 7.06(a), there is no litigation, investigation or
enforcement proceeding pending or threatened in writing with respect to any Obligor or any of its Subsidiaries by or before any Governmental Authority or arbitrator (i) that either individually or in the aggregate would reasonably be expected to
have a Material Adverse Effect or (ii) that involves this Agreement or the Transactions.
(b) Environmental Matters. The operations and the real Property of the Obligors and their Subsidiaries
comply with all applicable Environmental Laws, except to the extent the failure to so comply, either individually or in the aggregate, would not reasonably be expected to have a Material Adverse Effect. To each Obligor’s knowledge, there have been
no conditions, occurrences or release of Hazardous Materials which would reasonably be expected to have a Material Adverse Effect.
(c) Labor Matters. No Obligor has engaged in unfair labor practices and there is no pending or, to any
Obligor’s knowledge, threatened in writing labor actions, disputes, grievance or arbitration proceedings involving the employees of any Obligor, in each case that would reasonably be expected to have a Material Adverse Effect. There is no material
strike or work stoppage in existence or threatened in writing against any Obligor and to the knowledge of such Obligor, no union organization activity is taking place.
(a) Each Obligor and each of its Subsidiaries is in compliance with all Requirements of Law (including Healthcare Laws and Environmental Laws) and
all Contracts binding upon it or its Property, except (other than with respect to Material Intellectual Property) where the failure to do so, individually or in the aggregate, would not reasonably be expected to result in a Material Adverse Effect.
(b) Without limiting the generality of the foregoing:
(i) To the best of each Obligor’s knowledge, any financial relationships between or among the Borrowers or any other Obligor, on the one hand, and
any Person who is in a position to refer patients or other health care business to the Borrowers or any other Obligor (collectively a “Referral Source”), on the other hand, (A) comply in all material
respects with all applicable Healthcare Laws, (B) reflect fair market value, have commercially reasonable terms and were negotiated at arm’s length; and (C) do not obligate the Referral Source to purchase, use, recommend or arrange for the use of
any products or services of the Borrowers or any other Obligor, in any manner that could reasonably be expected to constitute a violation of a state, federal or foreign health care fraud and abuse law. No Obligor directly or indirectly, has
guaranteed a loan, made a payment toward a loan or otherwise subsidized a loan for any Referral Source including, without limitation, any loans related to financing the Referral Source’s ownership, investment or financial interest in any Obligor
- 66 -
(ii) Except as disclosed in Schedule 7.19(e), all Products have been developed, tested, manufactured, distributed, marketed and sold in compliance
in all material respects with (A) all applicable FDA Laws, including, without limitation, all requirements relating to pre‑market notification, good manufacturing practices/quality system regulations (21 CFR Part 820), labeling, advertising,
record‑keeping, and adverse event reporting; and (B) all applicable Health Canada Laws.
(iii) The Borrowers and each other Obligor are in compliance in all material respects with the Physician Payments Sunshine Act (Section 6002 of
the Affordable Care Act of 2010) and its implementing regulations and any applicable state disclosure and transparency laws.
(c) To the extent any Obligor shall participate or receive reimbursement from any Federal Health Care Program or other third‑party payor program,
(i) each Obligor shall have the requisite provider number or authorization necessary to bill any third‑party payor program in which it participates and (ii) there shall be no audits, inquiries, adjustments, appeals or recoupment efforts by any
third‑party payor programs of or against any Obligor with respect to any prior Claims, reports or billings that, individually or in the aggregate, would reasonably be expected to result in a Material Adverse Effect.
(d) Each Obligor will maintain and adhere to, in all material respects, a reasonable compliance program designed to promote compliance with and to
detect, prevent and address violations of all material Healthcare Laws (a “Health Care Compliance Program”). No Obligor is aware of any complaints from any employees, independent contractors, vendors,
physicians, customers, patients or other persons that could reasonably be considered to indicate a violation of Healthcare Laws which would be reasonably expected to result individually, or in the aggregate, in a Material Adverse Effect.
Section 7.08. Taxes. Each Obligor has
filed or caused to be filed which are true and correct in all material respects, all United States federal income and other material Tax returns and reports required to have been filed and has paid or caused to be paid all United States federal
income and other material Taxes required to have been paid by it prior to the date on which material penalties attach thereto, except Taxes that are being contested in good faith by appropriate proceedings and for which such Obligor has set aside
on its books adequate reserves with respect thereto substantially in accordance with IFRS.
Section 7.09. Full Disclosure. The
Obligors have disclosed to the Lenders all Material Agreements to which any Obligor is party, and all other matters to their knowledge, that, individually or in the aggregate, would reasonably be expected to result in a Material Adverse Effect.
None of the reports, financial statements, certificates or other written information furnished by or on behalf of the Obligors to the Lenders in connection with the negotiation of this Agreement and the other Loan Documents or delivered hereunder
or thereunder (as modified or supplemented by other information so furnished) contains any material misstatement of material fact or omits to state any material fact necessary to make the statements therein, taken as a whole, in the light of the
circumstances under which they were made, not misleading; provided that, with respect to Projections, the Obligors represent only that such information was prepared in good faith based upon assumptions
believed to be reasonable at the time.
- 67 -
(a) Investment Company Act. No Obligor is an “investment company” as defined in, or subject to regulation
under, the Investment Company Act of 1940.
(b) Margin Stock. No Obligor is engaged principally, or as one of its important activities, in the
business of extending credit for the purpose, whether immediate, incidental or ultimate, of buying or carrying Margin Stock and no part of the proceeds of the Term Loans will be used to buy or carry any Margin Stock in violation of Regulation T, U
or X.
Section 7.11. Solvency. (a) The
Obligors, when taken as a whole and (b) the Borrowers when taken as a whole, are and immediately after giving effect to the Borrowing of the Term Loans, the use of proceeds thereof, and the consummation of the Transactions, will be, Solvent.
Section 7.13. Indebtedness and Liens.
Set forth on Schedule 7.13A is a complete and correct list of each item of Permitted Indebtedness of each Obligor that exceeds $50,000 as of October 31, 2021; provided, that in no event shall an aggregate
amount in excess of $500,000 of Permitted Indebtedness be excluded from Schedule 7.13A. Set forth on Schedule 7.13B is a complete and correct list of each Permitted Lien described in Section 9.02(b) granted
by the Borrowers and other Obligors with respect to their respective Property that exceeds $50,000 and is outstanding as of October 31, 2021; provided, that in no event shall an aggregate amount in excess
of $500,000 of Permitted Liens be excluded from Schedule 7.13B.
Section 7.14. Material Agreements. Set
forth on Schedule 7.14 (as such Schedule may be updated by the Obligors from time to time, pursuant to Section 8.01(d)) is a complete and correct list of (a) each Material Agreement and (b) each Contract creating or evidencing any Material
Indebtedness, together with a summary reference to the product or purpose of each such Material Agreement and such Contract, to which an Obligor is a party. Accurate and complete copies of each such Contract listed on such schedule have been made
available to the Lenders. No Obligor is in default under any such Material Agreement or such Contract creating or evidencing any Material Indebtedness listed on such schedule, and no Obligor has knowledge of any default by any counterparty to such
Material Agreement or such Contract, in each case, other than bona fide disputes and defaults which could not, individually or in the aggregate, be reasonably expected to have a Material Adverse Effect. Except as otherwise disclosed on
Schedule 7.14 (as such Schedule may be updated by the Borrowers from time to time), all material vendor purchase agreements and provider Contracts of the Obligors, and all Material Agreements including a grant of rights under any Intellectual
Property to an Obligor, are in full force and effect without material modification from the form in which the same were disclosed to the Lenders.
- 68 -
Section 7.15. Restrictive Agreements.
None of the Obligors is party to any Restrictive Agreement, except (a) those listed on Schedule 7.15 or otherwise permitted under Section 9.11, (b) restrictions and conditions imposed by Law or by the Loan Documents, (c) any stockholder agreement,
investor rights agreement or other Organizational Documents of an Obligor and (d) limitations associated with Permitted Liens.
Section 7.16. Real Property. No Obligor
owns or leases (as tenant thereof) any real Property on the date hereof, except as described on Schedule 7.16.
Section 7.17. Pension and Other Plans.
(a) Schedule 7.17 sets forth, as of the Original Closing Date, a complete and correct list of, and that separately identifies, (a) all Title IV Plans, (b) all Multiemployer Plans and (c) all material Benefit Plans. Each Benefit Plan, and each
trust thereunder, intended to qualify for tax exempt status under Section 401 or 501 of the Code has received a favorable IRS determination as its tax exempt status, and to the knowledge of any Obligor, no event has occurred or circumstances exist
that would cause the loss of such status. Except for those that would not, in the aggregate, have a Material Adverse Effect, (i) each Benefit Plan is in compliance with applicable provisions of ERISA, the Code and other Requirements of Law,
(ii) there are no existing or pending (or to the knowledge of any Obligor, threatened) Claims (other than routine Claims for benefits in the normal course), sanctions, actions, lawsuits or other proceedings or investigations involving any Benefit
Plan to which any Obligor incurs or otherwise has or would have an obligation or any liability or Claim and (iii) no ERISA Event is reasonably expected to occur prior to the Maturity Date. The Borrowers and each of their ERISA Affiliates have met
all applicable requirements under the ERISA Funding Rules with respect to each Title IV Plan, and no waiver of the minimum funding standards under the ERISA Funding Rules has been applied for or obtained. As of the most recent valuation date for
any Title IV Plan, the funding target attainment percentage (as defined in Section 430(d)(2) of the Code) is at least 60%, and neither the Borrowers nor any of their ERISA Affiliates know of any facts or circumstances that would reasonably be
expected to cause the funding target attainment percentage to fall below 60% as of the most recent valuation date. To each Obligor’s knowledge, as of the Original Closing Date, no ERISA Event has occurred in connection with which obligations and
liabilities (contingent or otherwise) remain outstanding. No ERISA Affiliate would have any Withdrawal Liability as a result of a complete withdrawal from any Multiemployer Plan on the date this representation is made. (b) The Obligors do not
maintain, administrate, or contribute to any Canadian Defined Benefit Pension Plans, or, except as disclosed on Schedule 7.17, any other Canadian Pension Plans. With respect to Canadian Pension Plans: (i) no steps have been taken to terminate any
Canadian Pension Plan (wholly or in part) which could result in any Obligor being required to make a material additional contribution to any Canadian Pension Plan; (ii) no contribution failure has occurred with respect to any Canadian Pension Plan
sufficient to give rise to a lien or charge under any applicable pension benefits laws of any other jurisdiction (for certainty, not including payments in respect of contributions payable but not yet due); and (iii) no condition exists and no event
or transaction has occurred with respect to any Canadian Pension Plan which is reasonably likely to result in any Obligor incurring any material liability, fine or penalty. Each Canadian Pension Plan is in compliance (other than immaterial
non-compliance) with all applicable pension benefits and tax laws; (i) all contributions (other than immaterial amounts) (including employee contributions made by authorized payroll deductions or other withholdings) required to be made to the
appropriate funding agency in accordance with all Applicable Laws (other than immaterial non-compliance) and the terms of each pension plan have been made in accordance with all applicable Laws (other than immaterial non-compliance) and the terms
of each Canadian Pension Plan (other than immaterial non-compliance); (ii) all liabilities under each Canadian Pension Plan are funded in accordance with the terms of the respective Canadian Pension Plans, the requirements of applicable pension
benefits laws and of applicable regulatory authorities (other than immaterial non-compliance) and (iii) no event has occurred and no conditions exist with respect to any Canadian Pension Plan that has resulted or could reasonably be expected to
result in any Canadian Pension Plan having its registration revoked or refused by any administration of any relevant pension benefits regulatory authority or being required to pay any taxes (other than taxes the amounts of which are immaterial) or
penalties under any applicable pension benefits or tax laws.
- 69 -
Section 7.18. Collateral; Security Interest.
Each Security Document is effective to create in favor of the Administrative Agent for the benefit of the Lenders a legal, valid and enforceable security interest in the Collateral subject thereto and each such security interest is perfected to the
extent required by (and has the priority required by) the applicable Security Document, subject to Permitted Liens. The Security Documents collectively are effective to create in favor of the Administrative Agent for the benefit of the Lenders a
legal, valid and enforceable security interest in the Collateral, which upon the filing of financing statements and other similar statements filed in the appropriate offices, such security interests are perfected security interests (subject only to
Permitted Liens) to the extent that such perfection may be obtained by such filing.
(a) With respect to all Products, each Obligor holds either directly or through licensees and agents, all Regulatory Approvals and Permits necessary
or required for that Obligor to conduct all material Product Development and Commercialization Activities with respect to the Products.
(b) Set forth on Schedule 7.19(b) is a complete and accurate list as of the Original Closing Date of all Regulatory Approvals referred to in
clause (a) above that are with the FDA, WHO, CE-Mark EMA, HPRA, Health Canada, ANVISA or any other similar Regulatory Authority and identifying the Product related to such Regulatory Approval. All such Regulatory Approvals are (i) legally and/or
beneficially owned exclusively by the Obligor identified on Schedule 7.19(b), free and clear of all Liens other than Permitted Liens, (ii) validly registered and on file with the applicable Regulatory Authority, in material compliance with all
registration, filing and maintenance requirements (including any fee requirements) thereof, and (iii) in good standing, valid and enforceable with the applicable Regulatory Authority. All required and material notices, registrations and listings,
supplemental applications or notifications, reports (including annual reports, field alerts, Device reports or other reports of adverse experiences) and all other required and material filings with respect to the Products or any related Product
Development and Commercialization Activities have been filed with the FDA, WHO, CE-Mark EMA, HPRA, Health Canada, ANVISA and all other applicable Governmental Authorities.
- 70 -
(c) (i) All material regulatory filings required by any Regulatory Authority or in respect of any Regulatory Approval or Product Authorization with
respect to any Product or any Product Development and Commercialization Activities have been made, and all such filings are complete and correct in all material respects and have complied in all material respects with all applicable Requirements of
Law, (ii) all clinical and pre‑clinical trials, if any, of investigational Products have been and are being conducted by each Obligor according to all applicable Requirements of Law in all material respects along with appropriate monitoring of
clinical investigator trial sites for their compliance, and (iii) each Obligor has disclosed to the Lenders all such material regulatory filings and, to the extent requested by any Lender, any written material communications relating thereto
between representatives of each Obligor and any Regulatory Authority.
(d) Each Obligor and, to each Obligor’s knowledge, each of its agents are in compliance in all material respects with all applicable statutes, rules
and regulations (including all Regulatory Approvals and Product Authorizations) of all applicable Governmental Authorities, including the FDA, WHO, CE-Mark EMA, HPRA, Health Canada, ANVISA and all other Regulatory Authorities, with respect to each
Product and all Product Development and Commercialization Activities related thereto. Each Obligor has and maintains in full force and effect all the necessary and requisite Regulatory Approvals and Product Authorizations for its Products. Each
Obligor is in compliance in all material respects with all applicable registration and listing requirements set forth in all applicable FDA, WHO, CE-Mark EMA, HPRA, Health Canada, ANVISA or Laws or equivalent regulation of each other Governmental
Authority having jurisdiction over such Person. Each Obligor adheres in all material respects to all applicable regulations of all Regulatory Authorities with respect to its Products and all Product Development and Commercialization Activities
related thereto.
(e) Except as set forth on Schedule 7.19(e), (i) no Obligor has received from any Regulatory Authority any notice of adverse findings with respect
to any Product or any Product Development and Commercialization Activities related thereto, including any FDA Form 483 inspectional observations, notices of violations, warning letters, criminal proceeding notices under Section 305 of the FD&C
Act, or any other similar communication from any Regulatory Authority, (ii) there have been no seizures conducted or, to each Obligor’s knowledge, threatened by any Regulatory Authority with respect to any Product, and no recalls, market
withdrawals, field notifications, notifications of misbranding or adulteration or safety alerts conducted, requested or, to any Obligor’s knowledge, threatened by any Regulatory Authority with respect to any Product, and no recalls, market
withdrawals, field notifications, notifications of misbranding or adulteration or safety alerts have been conducted, requested or, to each Obligor’s knowledge, threatened by any Regulatory Authority relating to any Product, and (iii) no Obligor has
received any written notification that remains unresolved from the FDA, WHO, CE-Mark EMA, HPRA, Health Canada, ANVISA or any other Regulatory Authority indicating any breach or violation of any applicable Product Authorization or Regulatory
Approval, including that any Product is misbranded or adulterated as defined in the FD&C Act or the rules and regulations promulgated thereunder, in each case of (i), (ii) and (iii) that has had, or could reasonably be expected to have, a
Material Adverse Effect.
- 71 -
(f) Neither any Obligor nor, to any Obligor’s knowledge, any officer, employee or agent thereof, has made an untrue statement of a material fact or
fraudulent statements to the FDA, WHO, CE-Mark EMA, HPRA, Health Canada, ANVISA or any other Regulatory Authority, failed to disclose a material fact required to be disclosed to the FDA, WHO, CE-Mark EMA, HPRA, Health Canada, ANVISA or any other
Regulatory Authority, or committed an act, made a statement, or failed to make a statement that, at the time such disclosure was made (or was not made), would reasonably be expected to provide a basis for the FDA, WHO, CE-Mark EMA, HPRA, Health
Canada, ANVISA or any other Regulatory Authority to invoke its policy respecting Fraud, Untrue Statements of Material Facts, Bribery and Illegal Gratuities, set forth in 56 Fed. Reg. 46191 (September 10, 1991) or any similar policy.
(g) No Obligor has received any written notice that the FDA, WHO, CE-Mark EMA, HPRA, Health Canada, ANVISA or any other applicable Regulatory
Authority has commenced or initiated, or, to the knowledge of any such Obligor, threatened to commence or initiate, any action to withdraw any Regulatory Approval or Product Authorization or requested the recall of any Products or commenced or
initiated or, to the knowledge of such Obligor, threatened to commence or initiate, any action to enjoin any Product Development and Commercialization Activities of such Obligor.
(h) The clinical, preclinical, safety and other studies and tests conducted by or on behalf of or sponsored by each Obligor, or in respect of which
any Products or Product candidates under development have participated, were (and if still pending, are) being conducted materially in accordance with standard medical and scientific research procedures and all applicable Product Authorizations.
Each Obligor has operated within, and currently is in compliance in all material respects with, all applicable Laws (including, without limitation, all applicable Health Canada Laws), Product Authorizations and Regulatory Approvals, as well as the
rules and regulations of the FDA, Health Canada and each other Regulatory Authority. No Obligor has received any notices or other correspondence from the FDA, Health Canada, or any other Regulatory Authority requiring the termination or suspension
of any clinical, preclinical, safety or other studies or tests used to support regulatory clearance of, or any Product Authorization or Regulatory Approval for, any Product.
(i) No material debarment or exclusionary Claims, actions, proceedings or investigations in respect of any Obligor’s business is pending, or to such
Obligor’s knowledge, threatened in writing against such Obligor or its officers, employees or agents. No Obligor or, to such Obligor’s knowledge, any officer, employee or agent of such Obligor, has been convicted of any crime or engaged in any
conduct that would reasonably be expected to result in a debarment or exclusion (i) Section 335a of the FD&C Act or (ii) any similar applicable Law.
- 72 -
Section 7.20. Capitalization. All of
the issued and outstanding securities of each Obligor have been duly authorized, are validly issued, fully paid, and non‑assessable. Parent has the legal right and full power and authority to execute and deliver, and to perform its obligations
under, the Warrant Certificates. Parent has sufficient authorized but unissued share capital in Parent to satisfy in full, without the need for the passing of any further resolutions of its shareholders, the Warrant Certificates and the
outstanding right to subscribe for shares in Parent as represented by the Warrant Certificates, without first having to offer the same to any existing shareholders of Parent or any other person. As of the Funding Date, except as set forth on
Schedule 7.20 and the Warrant Certificates, there are no outstanding or authorized options, warrants, purchase rights, subscription rights, conversion rights, exchange rights, or other Contracts or commitments that could require the Obligors to
issue, sell, or otherwise cause to become outstanding any of their ownership interests. There are no outstanding or authorized stock appreciation, phantom stock, profit participation, or similar rights with respect to the Obligors (other than the
Parent). There are no voting trusts, proxies, or other agreements or understandings with respect to the voting of the ownership interests of the Obligors (other than the Parent). None of the Equity Interests in any Obligor has been mortgaged,
assigned or pledged in favor of any Person, other than pursuant to the Security Documents.
Section 7.21. Insurance. Each Obligor
has obtained (and is maintaining), insurance for its assets (including the Collateral) and business as required under the Loan Documents.
Section 7.22. Certain Fees. Except as
described on Schedule 7.22, no broker’s or finder’s fee will be payable in connection with the execution and delivery of this Agreement.
Section 7.23. Trade Compliance. Except
as disclosed in Schedule 7.23, Obligors and, to the knowledge of the Obligors, any director, officer or employee of an Obligor acting on behalf of the Obligors, are in compliance with the Sanctions Laws.
Section 7.24. Anti‑Corruption Laws. No
Obligor nor any of its Subsidiaries has, nor, to the knowledge of any Responsible Officer of any Obligor, has any director, officer, agent or employee of any Obligor acting on behalf of such Obligor (a) taken any action, directly or indirectly,
that would result in a violation by such Persons of the Anti‑Corruption Laws or Irish Anti-Corruption Laws, (b) made, offered to make, promised to make or authorized the payment or giving of, directly or indirectly, any Prohibited Payment or
(c) been subject to any investigation by any Governmental Authority with regard to any actual or alleged Prohibited Payment.
Section 7.25. Anti‑Terrorism Laws. The
Obligors (i) have taken reasonable measures to ensure compliance with applicable Economic Sanctions Laws, Anti‑Terrorism Laws and Irish Anti-Terrorism Laws, (ii) are not Designated Persons and (iii) have not used any part of the proceeds from any
advance on behalf of any Designated Person or, has not used, directly by it or indirectly through any Subsidiary, such proceeds in connection with any investment in, or any transactions or dealings with, any Designated Person.
Section 7.26. Royalty and Other Payments.
Except as set forth on Schedule 7.26 and commissions or other sales based compensation to its employees or agents, no Obligor is obligated to pay any material royalty, milestone payment, deferred payment or any other contingent payment in respect
of any Product.
- 73 -
Each Obligor covenants and agrees with the Administrative Agent and the Lenders that, until the Commitments have expired or been terminated and all Obligations (other than the
Warrant Obligations and inchoate indemnity obligations) have been paid in full in cash:
Section 8.01. Financial Statements and Other
Information. The Administrative Borrower will furnish to the Administrative Agent for distribution to the Lenders:
(a) within forty-five (45) days of the end of each fiscal Quarter, a Flash Financial Report.
(b) as soon as available and in any event within fifty-five (55) days after the end of the first and third fiscal quarters, sixty (60) days after
the end of the second fiscal quarter and ninety (90) days after the end of the fiscal year, the consolidated balance sheets of Parent and its Subsidiaries as at the end of such fiscal quarter and the related consolidated statements of income,
stockholders’ equity and cash flows of Parent and its Subsidiaries for such fiscal quarter and for the period from the beginning of the then current fiscal year to the end of such fiscal quarter, setting forth in each case in comparative form the
corresponding figures for the corresponding periods of the previous fiscal year and the corresponding figures from the Financial Plan for the current fiscal year, all in reasonable detail together with (i) a certificate of a Responsible Officer of
the Administrative Borrower stating that such financial statements fairly present in all material respects the financial condition of Parent and its Subsidiaries as at such date and the results of operations of Parent and its Subsidiaries for the
period ended on such date and have been prepared substantially in accordance with IFRS consistently applied, subject to changes resulting from normal quarterly or year‑end adjustments and except for the absence of footnotes and (ii) a management’s
discussion and analysis of the financial condition and results of operations, including Parent and its Subsidiaries’ liquidity and capital resources; provided that documents required to be furnished
pursuant to this Section 8.01(b) shall be deemed furnished on the date that such documents are publicly available on “EDGAR” so long as such filings include quarterly income statements, balance sheets and cash flow statements.
- 74 -
(c) as soon as available and in any event within one hundred twenty (120) days after the end of each fiscal year, the consolidated balance sheets of
Parent and its Subsidiaries as of the end of such fiscal year, and the related consolidated statements of income, shareholders’ equity and cash flows of Parent and its Subsidiaries for such fiscal year, setting forth in each case in comparative
form the corresponding figures for the previous fiscal year and the corresponding figures from the Financial Plan for the fiscal year covered by such financial statements, prepared substantially in accordance with IFRS consistently applied, all in
reasonable detail accompanied by (i) a report and opinion thereon of Grant Thornton or another firm of independent certified public accountants of recognized national standing, which report and opinion shall be prepared in accordance with generally
accepted auditing standards and shall not be subject to any “going concern” or like qualification or exception audit (other than solely with respect to, or resulting solely from the upcoming Stated Maturity Date occurring within one year from the
time such report is delivered) or any qualification or exception as to the scope of such audit or related to the maturity of the Transactions and (ii) a management’s discussion and analysis of the financial condition and results of operations,
including the Obligors’ liquidity and capital resources; provided that, so long as Parent is a Publicly Reporting Company, Parent’s filing of an Annual Report on Form 20-F with the SEC shall be deemed to
satisfy the requirements of this Section 8.01(c) on the date on which such report is first available via the SEC’s EDGAR system or a successor system related thereto;
(d) concurrently with the delivery of the reports described in Section 8.01(b) and (c), and within thirty (30) days after the end of each month
which does not end at the end of a fiscal year or fiscal quarter of Parent, a compliance certificate of a Responsible Officer of the Administrative Borrower as of the end of the applicable accounting period (which delivery may, unless a Lender
requests executed originals, be by electronic communication including email and shall be deemed to be an original authentic counterpart thereof for all purposes) in the form of Exhibit E (a “Compliance
Certificate”) which, for purposes of clarification, shall (i) confirm the Obligors’ compliance with Section 8.15 and (ii) for each month end that coincides with the end of a fiscal quarter or fiscal year of Parent, (A) confirm the
Obligors’ compliance with Section 8.11 and Section 8.16, (B) notify the Administrative Agent if a Subsidiary which qualified as an Immaterial Foreign Subsidiary at the time of the delivery of the previous Compliance Certificate ceases to qualify as
an Immaterial Foreign Subsidiary, (C) state the representations and warranties made by the Obligors in Article 7 are true in all material respects on and as of the date thereof; provided that to the extent
that such representations and warranties specifically refer to an earlier date, they shall be true and correct in all material respects as of such earlier date; provided further that any representation and
warranty that is qualified as to “materiality”, “Material Adverse Effect” or similar language shall be true and correct (after giving effect to any qualification therein) in all respects, (D) confirm that no Default or Event of Default is
continuing (and if a Default or Event of Default has occurred and is continuing state the proposed actions that the Obligors intend to take in connection with such Default or Event of Default), (E) provide a copy of any new Material Agreement and
(F) provide updated Schedules (if any) to this Agreement;
(e) promptly, and in any event within five (5) Business Days after receipt thereof by an Obligor, copies of each notice or other correspondence
received from any securities regulator or exchange to the authority of which an Obligor is subject concerning any investigation or possible investigation or other inquiry by such agency regarding financial or other operational results of such
Obligor;
(f) upon any renewal or replacement, the information regarding insurance maintained by the Obligors as and when required under Section 8.05;
(g) promptly following the Lenders’ written request at any time, proof of the Obligors’ compliance with Section 8.15, which may include statements
showing the current balance of each account of the Obligors holding Unrestricted Cash necessary to establish compliance with Section 8.15;
- 75 -
(h) within ten (10) days of delivery, copies of all periodic reports distributed by Parent to its shareholders generally; provided that (i) any such material may be redacted by Parent to exclude information relating to the Loan Documents or the Lenders and (ii) the Lenders shall not be entitled to receive statements, reports and notices relating to
topics that (A) are subject to attorney‑client privilege or (B) present a conflict of interest for the Lenders; provided that, so long as Parent is a Publicly Reporting Company, Parent’s filing of any such
material with the SEC shall be deemed to satisfy the requirements of this Section 8.01(h) on the date on which such report is first available via the SEC’s EDGAR system or a successor system related thereto;
(i) a financial forecast for Parent and its Subsidiaries for each fiscal year, including forecasted balance sheets, statements of income and cash
flows of the Borrower and its Subsidiaries (the “Financial Plan”), all of which shall be prepared on a consolidated basis and delivered not later than March 31 of such fiscal year;
(j) within five (5) Business Days following any Lender’s written request, certification that such Obligor is not a passive foreign investment
company (“PFIC”) within the meaning of Sections 1291 through 1297 of the Code, or, if such Obligor determines that it is a PFIC, such information as would allow the Lender to make a qualified electing fund
election with respect to the Equity Interest of the Obligor;
(k) so long as Parent is a Publicly Reporting Company, the Administrative Borrower shall within five (5) Business Days of Parent filing, provide
access (via posting and/or links on Parent’s web site) to all reports on Form 20-F and Form 6-K filed with the SEC, any Governmental Authority succeeding to any or all of the functions of the SEC or with any national securities exchange; and within
five (5) Business Days of filing, provide notice and access (via posting and/or links on Parent’s web site) to all reports filed with the SEC, and copies of (or access to, via posting and/or links on Parent’s web site) all other reports, proxy
statements and other materials filed by Parent with the SEC, any Governmental Authority succeeding to any of the functions of the SEC or with any national securities exchange; and
(l) commencing with January 14, 2025 and every Tuesday thereafter, cash flow forecasts and accounts payable agings of Parent and its Subsidiaries,
in form and substance satisfactory to the Administrative Agent.
Section 8.02. Notices of Material Events. The
Administrative Borrower will furnish to the Administrative Agent for distribution to the Lenders written notice of the following events within the time frames listed below:
(a) promptly after the occurrence of any Default or Event of Default;
(b) within three (3) Business Days after the occurrence of any Casualty Event with respect to any Obligor’s Property;
- 76 -
(c) (i) prior to the execution of a definitive agreement for any proposed Acquisition by any Obligor that would reasonably be expected to result in
environmental liability under Environmental Laws in excess of $250,000, and (ii) in each case, to the extent that any of the following would reasonably be expected to result in liability in excess of $500,000: (A) spillage, leakage, discharge,
disposal, leaching, migration or release of any Hazardous Material required to be reported to any Governmental Authority under applicable Environmental Laws, and (B) all actions, suits, Claims, notices of violation, hearings, investigations or
proceedings pending, or threatened in writing against or affecting any Obligor or with respect to the ownership, use, maintenance and operation of their respective businesses, operations or properties, relating to Environmental Laws or Hazardous
Material;
(d) within three (3) Business Days of obtaining written notice or knowledge thereof, the assertion of any environmental matter by any Person in
writing against, or with respect to the activities of, any Obligor and any alleged violation of or non‑compliance with any Environmental Laws or any Permits, licenses or authorizations, in each case, which would reasonably be expected to involve
damages in excess of $250,000 other than any environmental matter or alleged violation that, if adversely determined, would not (either individually or in the aggregate) have a Material Adverse Effect;
(e) within three (3) Business Days of obtaining notice to an Obligor of the filing or commencement of any action, suit or proceeding by or before
any arbitrator or Governmental Authority against or directly affecting any Obligor, in each case, that would reasonably be expected to result in a Material Adverse Effect;
(f) (i) on or prior to any filing by any ERISA Affiliate of any notice of intent to terminate any Title IV Plan, a copy of such notice and
(ii) promptly, and in any event within ten (10) days, after any Responsible Officer of any ERISA Affiliate knows or has reason to know that a request for a minimum funding waiver under Section 412 of the Code has been filed with respect to any
Title IV Plan or Multiemployer Plan, a notice (which may be made by telephone if promptly confirmed in writing) describing such waiver request and any action that any ERISA Affiliate proposes to take with respect thereto, together with a copy of
any notice filed with the PBGC or the IRS pertaining thereto;
(g) within ten (10) Business Days of obtaining written notice or knowledge thereof, (i) the termination of any Material Agreement other than in the
Ordinary Course of Business pursuant to its terms; (ii) the receipt by any Obligor of a written notice under any Material Agreement (and a copy thereof) asserting a default by such Obligor where such alleged default would permit such counterparty
to terminate such Material Agreement; (iii) the entering into any new Material Agreement by an Obligor (and a copy thereof); or (iv) any amendment to a Material Agreement that would be materially adverse to the Lenders (and a copy thereof) (which
includes, but is not limited to, any amendments to provisions relating to pricing and term); provided that notices required under this subsection (g) may be delivered with the next Compliance Certificate
unless any of the foregoing events would reasonably be expected to have a Material Adverse Effect;
(h) within three (3) Business Days of obtaining written notice or knowledge thereof, any product recalls, safety alerts, corrections, withdrawals,
marketing suspensions, removals or the like conducted, to be undertaken or issued by any Obligor, whether or not at the request, demand or order of any Governmental Authority or otherwise with respect to any Product;
- 77 -
(i) within five (5) Business Days of obtaining written notice or knowledge thereof, any infringement or other violation by any Person of any Obligor
Intellectual Property that would reasonably be expected to result in a Material Adverse Effect;
(j) within five (5) Business Days of obtaining written notice or knowledge thereof, a material licensing agreement or arrangement entered into by
any Obligor in connection with any infringement or alleged infringement of the Intellectual Property of another Person that could reasonably be likely to result in a Material Adverse Effect;
(k) within five (5) Business Days of obtaining written notice or knowledge thereof, any written Claim by any Person that the conduct of any
Obligor’s business, including the development, manufacture, use, sale or other commercialization of any Product, infringes any Intellectual Property of such Person, except to the extent any such Claim would not reasonably be expected to result in a
Material Adverse Effect;
(l) the distribution of the reports and notices as and when required by the Security Documents;
(m) within thirty (30) days of the date thereof, or, if earlier, on the date of delivery of any financial statements pursuant to Section 8.01,
notice of any material change in accounting policies or financial reporting practices by the Obligors;
(n) within thirty (30) days after the occurrence thereof, notice of any labor controversy resulting in or threatening to result in any strike, work
stoppage, boycott, shutdown or other labor disruption against or involving an Obligor that is reasonably expected to have a Material Adverse Effect;
(o) within five (5) Business Days of any other development that results in, or would reasonably be expected to result in, a Material Adverse Effect;
(p) within five (5) Business Days of the failure to pay any Taxes or obligations in accordance with Section 8.04;
(q) concurrently with the delivery of financial statements under Section 8.01, after the date hereof and during such prior fiscal year, the creation
or other acquisition of any Intellectual Property by any Obligor that is registered or becomes registered or is the subject of an application for registration with the United States Copyright Office, the United States Patent and Trademark Office or
the Canadian Intellectual Property Office, as applicable, or with any other equivalent foreign Governmental Authority; and
(r) five (5) Business Days prior to any change to any Obligor’s ownership of Deposit Accounts, Securities Accounts and Commodity Accounts, by
delivering to the Lenders an updated Schedule 7 to the Security Agreements setting forth a complete and correct list of all such accounts as of the date of such change.
- 78 -
The specified time periods in this Section 8.02 shall begin accruing after a Responsible Officer of an Obligor first learns of the existence of a circumstance requiring notice.
Each notice delivered under this Section 8.02 shall be accompanied by a statement of a Responsible Officer of the Administrative Borrower setting forth in reasonable detail the
event or development requiring such notice and any action taken or proposed to be taken with respect thereto; provided that, so long as Parent is a Publicly Reporting Company, Parent’s filing of notice of
any such event with the SEC shall be deemed to satisfy the requirements of this Section 8.02 on the date on which such report is first available via the SEC’s EDGAR system or a successor system related thereto.
Notwithstanding any contrary provision of this Agreement or any other Loan Document (including, without limitation, Sections 8.01 and 8.02), so long as Parent is a Publicly
Reporting Company, in the event that the Administrative Agent provides notice to the Administrative Borrower that it no longer desires to receive any information that constitutes material non‑public information, the Obligors shall not be required
to provide any information pursuant to the terms hereof or thereof unless Parent is disclosing such information pursuant to a filing with the SEC; provided that notwithstanding the foregoing, the Obligors
shall at all times comply with Section 8.01(d) and 8.02(a).
(a) Each Obligor will do or cause to be done all things necessary to preserve, renew and keep in full force and effect its legal existence;
provided that the foregoing shall not prohibit any merger, amalgamation, plan of arrangement, consolidation, liquidation or dissolution permitted under Section 9.03.
(b) Each Obligor shall maintain and preserve all rights, licenses, permits, privileges and franchises material to the conduct of its business, and
maintain and preserve all of its assets and properties, including all Product Assets, necessary to the conduct of its business in good working order and condition, ordinary wear and tear and damage from casualty or condemnation excepted.
(c) Each Obligor shall use commercially reasonable efforts to cause each new Key Employee and each contractor with access to material Obligor
Intellectual Property to execute and deliver a customary confidentiality, non‑disclosure and Intellectual Property assignment agreement that includes a waiver of moral rights to the extent permitted by Law and such agreements are customary in the
applicable jurisdiction.
(d) Parent shall maintain sufficient authorized but unissued share capital in Parent to satisfy in full, without the need for the passing of any
further resolutions of its shareholders, the outstanding rights represented by the Warrant Certificates.
- 79 -
Section 8.04. Payment of Obligations.
Each Obligor shall pay and discharge (a) all United States federal income and other material Taxes, fees, assessments and governmental charges or levies imposed upon it or upon its properties or assets prior to the date on which material penalties
attach thereto, and all lawful Claims for labor, materials and supplies which, if unpaid, might become a Lien (other than a Permitted Lien) upon any properties or assets of any Obligor, except to the extent such Taxes, fees, assessments or
governmental charges or levies, or such Claims, are being contested in good faith by appropriate proceedings and are adequately reserved against substantially in accordance with IFRS, (b) all lawful Claims which, if unpaid, would by Law become a
Lien upon its Property not constituting a Permitted Lien and (c) all other obligations, if the failure to discharge such obligation would reasonably be expected to result in a Material Adverse Effect.
Section 8.05. Insurance. Each Obligor
shall, at its own cost and expense obtain and maintain, with financially sound and reputable insurers, insurance of the kinds, and in the amounts, as are consistent with customary practices and standards of its industry in the same or similar
locations, it being understood and agreed that the insurance held by the Obligors on the Fifth Amendment Restatement Date is deemed to fulfill this requirement on the date hereof. All of the insurance policies required pursuant to this
Section 8.05 with respect to the Obligors, will name the Administrative Agent as a “lender’s loss payee,” “additional insured” or “mortgagee,” as applicable and as its interests may appear. Each Obligor will use its commercially reasonable efforts
to ensure, or to cause others to ensure, that all insurance policies required pursuant to this Section 8.05 with respect to the Obligors, shall provide that they shall not be terminated or cancelled nor shall any policy be materially changed in a
manner adverse to the insured Person without at least thirty (30) days’ written notice (or ten (10) days’ written notice if termination is due to non-payment) to insured Person and the Administrative Agent. Receipt of notice of termination or
cancellation of any such insurance policies shall entitle the Administrative Agent to renew any such policies, all in accordance with the first sentence of this Section 8.05 or otherwise obtain similar insurance in place of such policies, in each
case at the expense of such Obligor (payable within three (3) Business Days of any Obligor’s receipt of written demand therefor) and, unless an Event of Default has occurred and is continuing, with the prior written consent of such Obligor (such
consent not to be unreasonably withheld). The amount of any such expenses shall accrue interest at the Default Rate if not paid when due and shall constitute “Obligations.” All of the insurance policies required hereby with respect to the
Obligors, will be evidenced by one or more certificates of insurance, together with appropriate lender’s loss payee or additional insured clauses or endorsements in favor of the Administrative Agent as required by this Section 8.05, delivered to
the Administrative Agent on or prior to the date hereof and at such other times as the Administrative Agent may request from time to time.
Section 8.06. Books and Records; Inspection
Rights. Each Obligor will keep proper books of record and account in which full, true and correct entries are made of all dealings and transactions in relation to its business and activities. It will permit any representatives designated
by the Administrative Agent, upon reasonable prior notice and at reasonable times, to visit and inspect its properties, to examine and make extracts from its books and records, and to discuss its affairs, finances and condition with its officers
and independent accountants, all at such reasonable times during normal business hours and with reasonable advance notice as the Administrative Agent may request. It will, pay all reasonable and documented out‑of‑pocket expenses incurred by the
Administrative Agent (a) so long as no Default has occurred and is continuing, of two (2) such inspections each calendar year and (b) during a continuing Default, all such inspections.
- 80 -
(a) Each Obligor will, and will cause each of its Subsidiaries to, (i) comply in all material respects with all Requirements of Law (including
Healthcare Laws and Environmental Laws) and (ii) comply in all material respects with all terms of outstanding Indebtedness and all Material Agreements, except (other than with respect to Material Intellectual Property) where the failure to do so,
individually or in the aggregate, would not reasonably be expected to result in a Material Adverse Effect.
(b) Each Obligor will maintain all records required to be maintained by a Governmental Authority or otherwise under any applicable Healthcare Law,
except where failure to do so, individually or in the aggregate, would not reasonably be expected to have a Material Adverse Effect.
(c) Each Obligor will maintain a Health Care Compliance Program, which will be reviewed and updated annually, as necessary.
Section 8.08. Licenses. Each Obligor
will obtain and maintain all licenses, authorizations, consents, filings, exemptions, registrations and other Governmental Approvals necessary in connection with the execution, delivery and performance of the Loan Documents, the consummation of the
Transactions or the operation and conduct of its business and ownership of its properties, except where failure to do so would not reasonably be expected to have a Material Adverse Effect.
Section 8.09. Action under Environmental Laws.
Each Obligor will, upon a Responsible Officer becoming aware of the release of any Hazardous Materials or the existence of any environmental liability under applicable Environmental Laws with respect to their respective businesses, operations or
properties, take all actions, at their cost and expense, as shall be required by applicable Law to investigate and clean up the condition of their respective businesses, operations or properties, including all required removal, containment and
remedial actions, and restore their respective businesses, operations or properties to a condition, except where failure to do so would not reasonably be expected to have a Material Adverse Effect.
Section 8.10. Use of Proceeds. The
proceeds of the Term Loans will be used only as provided in Section 2.05. No part of the proceeds of the Term Loans will be used, whether directly or indirectly, for any purpose that violates any of the regulations of the Board of Governors of the
Federal Reserve System, including Regulations T, U and X.
- 81 -
Section 8.11. Certain Obligations Respecting
Subsidiaries; Further Assurances; and Intellectual Property.
(a) Subsidiaries. Each Obligor will take such action, and will cause each of its Subsidiaries to take such
action, from time to time as shall be necessary to ensure that all Subsidiaries are “Guarantors” hereunder. Without limiting the generality of the foregoing, in the event that any Obligor or any of its Subsidiaries shall form or acquire any new
Subsidiary, it and its Subsidiaries will promptly and in any event within fifteen (15) days (or such longer time as consented to by the Administrative Agent in writing) of the formation or Acquisition of such Subsidiary:
(i) cause such new Subsidiary to become a “Guarantor” hereunder, and a “Grantor” under the Security Documents, pursuant to a Guarantee
Assumption Agreement and cause such new Subsidiary to become an “Obligor” under the Intercompany Subordination Agreement and the Luxembourg Subsidiary Intercompany Subordination Agreement;
(ii) take such action or cause such Subsidiary to take such action (including delivering originals of any certificated Equity Interests of such
Subsidiary, together with original, executed, undated transfer powers executed in blank and originals of any intercompany notes with undated endorsements executed in blank) as shall be necessary to create and perfect valid and enforceable first
priority (subject to Permitted Liens) Liens on substantially all of the personal Property of such new Subsidiary as collateral security for the obligations of such new Subsidiary hereunder;
(iii) to the extent that the parent of such Subsidiary is not a party to the Security Documents or has not otherwise pledged Equity Interests in
its Subsidiaries in accordance with the terms of the Security Documents and this Agreement, cause the parent of such Subsidiary to execute and deliver a pledge agreement in favor of the Lenders, in respect of all outstanding issued shares of such
Subsidiary; and
(iv) deliver such proof of corporate action, incumbency of officers, opinions of counsel and other documents as is consistent with those delivered
by each Obligor pursuant to Section 6.01 or as the Majority Lenders shall have requested;
provided that, solely with respect to any Subsidiary that is an Immaterial Foreign Subsidiary, no such actions shall be required other than (x) a pledge by
the owner of such Immaterial Foreign Subsidiary (to the extent such owner is a Canadian Obligor or a Borrower) of 100% of the Equity Interests of such Immaterial Foreign Subsidiary, which pledge shall not be required to be perfected under the Law
of such Immaterial Foreign Subsidiary’s jurisdiction of formation and (y) causing such Immaterial Foreign Subsidiary to the execute a joinder to the Intercompany Subordination Agreement; provided further,
that at the request of the Administrative Agent, with respect to an Immaterial Foreign Subsidiary that is owned by an Irish Obligor, the owner of such Immaterial Foreign Subsidiary shall pledge 100% of the Equity Interests of such Immaterial
Foreign Subsidiary, which pledge shall be perfected under the Law of such Immaterial Foreign Subsidiary’s jurisdiction of formation. Upon the creation or designation of a Foreign Subsidiary as an Immaterial Foreign Subsidiary, the Administrative
Borrower shall provide notice to the Administrative Agent designating such Foreign Subsidiary as an Immaterial Foreign Subsidiary. For the avoidance of doubt, in the event that any Subsidiary ceases to qualify as an Immaterial Foreign Subsidiary,
such Foreign Subsidiary shall, at the request of the Administrative Agent, or the election of the Borrowers, promptly comply with clauses (a)(i)-(iv) hereof.
- 82 -
On the Original Closing Date, and until such time that the Administrative Agent may request, the Luxembourg Subsidiary shall not be a Guarantor, shall not be required to take the actions set forth
in this Section 8.11 and the owner of the Luxembourg Subsidiary shall not be required to pledge the Equity Interests of the Luxembourg Subsidiary.
(b) Further Assurances. Each Obligor will take such action from time to time as shall reasonably be
requested in writing by the Majority Lenders to effectuate the purposes and objectives of this Agreement. Without limiting the generality of the foregoing, it will, and will cause each Person that is required to be a Guarantor to, take such action
from time to time (including executing and delivering such assignments, security agreements, control agreements and other instruments) as shall be reasonably requested in writing by the Majority Lenders to create, in favor of the Lenders, perfected
security interests and Liens (subject to Permitted Liens) in substantially all of the personal Property of such Obligor as collateral security for the Obligations; provided that any such security interest
or Lien shall be subject to the relevant requirements of the Security Documents.
(c) Intellectual Property. In the event that any Obligor creates, develops or acquires Obligor
Intellectual Property during the term of this Agreement, then the provisions of this Agreement shall automatically apply thereto and any such Obligor Intellectual Property shall automatically constitute part of the Collateral under the Security
Documents, without further action by any party, in each case from and after the date of such creation, development or acquisition (except that any representations or warranties of any Obligor shall apply to any such Obligor Intellectual Property
only from and after the date, if any, subsequent to such acquisition that such representations and warranties are brought down or made anew as provided herein). In the event that any Obligor holds or acquires Obligor Intellectual Property during
the term of this Agreement, then, upon the request of the Administrative Agent, such Obligor shall take any action as shall be reasonably necessary and reasonably requested by the Administrative Agent to ensure that the provisions of this Agreement
and the Security Agreements shall apply thereto and any such Obligor Intellectual Property shall constitute part of the Collateral under the Security Documents.
Section 8.12. Termination of Non‑Permitted
Liens. In the event that any Responsible Officer of any Obligor shall become aware or be notified by the Lenders of the existence of any outstanding Lien against any Property of any Obligor or any of its Subsidiaries, which Lien is not a
Permitted Lien, such Obligor shall use its best efforts to promptly terminate or cause the termination of such Lien.
Section 8.13. Non-Consolidation. Each
Obligor will maintain entity records and books of account separate from those of any other entity, other than the Obligors, which is an Affiliate of such entity.
- 83 -
Section 8.14. Anti‑Terrorism and
Anti‑Corruption Laws. No Obligor nor any of its Subsidiaries shall engage in any transaction that violates any of the applicable prohibitions set forth in any Economic Sanctions Law, Irish Economic Sanctions Laws, Anti‑Terrorism Law,
Irish Anti-Terrorism Laws or the US Foreign Corrupt Practices Act of 1977 (15 USC. §§ 78dd‑1 et seq.). No Obligor will use any part of the proceeds from the loan
on behalf of any Designated Person and will not use, directly by it or indirectly through any Subsidiary, such proceeds in connection with any investment in, or any transactions or dealings with, any Designated Person. None of the funds or assets
of such Obligor or any Subsidiary that are used to repay the Term Loans shall constitute property of, or shall be beneficially owned by, any Designated Person or, to such Obligor’s knowledge, be the direct proceeds derived from any transactions
that violate the prohibitions set forth in any applicable Economic Sanctions Law or Irish Economic Sanctions Laws and no Designated Person shall have any direct or indirect interest in such Obligor or such Subsidiary insofar as such interest would
violate any Economic Sanctions Laws or Irish Economic Sanctions Laws applicable to such Obligor or such Subsidiary.
Section 8.15. Minimum Liquidity. (i)
Commencing July 1, 2025 and ending on October 31, 2025, the Obligors shall have aggregate Unrestricted Cash of not less than $1,000,000 at all times and (ii) commencing November 1, 2025, the Obligors shall have aggregate Unrestricted Cash of not
less than $3,000,000 at all times.
Section 8.16 Minimum Net Revenue. As of the
end of the fiscal quarter ended December 31, 2023, and each fiscal quarter thereafter, Parent and its Subsidiaries shall maintain, on a consolidated basis, Net Revenue for the twelve (12) month period most recently ended on such date of not less
than the amount set forth in the table below:
|
Twelve-Month Period Ended
|
Minimum Net Revenue
|
|
December 31, 2023
|
$0
|
|
March 31, 2024
|
$53,100,000
|
|
June 30, 2024
|
$54,300,000
|
|
September 30, 2024
|
$55,700,000
|
|
December 31, 2024
|
$0
|
|
March 31, 2025
|
$0
|
|
June 30, 2025
|
$43,000,000
|
|
September 30, 2025
|
$45,000,000
|
|
December 31, 2025
|
$47,000,000
|
|
March 31, 2026
|
$55,000,000
|
|
June 30, 2026
|
$60,000,000
|
- 84 -
Section 8.17. Maintenance of Regulatory
Approvals, Contracts, Intellectual Property, Etc. With respect to each Product, each Obligor will (a) maintain in full force and effect all material Regulatory Approvals (including the Product Authorizations), Material Agreements, or
other rights necessary for the current operations of such Obligor’s business, as the case may be, including in respect of all related Product Development and Commercialization Activities; (b) maintain in full force and effect all Material
Intellectual Property and Material WaveForm IP that is used in and necessary for related Product Development and Commercialization Activities; and (c) use commercially reasonable efforts to pursue and maintain in full force and effect legal
protection for all new, Material Intellectual Property and Material WaveForm IP that is used in and necessary in connection with any Product Development and Commercialization Activities relating to any such Product.
(a) maintain all Deposit Accounts, Securities Accounts, Commodity Accounts and lockboxes (other than
Excluded Accounts) with a bank or financial institution that has either (i) other than in respect of any such account charged pursuant to the Irish Debenture, executed and delivered to the Administrative Agent an account control agreement
(provided that, for greater certainty, if under the applicable laws of any Canadian jurisdiction control over Deposit Accounts is not available, then an account control agreement shall be deemed to constitute a springing blocked account or
springing cash dominion agreement in respect of such Deposit Accounts) or (ii) in respect of any such account charged pursuant to the Irish Debenture, executed and delivered to the Administrative Agent an acknowledgment to the notice of assignment
delivered to such bank or financial institution by the relevant Irish Obligor pursuant to the Irish Debenture, in each case in form and substance reasonably acceptable to the Administrative Agent (each such Deposit Account, Securities Account,
Commodity Account and lockbox, a “Controlled Account”);
(b) deposit promptly, and in any event no later than seven (7) Business Days after the date of receipt
thereof, all cash, checks, drafts or other similar items of payment relating to or constituting payments greater than $75,000 in the aggregate at any time made in respect of any and all accounts and other rights and interests into Controlled
Accounts; and
- 85 -
(c) in order to segregate and to facilitate perfection of Administrative Agent’s security interest in
funds received by any Obligor from any Federal Health Care Programs, the applicable Obligor shall, with respect to an Obligor’s future participation in any Federal Health Care Program, prior to such Obligor’s receipt of payments exceeding $50,000
in any month from Federal Health Care Programs, notify all Government Authorities making any payments under any Federal Health Care Program to make any such payments only to one or more Segregated Health Care Accounts. No Obligor shall deposit any
funds to a Segregated Health Care Account or direct or permit any other Person to deposit any funds to a Segregated Health Care Account, other than payments received from Federal Health Care Programs. The Obligors shall upon the date the
applicable Obligor begins receiving payments from any Federal Health Care Program, to cause all amounts deposited into the Segregated Health Care Accounts to be automatically swept on a daily basis to a Controlled Account pursuant to a Sweep
Agreement. Any such Sweep Agreement will require such depository bank to waive all of its existing and future rights of recoupment and set-off and banker’s lien against any Segregated Health Care Accounts, but shall permit such depository bank to
maintain its existing and future rights of recoupment and set-off and banker’s lien against any Controlled Account.
Section 8.20. COMI. The Parent and each
other Irish Obligor will maintain its COMI in Ireland and not have an establishment (within the meaning of the EU Insolvency Regulation) outside Ireland.
Section 8.21. Cashless Exercise of Warrant
Certificate and Par Value. If Perceptive (or its permitted successors or assigns with respect to a Warrant Certificate) exercises at any time, in whole or in part, a Warrant Certificate by means of the “cashless exercise” procedure
specified in that Warrant Certificate, then the following shall apply. With respect to the American Depositary Shares relating to the American Depositary Receipts the subject of such cashless exercise (the “Relevant
ADSs”) the Non-EEA Obligors shall procure (on a joint and several basis) that a cash amount is paid to the Parent sufficient to ensure that, immediately following the exercise of such cashless exercise, the shares in the capital of the
Parent represented by the Relevant ADSs are fully paid up to their par value to the extent required by the Constitution of the Parent and the Companies Act 2014 of Ireland (as amended). Capitalized terms used in this Section 8.21 and not otherwise
defined in this Agreement have the meaning given to them in the applicable Warrant Certificate. For avoidance of doubt: (i) none of Perceptive (or its successors or assigns) shall be liable to account to any Obligor or other person with respect to
any amount paid pursuant to this Section and (ii) notwithstanding any other provision of this Agreement, no EEA Obligor shall be liable (whether as principal or surety or otherwise) to make payment under this Section 8.21 in any circumstances.
Section 8.22. Canadian Pension Plans. Maintain all Canadian Pension Plans relating to each Obligor
in compliance with all applicable Laws in all material respects.
Section 8.23. Payment of Warrant Stamp Amount. As soon as possible following the Third Amendment
Restatement Date (but in any event no less than fifteen (15) Business Days prior to the deadline for filing such return with the Irish Revenue Commissioners) the Lenders and their Affiliates shall provide the Parent with a draft form of stamp duty
return and within ten (10) days of being provided with such draft form of stamp duty return, the Parent shall provide the Lenders and their Affiliates with its reasonable comments thereon. The Lenders and their Affiliates shall consider any such
reasonable comments and shall ensure that the return is filed with the Irish Revenue Commissioners in advance of the deadline for filing such return.
- 86 -
Each Obligor covenants and agrees with the Administrative Agent and the Lenders that, until the Commitments have expired or have been terminated and all Obligations (other than
the Warrant Obligations and inchoate indemnity obligations) have been paid in full in cash:
Section 9.01. Indebtedness. Each
Obligor will not, and will not permit any of its Subsidiaries to, create, incur, assume or permit to exist any Indebtedness, whether directly or indirectly, except:
(a) the Obligations;
(b) Permitted Indebtedness and Permitted Refinancings thereof; provided,
that the aggregate principal amount of Permitted Indebtedness on the Original Closing Date not listed on Schedule 7.13A shall not exceed $500,000;
(c) accounts payable to trade creditors for goods and services and current operating liabilities (not the
result of the borrowing of money) incurred in the Ordinary Course of Business after the Original Closing Date;
(d) Indebtedness consisting of Guarantees resulting from endorsement of negotiable instruments for
collection by an Obligor or any of its Subsidiaries in the Ordinary Course of Business;
(e) Indebtedness in the form of intercompany receivables and payables: (i) among Obligors; (ii) among
Immaterial Foreign Subsidiaries; and (iii) among Immaterial Foreign Subsidiaries and an Obligor; provided that (x) all additional liabilities from an Obligor to an Immaterial Foreign Subsidiary (other than
liabilities from an Obligor to the Brazilian Subsidiary) pursuant to clause (iii) arising after the Original Closing Date, together with the Investments in Immaterial Foreign Subsidiaries permitted pursuant to Section 9.05(m), made after the
Original Closing Date, shall in an aggregate amount not exceed $1,000,000 plus interest accrued thereon and (y) until such time as the Brazilian Subsidiary becomes a “Guarantor” hereunder, and a “Grantor” under the Security
Documents, additional liabilities from an Obligor to the Brazilian Subsidiary, together with the Investments in the Brazilian Subsidiary permitted pursuant to Section 9.05(l) made after the Original Closing Date, shall in an aggregate amount not
exceed $1,500,000 per fiscal year plus interest accrued thereon; provided further that all such intercompany liabilities pursuant to clause (iii) shall be unsecured and subordinated in right of payment to
the payment in full of the Obligations pursuant to the terms of the Intercompany Subordination Agreement;
(f) Indebtedness constituting of deposits or prepayments received from customers in the ordinary course
of business;
(g) Guarantees by an Obligor of Indebtedness of any other Obligor;
- 87 -
(h) Purchase money Indebtedness and Capital Lease Obligations; provided
that (i) if secured, the collateral therefor consists solely of the assets being financed, the products and proceeds thereof and books and records related thereto, (ii) in the case of purchase money Indebtedness, such Indebtedness shall constitute
at least 75% of the aggregate consideration paid with respect to such asset and (iii) the aggregate outstanding principal amount of such Indebtedness incurred after the Original Closing Date does not exceed $1,500,000 at any time;
(i) unsecured workers’ compensation Claims, payment obligations in connection with health, disability or
other types of social security benefits, unemployment or other insurance obligations, reclamation and statutory obligations, in each case incurred in the Ordinary Course of Business;
(j) Indebtedness under Hedging Agreements permitted pursuant to Section 9.05(f);
(k) Indebtedness approved in advance in writing by the Majority Lenders;
(l) Indebtedness of the Obligors and their Subsidiaries with respect to overdrafts, or corporate credit
cards not to exceed $750,000 at any time outstanding;
(m) Indebtedness incurred in connection with letters of credit, entered into in the Ordinary Course of
Business, that are secured solely by cash or cash equivalents and issued on behalf of the Borrower in an aggregate amount outstanding not to exceed $2,000,000 at any time;
(n) other unsecured Indebtedness incurred after the Original Closing Date in an aggregate amount not to
exceed $2,500,000;
(o) Indebtedness in the form of intercompany receivables and payables among the Luxembourg Subsidiary and
the Obligors; provided that (i) the aggregate amount of all such intercompany liabilities to the Luxembourg Subsidiary shall not exceed the amounts outstanding on the Funding Date (plus any accrued interest
thereon) and (ii) all such intercompany liabilities shall be unsecured and subordinated in right of payment to the payment in full of the Obligations pursuant to the terms of the Luxembourg Subsidiary Intercompany Subordination Agreement;
(p) [reserved];
(q) any “Contingent Consideration” (as such term is defined under the Effective Date Acquisition
Agreement) owed by U.S. TRIB pursuant to the Effective Date Acquisition Agreement;
(r) [reserved];
(s) the Outstanding Convertible Notes; and
- 88 -
(t) Indebtedness pursuant to the Investor Convertible Note, in an amount not to exceed $20,000,000; provided that such Indebtedness shall be unsecured and subordinated in right of payment to the payment in full of the Obligations pursuant to the terms of the Investor Subordination Agreement.
Section 9.02. Liens. Each Obligor will
not, and will not permit any of its Subsidiaries to, create, incur, assume or permit to exist any Lien on any Property now owned by it, except:
(a) Liens securing the Obligations;
(b) any Lien on any Property of any Obligor existing on the Original Closing Date and set forth in
Schedule 7.13B; provided that (i) no such Lien shall extend to any other Property of such Obligor and (ii) any such Lien shall secure only those obligations which it secures on the Original Closing Date and
extensions, renewals and replacements thereof that do not increase the outstanding principal amount thereof;
(c) Liens securing Indebtedness permitted under Section 9.01(h); provided
that such Liens are restricted solely to the collateral described in Section 9.01(h);
(d) Liens imposed by Law which were incurred in the Ordinary Course of Business, including (but not
limited to) carriers’, warehousemen’s, landlords’ and mechanics’ Liens, Liens relating to leasehold improvements and other similar liens arising in the Ordinary Course of Business and which (i) do not in the aggregate materially detract from the
value of the Property subject thereto or materially impair the use thereof in the operations of the business of such Person or (ii) are being contested in good faith by appropriate proceedings, which proceedings have the effect of preventing the
forfeiture or sale of the Property subject to such Liens and for which adequate reserves have been made if required substantially in accordance with IFRS;
(e) Liens, pledges or deposits made in the Ordinary Course of Business in connection with bids, grant
applications, Contracts, leases, appeal bonds, workers’ compensation, unemployment insurance or other similar social security legislation;
(f) Liens securing Taxes, assessments and other governmental charges, the payment of which is not yet due
or is being contested in good faith by appropriate proceedings promptly initiated and diligently conducted and for which such reserve or other appropriate provisions, if any, as shall be required by IFRS shall have been made;
(g) servitudes, easements, rights of way, restrictions and other similar encumbrances on real Property
imposed by applicable Laws and encumbrances consisting of zoning or building restrictions, easements, licenses, restrictions on the use of Property or minor imperfections in title thereto which, in the aggregate, are not material, and which do not
in any case materially detract from the value of the Property subject thereto or materially interfere with the ordinary conduct of the business of any of the Obligors;
- 89 -
(h) bankers’ Liens, rights of setoff and similar Liens incurred in the Ordinary Course of Business and
arising in connection with the Obligors’ Deposit Accounts or Securities Accounts held at financial institutions solely to secure payment of fees and similar costs and expenses of such financial institutions with respect to such accounts;
(i) Liens in connection with transfers permitted under Section 9.09;
(j) any judgment Lien or Lien arising from decrees or attachments not constituting an Event of Default;
(k) leases or subleases of real property granted in the Ordinary Course of Business, and leases,
subleases, nonexclusive licenses or sublicenses of personal property (other than Intellectual Property) granted in the Ordinary Course of Business;
(l) Liens in favor of customs and revenue authorities arising as a matter of law to secure the payment of
custom duties in connection with the importation of goods in the Ordinary Course of Business;
(m) Liens on a Deposit Account of the Obligors and the cash and cash equivalents therein, in each case,
securing Indebtedness described in Section 9.01(l);
(n) Permitted Licenses solely to the extent that such Permitted License would constitute a Lien; and
(o) Liens securing Indebtedness permitted pursuant to Sections 9.01(r);
provided that no Lien otherwise permitted under any of the foregoing Sections 9.02(b), (c), (d), (e), (g), (h), (i), (k), (l) or (m) shall apply to any
Material Intellectual Property and any Material WaveForm IP.
Section 9.03. Fundamental Changes and
Acquisitions. Each Obligor will not, and will not permit any of its Subsidiaries to:
(a) enter into or consummate any transaction of merger, amalgamation, plan of arrangement, or
consolidation, including without limitation, a reverse‑triangular merger, or other similar transaction or series of related transactions;
(b) liquidate, wind up or dissolve itself (or suffer any liquidation, wind up or dissolution) (including in
connection with any division or plan of division under Delaware law or any comparable event under a different jurisdiction’s laws), except as permitted by Section 9.03(c)(v); and
(c) make or consummate any Acquisition or sell or issue any Disqualified Equity Interests except, in each
case:
(i) Investments permitted under Section 9.05;
- 90 -
(ii) Permitted Acquisitions for (A) an aggregate cash consideration not to exceed $2,500,000 and (B) total consideration not to exceed $5,000,000,
in each case, for the duration of this Agreement; provided, that any Obligor may make a Permitted Acquisition in excess of the consideration amounts set forth above, so long as the consideration for such
Acquisition is funded with the proceeds of the Delayed Draw Term Loan;
(iii) the merger, amalgamation, plan of arrangement, or consolidation of any Obligor with or into any other Obligor, provided that if a Borrower is a party to such merger, amalgamation, plan of arrangement, or consolidation, such Borrower shall be the surviving entity;
(iv) the merger, amalgamation, plan of arrangement, or consolidation of any Immaterial Foreign Subsidiary with or into any other Immaterial
Foreign Subsidiary;
(v) the liquidation, winding up or dissolution of the Subsidiaries listed in Schedule 9.03, any Immaterial Foreign Subsidiary and the Luxembourg
Subsidiary; and
(vi) the Effective Date Acquisition.
(a) Each Obligor will not, and will not permit any of its Subsidiaries to, engage to any material extent
in any business other than (i) the business engaged in on the Fifth Amendment Restatement Date by such Obligor, or (ii) a business reasonably related, incidental or complementary thereto or reasonable extensions thereof, including, without
limitation, the development, acquisition, manufacture or marketing of biosensor products and related services.
(b) Parent shall not have any material liabilities (other than liabilities to other Obligors and
liabilities arising under the Loan Documents), own any material assets (other than Investments in its Subsidiaries) or engage in any material operations or business (other than the ownership of its Subsidiaries, exercising its rights and performing
its obligations under (i) the Loan Documents, (ii) its obligations to other Obligors and (iii) Investments in Subsidiaries and activities reasonably incident to (i), (ii) and (iii)).
(c) U.S. Holdings shall not have any material liabilities (other than liabilities to other Obligors and
liabilities arising under the Loan Documents), own any material assets (other than Investments in its Subsidiaries) or engage in any material operations or business (other than the ownership of its Subsidiaries, exercising its rights and performing
its obligations under (i) the Loan Documents, (ii) its obligations to other Obligors and (iii) Investments in Subsidiaries and activities reasonably incident to (i), (ii) and (iii)).
- 91 -
Section 9.05. Investments. Each Obligor
will not, and will not permit any of its Subsidiaries to, make, directly or indirectly, or permit to remain outstanding any Investments except:
(a) Investments outstanding on the Original Closing Date and identified in Schedule 9.05(a) and any
modification, replacement, renewal or extension thereof to the extent not involving new or additional Investments;
(b) operating Deposit Accounts with banks, Securities Accounts and Commodities Accounts;
(c) extensions of credit in the nature of accounts receivable or notes receivable arising from the sales
of goods or services in the Ordinary Course of Business of the relevant Obligor;
(d) Permitted Cash Equivalent Investments;
(e) (i) Investments consisting of the ownership of the Equity Interests of its Subsidiaries, (ii)
intercompany Investments by an Obligor in any other Obligor or (iii) Investments by the Obligors and its Subsidiaries consisting of 100% of the ownership of the Equity Interests of the Person acquired in connection with a Permitted Acquisition and
the Effective Date Acquisition;
(f) Hedging Agreements entered into in the ordinary course of any Obligor’s financial planning solely to
hedge interest rate or foreign currency exchange risks (and not, in either case, for speculative purposes);
(g) Investments consisting of prepaid expenses, negotiable instruments held for collection or deposit,
security deposits with utilities, landlords and other like Persons, and deposits in connection with workers’ compensation and similar deposits, in each case made in the Ordinary Course of Business;
(h) Investments received in connection with any Insolvency Proceedings in respect of any customers,
suppliers or clients and in settlement of delinquent obligations of, and other disputes with, customers, suppliers or clients;
(i) Investments permitted under Section 9.01(e), Section 9.01(o) and Section 9.03;
(j) Investments consisting of notes receivable of, or prepaid royalties and other credit extensions, to
customers and suppliers who are not Affiliates, in the Ordinary Course of Business;
(k) Investments consisting of (i) travel advances and employee relocation loans and other employee loans
and advances in the Ordinary Course of Business, and (ii) loans to employees, officers or directors relating to the purchase of equity securities of the Obligors pursuant to employee stock purchase plans or agreements made after the Original
Closing Date approved by an Obligor’s Board in an aggregate amount not to exceed $250,000 for subclauses (i) and (ii) in any fiscal year;
- 92 -
(l) so long as no Default or Event of Default shall have occurred and is continuing at the time of such
Investment and until such time as the Brazilian Subsidiary becomes a “Guarantor” hereunder, and a “Grantor” under the Security Agreement, Investments by an Obligor in the Brazilian Subsidiary in an aggregate amount not to exceed $1,500,000 in any
fiscal year;
(m) so long as no Default or Event of Default shall have occurred and is continuing at the time of such
Investment, Investments by Obligors in Immaterial Foreign Subsidiaries (other than the Brazilian Subsidiary), made after the Original Closing Date, in an aggregate amount not to exceed $1,000,000 in any fiscal year;
(n) Investments by Immaterial Foreign Subsidiaries in other Immaterial Foreign Subsidiaries;
(o) [reserved];
(p) so long as no Default or Event of Default shall have occurred and is continuing at the time of such
Investment, or after giving effect thereto, other Investments made after the Original Closing Date in an amount not to exceed $500,000 in any fiscal year; and
(q) the imaware Convertible Note Investment.
Section 9.06. Restricted Payments. Each
Obligor will not, and will not permit any of its Subsidiaries to, declare or make, or agree to pay or make, directly or indirectly, any Restricted Payment, other than:
(a) dividends or distributions with respect to any Equity Interests of Parent payable solely in additional
units or shares of its Qualified Equity Interests;
(b) any Restricted Payment by an Obligor or a Subsidiary of an Obligor to an Obligor;
(c) any purchase, redemption, retirement, or other Acquisition by Parent or any of its Subsidiaries units
or shares of its Equity Interests with the proceeds received from a substantially concurrent issue of new units or shares of its Equity Interests;
(d) cashless exercises of options and warrants;
(e) repurchases pursuant to the terms of employee stock purchase plans, employee restricted stock
agreements, stockholder rights plans, director or consultant stock option plans, or similar plans in an aggregate amount not to exceed $500,000 in any fiscal year;
- 93 -
(f) the making of cash payments in lieu of the issuance of fractional shares upon the conversion of
convertible securities (or in connection with the exercise of warrants or similar securities) not to exceed $25,000 in any fiscal year;
(g) the issuance of the Warrant Certificates; and
(h) cash payments made to redeem, purchase, repurchase or retire the Warrant Obligations in accordance
with the terms of the Warrant Certificates.
Section 9.07. Payments of Indebtedness.
Each Obligor will not, and will not permit any of its Subsidiaries to, make any payments in respect of any Material Indebtedness other than (a) payments of the Obligations and (b) so long as no Default or Event of Default has occurred and is
continuing or would result therefrom, (i) scheduled payments of other Permitted Indebtedness and repayment of intercompany Indebtedness permitted in reliance upon Section 9.01(e) (subject in each case to any subordination agreement entered into in
connection therewith), (ii) regularly scheduled payments of interest on the Outstanding Convertible Notes and the repayment in full of the principal amount of the Outstanding Convertible Notes, (iii) regularly scheduled payments of interest on the
Investor Convertible Note, subject to the Investor Subordination Agreement and (iv) the conversion of the principal amount of the Investor Convertible Note into Qualified Equity Interests of Parent.
Section 9.08. Change in Fiscal Year.
Each Obligor will not change the last day of its fiscal year from that in effect on the date hereof, without prior written notice to the Administrative Agent, except to change the fiscal year of a Subsidiary acquired in connection with a Permitted
Acquisition to conform its fiscal year to that of Parent.
Section 9.09. Sales of Assets, Etc.
Each Obligor will not, and will not permit any of its Subsidiaries to, sell, lease, exclusively license (in terms of geography or field of use), as a licensor, transfer (including in connection with any division or plan of division under Delaware
law or any comparable event under a different jurisdiction’s laws) or otherwise dispose of any of its Property (including accounts receivable and Equity Interests of Subsidiaries), or forgive, release or compromise any amount owed to any Obligor or
any of its Subsidiaries, in each case, in one transaction or series of transactions (any thereof, an “Asset Sale”), except:
(a) transfers of cash in the Ordinary Course of Business for equivalent value;
(b) sales or leases of inventory in the Ordinary Course of Business;
(c) the forgiveness, release or compromise of any amount owed to any Obligor or any of its Subsidiaries in
the Ordinary Course of Business;
(d) entering into, or becoming bound, by a Permitted License to the extent not otherwise prohibited by
this Agreement;
(e) development and other collaborative arrangements where such arrangements provide for the license or
disclosure of Patents, Trademarks, Copyrights or other Intellectual Property rights of any Obligor or any of its Subsidiaries in the Ordinary Course of Business and consistent with general market practices; provided
that (i) such licenses must be true licenses that do not result in a legal transfer of title of the licensed Property or otherwise constitute sales transactions in substance and (ii) the aggregate amount of such periodic payments to the Obligors
and its Subsidiaries in any fiscal year shall not exceed $500,000;
- 94 -
(f) a sale, lease, exclusive license, transfer or other disposition (including by way of abandonment,
cancellation or trade-in) of any Property that is obsolete, worn out, surplus or no longer used or useful in connection with the business of the Obligors and its Subsidiaries or with respect to which a newer and improved version is available;
(g) dispositions resulting from Casualty Events;
(h) any transaction permitted under Section 9.02, 9.03, 9.05. 9.10 and 9.20;
(i) a sale, transfer or other disposition (including by way of abandonment, cancellation or trade-in) of
any Property of an Immaterial Foreign Subsidiary in connection with the liquidation, wind up or dissolution of such Immaterial Foreign Subsidiary;
(j) so long as no Default or Event of Default shall have occurred and is continuing at the time of such
Asset Sale, or after giving effect thereto, Asset Sales of other property not to exceed $3,000,000 in the aggregate per fiscal year;
(k) the Fitzgerald and Benen Sale;
(l) so long as no Default or Event of Default shall have occurred and is continuing at the time of such
Asset Sale, licenses and other Asset Sales made in connection with Partner Agreements; and
(m) the sale of WaveForm Slovenia to WaveForm in the event of an FDI Rejection (as defined in the WaveForm
Slovenia Side Agreement) pursuant to the terms of the WaveForm Slovenia Side Agreement.
Section 9.10. Transactions with Affiliates.
Each Obligor will not, and will not permit any of its Subsidiaries to, sell, lease, license or otherwise transfer any assets to, or purchase, lease, license or otherwise acquire any assets from, or otherwise engage in any other transactions with,
any of its Affiliates, except:
(a) transactions between or among the Obligors;
(b) any transaction permitted under Section 9.01, 9.03, 9.05, 9.06 or 9.09;
(c) customary compensation and indemnification of, and other employment arrangements with, directors,
officers and employees of any Obligor in the Ordinary Course of Business;
- 95 -
(d) transactions upon fair and reasonable terms that are no less favorable to any Obligor than would be
obtained in a comparable arm’s‑length transaction with a Person not an Affiliate;
(e) the transactions set forth on Schedule 9.10; and
(f) the Bray Leases.
Section 9.11. Restrictive Agreements.
Each Obligor will not, and will not permit any of its Subsidiaries to, directly or indirectly, enter into, incur or permit to exist any Restrictive Agreement other than (a) restrictions and conditions imposed by Law or by the Loan Documents,
(b) Restrictive Agreements listed on Schedule 7.15, (c) any stockholder agreement or investor rights agreement, or other Organizational Documents of an Obligor as in effect on the date hereof or (d) limitations associated with Permitted Liens or
with any transaction permitted under Section 9.01, 9.03, 9.05, 9.06 or 9.09.
(a) Each Obligor will not enter into any amendment to or modification of any Organizational Document
without the prior written consent of the Administrative Agent.
(b) Each Obligor will not (i) enter into any material waiver, amendment or modification of any Material
Agreement (including, but not limited to, any amendments to provisions relating to pricing and term) that would be reasonably expected to adversely affect the Lenders in any material respect or (ii) take or omit to take any action that results in
the termination of, or permits any other Person to terminate, any Material Agreement, Material Intellectual Property or Material WaveForm IP that would be reasonably expected to have a Material Adverse Effect, without, in each case, the prior
written consent of the Administrative Agent, such consent not to be unreasonably withheld or delayed.
(c) Each Obligor will not enter into any amendment to or modification of the Bray Leases, which is less
favorable to the Obligors, without the prior written consent of the Administrative Agent.
(d) Each Obligor will not enter into any amendment to or modification of the Investor Convertible Note
that is in violation of the Investor Subordination Agreement without the prior written consent of the Administrative Agent.
(e) Each Obligor will not enter into any material waiver, amendment or modification of the Effective Date
Acquisition Agreement or the Waveform Slovenia Side Agreement (including, but not limited to, any amendments to provisions relating to pricing, term and any contingent payments) that would be reasonably expected to adversely affect the Lenders in
any material respect, without, in each case, the prior written consent of the Administrative Agent.
- 96 -
Section 9.14. Sales and Leasebacks.
Except as permitted by Section 9.01(h), each Obligor will not, and will not permit any of its Subsidiaries to, become liable, directly or indirectly, with respect to any lease, whether an operating lease or a Capital Lease Obligation, of any
Property (whether real, personal, or mixed), whether now owned or hereafter acquired, (i) which any Obligor or such Subsidiary has sold or transferred or is to sell or transfer to any other Person and (ii) which any Obligor or such Subsidiary
intends to use for substantially the same purposes as Property which has been or is to be sold or transferred.
Section 9.15. Hazardous Material. Each
Obligor will not, use, generate, manufacture, install, treat, release, store or dispose of any Hazardous Material, except in compliance with all applicable Environmental Laws or where the failure to comply would not reasonably be expected to result
in a Material Adverse Change.
Section 9.16. Accounting Changes.
Except as required or permitted by IFRS, each Obligor will not make any significant change in accounting treatment without the consent of the Lenders, such consent not be unreasonably withheld or delayed.
Section 9.17. Compliance with ERISA. No
ERISA Affiliate of any Obligor shall cause (a) any event that would result in the imposition of a Lien with respect to any Title IV Plan or Multiemployer Plan or (b) any other ERISA Event that would, in the aggregate, have a Material Adverse
Effect. No Obligor shall cause or suffer to exist any event that could result in the imposition of a Lien with respect to any Benefit Plan that would have a Material Adverse Effect.
Section 9.18. Deposit Accounts. Each
Obligor will not establish or maintain any bank account (other than an Excluded Account) that is not a Controlled Account and will not deposit proceeds in a bank account that is not a Controlled Account (other than an Excluded Account).
Section 9.19. Outbound Licenses. Each
Obligor will not enter into or become bound by any outbound license or agreement for use of such Obligor’s Intellectual Property unless such outbound license or agreement is a Permitted License.
Section 9.20. Inbound Licenses. Each
Obligor will not enter into or become bound by any inbound license or agreement (other than Permitted Licenses) for aggregate consideration paid for all such inbound licenses entered into pursuant to this Section 9.20 in excess of $2,500,000 per
fiscal year unless (a) no Default has occurred and is continuing and (b) if the license or agreement is with an Obligor, such Obligor has taken such commercially reasonable actions as the Administrative Agent may reasonably request to obtain the
consent of, or waiver by, any Person whose consent or waiver is necessary for the Administrative Agent to be granted a valid and perfected security interest in such license or agreement and to allow the Administrative Agent to fully exercise its
rights under any of the Loan Documents in the event of a disposition or liquidation of the rights, assets or property that is the subject of such license or agreement. The Administrative Borrower shall provide written notice to the Administrative
Agent of the material terms of such license or agreement with a description of its anticipated and projected impact on such Person’s business or financial condition.
- 97 -
Section 9.21. Non-Commingling. Each
Obligor will not commingle its funds or assets with those of any other entity, other than the Obligors, which is an Affiliate of such entity.
Section 9.22. Canadian Defined Benefit Pension
Plans. Each Obligor will not contribute to, administrate, maintain, terminate, or underfund a Canadian Defined Benefit Pension Plan.
Section 10.01. Events of Default. Each
of the following events shall constitute an “Event of Default”:
(a) the Borrowers shall fail to pay any principal on the Term Loans when and as the same shall become due
and payable, whether at the due date thereof or at a date fixed for mandatory prepayment thereof or otherwise; or
(b) any Obligor shall fail to pay any Obligation (other than an amount referred to in Section 10.01(a))
when and as the same shall become due and payable, and such failure shall continue unremedied for a period of three (3) Business Days; or
(c) any representation or warranty made by or on behalf of an Obligor or any of its Subsidiaries (as
applicable) in or in connection with this Agreement or any other Loan Document or any amendment or modification hereof or thereof, or in any report, certificate, financial statement or other document furnished pursuant to or in connection with this
Agreement or any other Loan Document or any amendment or modification hereof or thereof, shall: (i) prove to have been incorrect when made or deemed made to the extent that such representation or warranty contains any materiality or Material
Adverse Effect qualifier; or (ii) prove to have been incorrect in any material respect when made or deemed made to the extent that such representation or warranty does not otherwise contain any materiality or Material Adverse Effect qualifier; or
(d) any Obligor shall fail to observe or perform any covenant, condition or agreement contained in
Sections 8.01(a)-(d), 8.02(a) and (b), 8.03(a) (with respect to such Obligor’s existence), 8.10, 8.11, 8.13, 8.15, 8.16, 8.17, 8.18, 8.19, or Article 9; or
(e) any Obligor shall fail to observe or perform any covenant, condition or agreement contained in Section
8.01 (other than in clauses (a)-(d)) and 8.02 (other than in clauses (a) and (b)), and, in the case of any failure that is capable of cure, such failure shall continue unremedied for a period of ten (10) or more days; or
(f) any Obligor shall fail to observe or perform any covenant, condition or agreement contained in this
Agreement (other than those specified in Section 10.01(a), (b), (d) or (e)) or any other Loan Document, and, in the case of any failure that is capable of cure, such failure shall continue unremedied for a period of thirty (30) or more days; or
- 98 -
(g) any Obligor shall fail to make any payment (whether of principal or interest and regardless of amount)
in respect of any Material Indebtedness (other than with respect to Item 4 in Schedule 7.13A, so long as such non-payment is subject to a bona fide dispute contested in good faith by appropriate proceedings and for which such Obligor has set aside
on its books adequate reserves with respect thereto substantially in accordance with IFRS), when and as the same shall become due and payable after giving effect to any applicable grace or cure period as originally provided by the terms of such
Indebtedness; or
(h) (i) any material breach of, or “event of default” or similar event under, the Contract governing any
Material Indebtedness shall occur and such breach or “event of default” or similar event shall continue unremedied, uncured or unwaived after a period of five (5) Business Days after the expiration of any cure period thereunder, or (ii) any event
or condition occurs (A) that results in any Material Indebtedness becoming due prior to its scheduled maturity or (B) that enables or permits (with or without the giving of notice, the lapse of time or both) the holder or holders of such Material
Indebtedness or any trustee or agent on its or their behalf to cause such Material Indebtedness to become due, or to require the prepayment, repurchase, redemption or defeasance thereof, prior to its scheduled maturity; provided that this Section 10.01(h) shall not apply to secured Indebtedness that becomes due as a result of the voluntary sale or transfer of the Property securing such Material Indebtedness; or
(i) any Obligor:
(i) generally does not or becomes unable to pay its debts or meet its liabilities as the same become due, or admits in writing its inability to
pay its debts generally, or declares any general moratorium on its Indebtedness, or proposes a compromise or arrangement or deed of company arrangement between it and any class of its creditors; or
(ii) shall (A) voluntarily commence any proceeding or file any petition seeking liquidation, reorganization or other relief under any United
States federal, state, provincial, territorial, Canadian federal, or other foreign bankruptcy, insolvency, receivership or similar law now or hereafter in effect, (B) consent to the institution of, or fail to contest in a timely and appropriate
manner, any proceeding or petition described in Section 10.01(j), (C) apply for or consent to the appointment of a receiver, receiver and manager, interim receiver, manager, liquidator, trustee, custodian, sequestrator, conservator or similar
official for an Obligor or for a substantial part of its assets, (D) file an answer admitting the material allegations of a petition filed against it in any such proceeding, (E) make a general assignment for the benefit of creditors or (F) take any
action for the purpose of effecting any of the foregoing; or
(j) an involuntary proceeding shall be commenced or an involuntary petition shall be filed seeking
(i) liquidation, reorganization or other relief in respect of an Obligor or its debts, or of a substantial part of its assets, under any United States federal, state, provincial, territorial, Canadian federal, or other foreign bankruptcy,
insolvency, receivership or similar law now or hereafter in effect or (ii) the appointment of a receiver, receiver and manager, interim receiver, manager, liquidator, trustee, custodian, sequestrator, conservator or similar official for an Obligor
or for a substantial part of its assets, and, in any such case, such proceeding or petition shall continue undismissed for sixty (60) days or an order or decree approving or ordering any of the foregoing shall be entered; or
- 99 -
(k) one or more judgments for the payment of money in an aggregate amount in excess of $1,000,000
(excluding any amounts covered by insurance as to which the applicable carrier has accepted coverage) shall be rendered against any Obligor or any combination thereof and the same shall remain undischarged for a period of forty-five
(45) consecutive days during which execution shall not be effectively stayed, or any action shall be legally taken by a judgment creditor to attach or levy upon any assets of any Obligor to enforce any such judgment; or
(l) (i) an ERISA Event shall have occurred that, in the reasonable opinion of the Lenders, when taken
together with all other ERISA Events that have occurred, would reasonably be expected to have a Material Adverse Effect or (ii) the institution of any steps by any Obligor or any applicable regulatory authority to terminate a Canadian Pension Plan if such termination would reasonably be expected to have a Material Adverse Effect; or
(m) a Change of Control shall have occurred; or
(n) [Reserved]; or
(o) a Material Adverse Change shall have occurred; or
(p) (i) any Lien created by any of the Security Documents shall at any time not constitute a valid and
perfected Lien in favor of the Administrative Agent on Collateral with an aggregate value in excess of $1,000,000, free and clear of all other Liens (other than Permitted Liens) except due to the action or inaction of the Administrative Agent or
any Lender(s), (ii) except for expiration in accordance with its terms and except due to the action or inaction of the Administrative Agent or any Lender(s), the Security Documents or any Guarantee of any of the Obligations shall for whatever
reason cease to be in full force and effect, or (iii) any of the Security Documents or any Guarantee of any of the Obligations, or the enforceability thereof, shall be repudiated or contested by any Obligor; or
(q) any injunction, whether temporary or permanent, shall be rendered against any Obligor that prevents
the Obligors from selling or manufacturing any Product that has a Material Adverse Effect; or
(r) (i) the FDA or any other Governmental Authority (A) issues a letter or other communication asserting
that any Product lacks a required Product Authorization (other than the revocation of any emergency use authorization), including in respect of CE marks or 510(k)s or (B) initiates enforcement action against, or issues a warning letter with respect
to, any Obligor, or any of their Products or the manufacturing facilities therefor, that causes any Obligor thereof to discontinue marketing or withdraw any of its Products, or causes a delay in the manufacture of any of its Products, which
discontinuance, withdrawal or delay would reasonably be expected to last for more than ninety (90) days, (ii) any Permit relating to any Product (including all Product Authorizations), or any of the Obligors’ material rights or interests
thereunder, is terminated, adversely amended or otherwise determined to be ineffective in any manner materially adverse to any of the Obligors, in each case, for more than ninety (90) days, (iii) there is a recall of any Product in any territory
in the case of (i) or (ii) that would reasonably be expected to result in a loss of revenue equal to at least $3,000,000 over the twelve (12) month period following such event or (iv) any Obligor thereof enters into a settlement agreement with the
FDA or any other Governmental Authority that results in aggregate liability as to any single or related series of transactions, incidents or conditions, in excess of $3,000,000 and such settlement remains unpaid past the payment date therefor.
- 100 -
(a) Upon the occurrence of any Event of Default, then, and in every such event (other than an Event of
Default described in Section 10.01(i) or (j)), and at any time thereafter during the continuance of such event, the Majority Lenders may, by notice to the Administrative Borrower, take either or both of the following actions, at the same or
different times: (i) terminate the Commitments, and thereupon the Commitments shall terminate immediately, and (ii) declare the Term Loans then outstanding to be due and payable in whole (or in part, in which case any principal not so declared to
be due and payable may thereafter be declared to be due and payable), and thereupon the principal of the Term Loans so declared to be due and payable, together with accrued interest thereon and all fees and other Obligations, shall become due and
payable immediately (in the case of the Term Loans, at the Redemption Price therefor), without presentment, demand, protest or other notice of any kind, all of which are hereby waived by each Obligor.
(b) Upon the occurrence of any Event of Default described in Section 10.01(i) or (j), the Commitments
shall automatically terminate and the principal amount of the Term Loans then outstanding, together with accrued interest thereon and all fees and other Obligations, shall automatically become due and payable immediately (in the case of the Term
Loans, at the Redemption Price therefor), without presentment, demand, protest or other notice of any kind, all of which are hereby waived by each Obligor.
(c) If any Lender collects any money or property pursuant to this Article 10, they shall pay out the
money or property in the order set forth in Section 4.01(b).
Section 10.03. Prepayment Premium and
Redemption Price. For the avoidance of doubt, the Prepayment Premium (as a component of the Redemption Price) shall be due and payable at any time the Term Loans become due and payable prior to the Stated Maturity Date for any reason,
whether due to acceleration pursuant to the terms of this Agreement (in which case it shall be due immediately, upon the giving of notice to the Administrative Borrower in accordance with Section 10.02(a), or automatically, in accordance with
Section 10.02(b)), by operation of law or otherwise (including, without limitation, on account of any bankruptcy filing). In view of the impracticability and extreme difficulty of ascertaining the actual amount of damages to the Lenders or profits
lost by the Lenders as a result of such acceleration, and by mutual agreement of the parties as to a reasonable estimation and calculation of the lost profits or damages of the Lenders, and any Prepayment Premium shall be due and payable upon such
date. Each Obligor hereby waives any defense to payment, whether such defense may be based in public policy, ambiguity, or otherwise. The Obligors and the Lenders acknowledge and agree that any Prepayment Premium due and payable in accordance
with this Agreement shall not constitute unmatured interest, whether under Section 502(b)(2) of the Bankruptcy Code or otherwise. Each Obligor further acknowledges and agrees, and waives any argument to the contrary, that payment of such amount
does not constitute a penalty or an otherwise unenforceable or invalid obligation.
- 101 -
Section 11.01. The Guarantee. The
Guarantors hereby jointly and severally guarantee to the Administrative Agent and each Lender, and their respective successors and assigns, the prompt payment in full when due (whether at stated maturity, by acceleration or otherwise) of the
principal of and interest on the Term Loans, all fees and other amounts and Obligations from time to time owing to the Administrative Agent and any Lender by the Borrowers under this Agreement or under any other Loan Document and by any other
Obligor under any of the Loan Documents, in each case strictly in accordance with the terms thereof (such obligations being herein collectively called the “Guaranteed Obligations”). The Guarantors hereby
further jointly and severally agree that if the Borrowers shall fail to pay in full when due (whether at stated maturity, by acceleration or otherwise) any of the Guaranteed Obligations, the Guarantors will promptly pay the same, without any demand
or notice whatsoever, and that in the case of any extension of time of payment or renewal of any of the Guaranteed Obligations, the same will be promptly paid in full when due (whether at extended maturity, by acceleration or otherwise) in
accordance with the terms of such extension or renewal.
Section 11.02. Obligations Unconditional.
The Obligations of the Guarantors under Section 11.01 are irrevocable, continuing, absolute and unconditional, joint and several, irrespective of the value, genuineness, validity, regularity or enforceability of the obligations of the Borrowers
under this Agreement or any other agreement or instrument referred to herein, or any substitution, release or exchange of any other guarantee of or security for any of the Guaranteed Obligations, and, to the fullest extent permitted by applicable
Law, irrespective of any other circumstance whatsoever that might otherwise constitute a legal or equitable discharge or defense of a surety or Guarantor, it being the intent of this Section 11.02 that the Obligations of the Guarantors hereunder
shall be absolute and unconditional, joint and several, under any and all circumstances. Without limiting the generality of the foregoing, it is agreed that the occurrence of any one or more of the following shall not alter or impair the liability
of the Guarantors hereunder, which shall remain absolute and unconditional as described above:
(a) at any time or from time to time, without notice to the Guarantors, the time for any performance of or
compliance with any of the Guaranteed Obligations shall be extended, or such performance or compliance shall be waived;
(b) any of the acts mentioned in any of the provisions of this Agreement or any other agreement or
instrument referred to herein shall be done or omitted;
- 102 -
(c) the maturity of any of the Guaranteed Obligations shall be accelerated, or any of the Guaranteed
Obligations shall be modified, supplemented or amended in any respect (including, without limitation, any modification, supplement, or amendment that results in any increase in the Guaranteed Obligations, any change in the interest or fees payable,
any renewal, extension, amendment, rescission, waiver, release, discharge, indulgence, compromise, arrangement, or any other variation in connection with the Guaranteed Obligations, any Loan Document, or any other agreement), or any right under
this Agreement or any other agreement or instrument referred to herein shall be waived or any other Guarantee of any of the Guaranteed Obligations or any security therefor shall be released or exchanged in whole or in part or otherwise dealt with;
(d) any Lien or security interest granted to, or in favor of, any Lender as security for any of the
Guaranteed Obligations shall fail to be perfected or otherwise be taken, exchanged, substituted, varied, released, impaired, or subordinated;
(e) any Guarantee of the Guaranteed Obligations shall be taken, released, impaired, amended, waived or
otherwise modified;
(f) any of the Guaranteed Obligations, any Loan Document, or any related agreement, security, or
instrument shall be illegal, invalid or unenforceable for any reason whatsoever;
(g) any Collateral or other assets shall be sold or disposed, and/or the proceeds of such sale or
disposition applied, to satisfy all or part of the Guaranteed Obligations;
(h) any of the security or Collateral held for the Guaranteed Obligations shall lose or diminish in value,
whether such loss or diminution arises from any act or omission of the Administrative Agent or any Lender;
(i) there shall be any Default, failure, or delay, willful or otherwise, in the payment and/or performance
of the Guaranteed Obligations;
(j) there shall be any change, restructuring or termination of the corporate structure, ownership or
existence of any Obligor or any of its Subsidiaries or any insolvency, bankruptcy, reorganization or other similar proceeding affecting any Obligor or its assets or any resulting restructuring, compromise, release or discharge of any Guaranteed
Obligations;
(k) there shall be any failure of any of the Administrative Agent or any Lender to disclose to any Obligor
any information relating to the business, condition (financial or otherwise), operations, performance, properties or prospects of any other Obligor, or any other information now or hereafter known to the Administrative Agent or such Lender;
(l) any person shall fail to execute or deliver this Agreement (including the Guarantee in this Article
11) or any other Guarantee or agreement or the release or reduction of liability of any Obligor or surety with respect to the Guaranteed Obligations;
- 103 -
(m) any of the Administrative Agent or any Lender shall fail to assert any claim or demand or to exercise
or enforce any right or remedy under the provisions of any Loan Document or otherwise;
(n) any Obligor shall assert any defense, set-off or counterclaim (other than a defense of payment or
performance) that may at any time be available to, or be asserted by, such against any of the Administrative Agent or any Lender; or
(o) any other circumstance (including, without limitation, any statute of limitations) or manner of
administering the Guaranteed Obligations shall exist or occur, or any of the Administrative Agent or any Lender shall rely on any representation, in each case, that might vary the risk of any Obligor or otherwise operate as a defense available to,
or a legal or equitable discharge of, any Obligor or surety.
The Guarantors hereby expressly waive diligence, presentment, demand of payment, demand for performance, protest, dishonor, promptness, presentment, default, acceleration, and
all notices whatsoever (including, without limitation, notice of non-performance and notice of acceptance), and any requirement that the Administrative Agent or any Lender exhaust any right, power or remedy or proceed against the Borrowers under
this Agreement or any other agreement or instrument referred to herein, or against any other Person under any other Guarantee of, or security for, any of the Guaranteed Obligations. Without limiting the generality of the foregoing, the
Administrative Agent and the Lenders may resort to the Guarantors for payment and performance of the Guaranteed Obligations whether or not the Administrative Agent and the Lenders shall have resorted to any Collateral therefor or shall have
proceeded against any Borrower or any other Obligors or guarantors with respect to the Guaranteed Obligations. The Administrative Agent and the Lenders may, at their option, proceed against the Guarantors and the Borrowers, jointly and severally,
or against one or more Guarantors only without having obtained a judgment against any Borrower.
Section 11.03. Reinstatement. The
obligations of the Guarantors under this Article 11 shall be automatically reinstated if and to the extent that for any reason any payment by or on behalf of the Borrowers in respect of the Guaranteed Obligations is rescinded or must be otherwise
restored by any holder of any of the Guaranteed Obligations, whether as a result of any proceedings in bankruptcy or reorganization or otherwise, and the Guarantors jointly and severally agree that they will indemnify the Administrative Agent and
each Lender on demand for all reasonable costs and expenses (including reasonable fees of counsel) incurred by such Persons in connection with such rescission or restoration, including any such reasonable costs and expenses incurred in defending
against any Claim alleging that such payment constituted a preference, fraudulent transfer or similar payment under any bankruptcy, insolvency or similar Law.
Section 11.04. Subrogation. The
Guarantors hereby jointly and severally agree that, until the payment and satisfaction in full of all Guaranteed Obligations (other than the Warrant Obligations and inchoate indemnity obligations) and the expiration and termination of the
Commitments, they shall not exercise any right or remedy arising by reason of any performance by them of their Guarantee in Section 11.01, whether by subrogation or otherwise, against the Borrowers or any other guarantor of any of the Guaranteed
Obligations or any security for any of the Guaranteed Obligations.
- 104 -
Section 11.05. Remedies. The
Guarantors jointly and severally agree that, as between the Guarantors, on one hand, and the Lenders, on the other hand, the obligations of the Borrowers under this Agreement and under the other Loan Documents may be declared to be forthwith due
and payable as provided in Article 10 (and shall be deemed to have become automatically due and payable in the circumstances provided in Article 10) for purposes of Section 11.01 notwithstanding any stay, injunction or other prohibition preventing
such declaration (or such obligations from becoming automatically due and payable) as against the Borrowers and that, in the event of such declaration (or such obligations being deemed to have become automatically due and payable), such obligations
(whether or not due and payable by the Borrowers) shall forthwith become due and payable by the Guarantors for purposes of Section 11.01.
Section 11.06. Instrument for the Payment of
Money. Each Guarantor hereby acknowledges that the Guarantee in this Article 11 constitutes an instrument for the payment of money, and consents and agrees that each Lender, at its sole option, in the event of a dispute by such Guarantor
in the payment of any moneys due hereunder, shall have the right to proceed by motion for summary judgment in lieu of complaint pursuant to N.Y. Civ. Prac. L&R § 3213.
Section 11.07. Continuing Guarantee.
The Guarantee in this Article 11 is a continuing guarantee, and shall apply to all Guaranteed Obligations whenever arising. Without limiting the generality of the foregoing, the Guarantors hereby unconditionally and irrevocably waive any right to
revoke this Guarantee in this Article 11 and acknowledge that the Guarantee in this Article 11 is continuing in nature, shall guarantee any ultimate balance owing to any of the Administrative Agent or any Lender, and applies to all presently
existing and future Guaranteed Obligations, until the complete, irrevocable and indefeasible payment and satisfaction in full of the Guaranteed Obligations. The Guarantee in this Article 11 shall continue to apply to all Guaranteed Obligations
owing to the Administrative Agent and the Lenders by any entity resulting from any Obligor merging, amalgamating, or otherwise entering into any other business combination transaction with one or more other entities.
Section 11.08. Rights of Contribution.
The Guarantors hereby agree, as between themselves, that if any Guarantor shall become an Excess Funding Guarantor (as defined below) by reason of the payment by such Guarantor of any Guaranteed Obligations, each other Guarantor shall, on demand of
such Excess Funding Guarantor (but subject to the next sentence), pay to such Excess Funding Guarantor an amount equal to such Guarantor’s Pro Rata Share (as defined below and determined, for this purpose, without reference to the properties, debts
and liabilities of such Excess Funding Guarantor) of the Excess Payment (as defined below) in respect of such Guaranteed Obligations. The payment obligation of a Guarantor to any Excess Funding Guarantor under this Section 11.08 shall be
subordinate and subject in right of payment to the prior payment in full of the obligations of such Guarantor under the other provisions of this Article 11 and such Excess Funding Guarantor shall not exercise any right or remedy with respect to
such excess until payment and satisfaction in full of all of such obligations.
- 105 -
For purposes of this Section 11.08, (a) “Excess Funding Guarantor” means, in respect of any Guaranteed Obligations, a Guarantor that has
paid an amount in excess of its Pro Rata Share of such Guaranteed Obligations, (b) “Excess Payment” means, in respect of any Guaranteed Obligations, the amount paid by an Excess Funding Guarantor in excess
of its Pro Rata Share of such Guaranteed Obligations and (c) “Pro Rata Share” means, as of the date of determination, for any Guarantor, the ratio (expressed as a percentage) of (i) the amount by which the
aggregate present fair saleable value of all properties of such Guarantor (excluding any shares of stock of any other Guarantor) exceeds the amount of all the debts and liabilities of such Guarantor (including contingent, subordinated, unmatured
and unliquidated liabilities, but excluding the obligations of such Guarantor hereunder and any obligations of any other Guarantor that have been guaranteed by such Guarantor) to (ii) the amount by which the aggregate fair saleable value of all
properties of all of the Guarantors exceeds the amount of all the debts and liabilities (including contingent, subordinated, unmatured and unliquidated liabilities, but excluding the obligations of the Borrowers and the Guarantors hereunder and
under the other Loan Documents) of all of the Guarantors, determined (A) with respect to any Guarantor that is a party hereto on the Original Closing Date, as of such date, and (B) with respect to any other Guarantor, as of the date such Guarantor
becomes a Guarantor hereunder.
Section 11.09. General Limitation on Guarantee
Obligations. In any action or proceeding involving any provincial, territorial, foreign or state corporate Law, or any state, federal, provincial, territorial, or foreign bankruptcy, insolvency, reorganization or other Law affecting the
rights of creditors generally, if the obligations of any Guarantor under Section 11.01 would otherwise, taking into account the provisions of Section 11.08, be held or determined to be void, invalid or unenforceable, or subordinated to the Claims
of any other creditors, on account of the amount of its liability under Section 11.01, then, notwithstanding any other provision hereof to the contrary, the amount of such liability shall, without any further action by such Guarantor, the
Administrative Agent, the Lenders or any other Person, be automatically limited and reduced to the highest amount that is valid and enforceable and not subordinated to the Claims of other creditors as determined in such action or proceeding.
Section 11.10. Irish Limitation on Guarantee
Obligations. The obligations of each Irish Obligor under Section 11.01 shall be deemed not to be undertaken or incurred to the extent the same would:
(a) constitute unlawful financial assistance prohibited by section 82 of the Companies Act 2014 of
Ireland; or
(b) constitute a breach of section 239 of the Companies Act 2014 of Ireland,
provided that (in the case of both (a) and (b) above), for the avoidance of doubt, to the extent that any such obligations under Section 11.01 have been
validated by a summary approval procedure in accordance with the Companies Act 2014 of Ireland, they shall not constitute unlawful financial assistance under the said section 82 or a breach of the said section 239 (as applicable).
- 106 -
Section 12.01. Appointment. Each of
the Lenders hereby irrevocably appoints Perceptive to act on its behalf as the Administrative Agent hereunder and under the other Loan Documents and authorizes the Administrative Agent to take such actions on its behalf and to exercise such powers
as are delegated to the Administrative Agent by the terms hereof or thereof, together with such actions and powers as are reasonably incidental thereto. The provisions of this Article 12 are solely for the benefit of the Administrative Agent and
the Lenders, and neither the Borrowers nor any other Obligor will have rights as a third‑party beneficiary of any of such provisions. It is understood and agreed that the use of the term “agent” herein or in any other Loan Documents (or any other
similar term) with reference to the Administrative Agent is not intended to connote any fiduciary or other implied (or express) obligations arising under agency doctrine of any applicable Law. Instead, such term is used as a matter of market
custom, and is intended to create or reflect only an administrative relationship between contracting parties.
Section 12.02. Rights as a Lender. The
Person serving as the Administrative Agent hereunder will have the same rights and powers in its capacity as a Lender as any other Lender and may exercise the same as though it were not the Administrative Agent, and the term “Lender” or “Lenders”
will, unless otherwise expressly indicated or unless the context otherwise requires, include the Person serving as the Administrative Agent hereunder in its individual capacity to the extent such Person is a Lender. The Lenders acknowledge and
agree that such Person and its Affiliates may accept deposits from, lend money to, own securities of, act as the financial advisor or in any other advisory capacity for, and generally engage in any kind of business with, the Borrowers, the other
Obligors or any other Subsidiaries or Affiliates of the Obligors as if such Person were not the Administrative Agent hereunder and without any duty to account therefor to the Lenders.
(a) The Administrative Agent will not have any duties or obligations except those expressly set forth
herein and in the other Loan Documents, and its duties hereunder are administrative in nature. Without limiting the generality of the foregoing, the Administrative Agent:
(i) will not be subject to any fiduciary or other implied duties, regardless of whether a Default has occurred and is continuing;
(ii) will not have any duty to take any discretionary action or exercise any discretionary powers, except discretionary rights and powers
expressly contemplated hereby or by the other Loan Documents that the Administrative Agent is required to exercise as directed in writing by the Majority Lenders (or such other number or percentage of the Lenders as will be expressly provided for
herein or in the other Loan Documents); provided that the Administrative Agent will not be required to take any action that, in its opinion or the opinion of its counsel, may expose the Administrative Agent
to liability or that is contrary to any Loan Document or applicable Law, including any action that may be in violation of the automatic stay under any Insolvency Proceeding; and
(iii) will not, except as expressly set forth herein and in the other Loan Documents, have any duty to disclose, and will not be liable for the
failure to disclose, any information relating to the Obligors or any of its Subsidiaries or Affiliates, that is communicated to or obtained by the Person serving as the Administrative Agent or any of its Affiliates in any capacity.
- 107 -
(b) The Administrative Agent will not be liable for any action taken or not taken by it (i) with the
consent or at the request of the Majority Lenders (or such other number or percentage of the Lenders as will be necessary, or as the Administrative Agent believes in good faith will be necessary, under the circumstances), or (ii) in the absence of
its own gross negligence or willful misconduct as determined by a court of competent jurisdiction by final and non‑appealable judgment. The Administrative Agent will be deemed not to have knowledge of any Default unless and until notice describing
such Default is given to the Administrative Agent in writing by the Borrowers or a Lender.
(c) The Administrative Agent will not be responsible for or have any duty to ascertain or inquire into
(i) any statement, warranty or representation made in or in connection with this Agreement or any other Loan Document, (ii) the contents of any certificate, report or other document delivered hereunder or thereunder or in connection herewith or
therewith, (iii) the performance or observance of any of the covenants, agreements or other terms or conditions set forth herein or therein or the occurrence of any Default, (iv) the validity, enforceability, effectiveness or genuineness of this
Agreement, any other Loan Document or any other agreement, instrument or document or (v) the satisfaction of any condition set forth in Article 6 or elsewhere herein, other than to confirm receipt of items expressly required to be delivered to the
Administrative Agent.
Section 12.04. Reliance by Administrative
Agent. The Administrative Agent will be entitled to rely upon, and will not incur any liability for relying upon, any notice, request, certificate, consent, statement, instrument, document or other writing (including any electronic
message, Internet or intranet website posting or other distribution) believed by it to be genuine and to have been signed, sent or otherwise authenticated by the proper Person. The Administrative Agent also may rely upon any statement made to it
orally or by telephone and believed by it to have been made by the proper Person, and will not incur any liability for relying thereon. In determining compliance with any condition hereunder to the making of the Term Loans that by its terms must
be fulfilled to the satisfaction of a Lender, the Administrative Agent may presume that such condition is satisfactory to such Lender unless the Administrative Agent has received notice to the contrary from such Lender prior to the making of the
Term Loans. The Administrative Agent may consult with legal counsel (who may be counsel for the Borrowers), independent accountants and other experts selected by it, and will not be liable for any action taken or not taken by it in accordance with
the advice of any such counsel, accountants or experts.
- 108 -
Section 12.05. Delegation of Duties.
The Administrative Agent may perform any and all of its duties and exercise its rights and powers hereunder or under any other Loan Document by or through any one or more sub‑agents appointed by the Administrative Agent. The Administrative Agent
and any such sub‑agent may perform any and all of its duties and exercise its rights and powers by or through their respective Affiliates. The exculpatory provisions of this Article 12 will apply to any such sub‑agent and to the Affiliates of the
Administrative Agent and any such sub‑agent, and will apply to their respective activities in connection with the syndication of the facility as well as activities as Administrative Agent. The Administrative Agent will not be responsible for the
negligence or misconduct of any sub‑agents except to the extent that a court of competent jurisdiction determines in a final and non‑appealable judgment that the Administrative Agent acted with gross negligence or willful misconduct in the
selection of such sub‑agents.
(a) The Administrative Agent may at any time give notice of its resignation to the Lenders and the
Administrative Borrower, which notice shall set forth the effective date of such resignation (the “Resignation Effective Date”), such date not to be earlier than the thirtieth (30th) day
following the date of such notice. The Majority Lenders and the Administrative Borrower shall mutually agree upon a successor to the Administrative Agent. If the Majority Lenders and the Administrative Borrower are unable to so mutually agree and
no successor shall have been appointed within twenty‑five (25) days after the retiring Administrative Agent gives notice of its resignation, then the retiring Administrative Agent may (but will not be obligated to), on behalf of the Lenders,
appoint a successor Administrative Agent it shall designate (in its reasonable discretion after consultation with the Borrowers and the Majority Lenders). Whether or not a successor has been appointed, such resignation will become effective in
accordance with such notice on the Resignation Effective Date.
(b) With effect from the Resignation Effective Date (i) the retiring Administrative Agent will be
discharged from its duties and obligations hereunder and under the other Loan Documents (except that in the case of any Collateral held by the Administrative Agent on behalf of the Lenders under any of the Loan Documents, the retiring
Administrative Agent will continue to hold such Collateral until such time as a successor Administrative Agent is appointed) and (ii) except for any indemnity payments owed to the retiring Administrative Agent, all payments, communications and
determinations provided to be made by, to or through the Administrative Agent will instead be made by or to each Lender directly, until such time, if any, as the Majority Lenders appoint a successor Administrative Agent as provided for above. Upon
the acceptance of a successor’s appointment as Administrative Agent hereunder, such successor will succeed to and become vested with all of the rights, powers, privileges and duties of the retiring Administrative Agent (other than any rights to
indemnity payments owed to the retiring Administrative Agent), and the retiring Administrative Agent will be discharged from all of its duties and obligations hereunder or under the other Loan Documents. The fees payable by the Borrowers to a
successor Administrative Agent will be the same as those payable to its predecessor unless otherwise agreed between the Administrative Borrower and such successor. After the retiring Administrative Agent’s resignation hereunder and under the other
Loan Documents, the provisions of this Article 12 and Sections 13.03 and 13.06 will continue in effect for the benefit of such retiring Administrative Agent, its sub‑agents and their respective Affiliates in respect of any actions taken or omitted
to be taken by any of them while the retiring Administrative Agent was acting as Administrative Agent.
- 109 -
Section 12.07. Non‑Reliance on Administrative
Agent and Other Lenders. Each Lender acknowledges that it has, independently and without reliance upon the Administrative Agent or any other Lender or any of their Affiliates and based on such documents and information as it has deemed
appropriate, made its own credit analysis and decision to enter into this Agreement. Each Lender also acknowledges that it will, independently and without reliance upon the Administrative Agent or any other Lender or any of their Affiliates and
based on such documents and information as it will from time to time deem appropriate, continue to make its own decisions in taking or not taking action under or based upon this Agreement, any other Loan Document or any related agreement or any
document furnished hereunder or thereunder.
Section 12.08. Administrative Agent May File
Proofs of Claim. In case of the pendency of any Insolvency Proceeding or any other judicial proceeding relative to the Borrowers, the Administrative Agent (irrespective of whether the principal of the Term Loans will then be due and
payable as herein expressed or by declaration or otherwise and irrespective of whether the Administrative Agent has made any demand on the Borrowers) will be entitled and empowered (but not obligated), by intervention in such proceeding or
otherwise:
(a) to file and prove a Claim for the whole amount of the principal and interest owing and unpaid in
respect of the Term Loans and all other Obligations that are owing and unpaid hereunder or under any other Loan Document and to file such other documents as may be necessary or advisable in order to have the Claims of the Lenders and the
Administrative Agent (including any Claim for the reasonable compensation, expenses, disbursements and advances of the Lenders and the Administrative Agent and their respective agents and counsel and all other amounts due the Lenders and the
Administrative Agent under this Agreement or any other Loan Document) allowed in such judicial proceeding; and
(b) to collect and receive any monies or other property payable or deliverable on any such Claims and to
distribute the same.
Any custodian, receiver, receiver and manager, interim receiver, manager, assignee, trustee, liquidator, sequestrator or other similar official in any such judicial proceeding is
hereby authorized by each Lender to make any payments of the type described above in this Section 12.08 to the Administrative Agent and, in the event that the Administrative Agent consents to the making of such payments directly to the Lenders, to
pay to the Administrative Agent any amount due for the reasonable compensation, expenses, disbursements and advances of the Administrative Agent and its agents and counsel, and any other amounts due the Administrative Agent under this Agreement or
any other Loan Document.
- 110 -
(a) Without limiting the provisions of Section 12.08, the Lenders irrevocably agree as follows:
(i) the Administrative Agent is authorized, at its option and in its discretion, to release any Lien on any property granted to or held by the
Administrative Agent under any Loan Document (A) on the date when all Obligations have been satisfied in full in cash (other than Warrant Obligations and contingent obligations as to which no Claims have been asserted), (B) that is sold or
otherwise disposed of or to be sold or otherwise disposed of as part of or in connection with any sale or other disposition permitted under the Loan Documents, or (C) subject to Sections 13.01 and 13.04, if approved, authorized or ratified in
writing by the Majority Lenders; and
(ii) the Administrative Agent is authorized, at its option and discretion, to release any Guarantor, from its obligations hereunder if such Person
ceases to be a Subsidiary as a result of a transaction permitted under the Loan Documents.
Upon request by the Administrative Agent at any time, each Lender will confirm in writing the Administrative Agent’s authority to release or subordinate its interest in
particular types or items of Collateral, or to release any Guarantor from its obligations under its guaranty pursuant to this Section 12.09.
(b) The Administrative Agent will not be responsible for or have a duty to ascertain or inquire into any
representation or warranty regarding the existence, value or collectability of the Collateral, the existence, priority or perfection of the Administrative Agent’s Lien thereon, or any certificate prepared by any Obligor in connection therewith, nor
will the Administrative Agent be responsible or liable to the Lenders for any failure to monitor or maintain any portion of the Collateral.
(c) Each Lender hereby appoints the Administrative Agent as its collateral agent under each of the
Security Documents and agrees that, in so acting, the Administrative Agent will have all of the rights, protections, exculpations, indemnities and other benefits provided to the Administrative Agent under this Agreement, and hereby authorizes and
directs the Administrative Agent, on behalf of such Lender and all Lenders, without the necessity of any notice to or further consent from any of the Lenders, from time to time to (i) take any action with respect to any Collateral or any Security
Document which may be necessary to perfect and maintain perfected the Liens on the Collateral granted pursuant to any such Security Document or protect and preserve the Administrative Agent’s ability to enforce the Liens or realize upon the
Collateral, (ii) act as collateral agent for each Lender for purposes of acquiring, holding, enforcing and perfecting all Liens created by the Loan Documents and all other purposes stated therein, (iii) enter into intercreditor or subordination
agreements, as the case may be, in connection with Indebtedness permitted pursuant to Sections 9.01(e), (iv) enter into non‑disturbance or similar agreements in connection with licensing agreements and arrangements permitted by this Agreement and
the other Loan Documents and (v) otherwise to take or refrain from taking any and all action that the Administrative Agent shall deem necessary or advisable in fulfilling its role as collateral agent under any of the Security Documents.
- 111 -
Section 13.01. No Waiver. No failure
on the part of the Administrative Agent or the Lenders to exercise and no delay in exercising, and no course of dealing with respect to, any right, power or privilege under any Loan Document shall operate as a waiver thereof, nor shall any single
or partial exercise of any right, power or privilege under any Loan Document preclude any other or further exercise thereof or the exercise of any other right, power or privilege. The remedies provided herein are cumulative and not exclusive of
any remedies provided by Law.
Section 13.02. Notices. All notices,
requests, instructions, directions and other communications provided for herein (including any modifications of, or waivers, requests or consents under, the Loan Documents) shall be given or made in writing (including by telecopy or electronic
mail) delivered, if to the Administrative Borrower, another Obligor, the Administrative Agent or the Lenders, to its address specified on Schedule 2 hereto or its Guarantee Assumption Agreement, as the case may be, or at such other address as shall
be designated by such party in a notice to the other parties. Except as otherwise provided in this Agreement, all such communications shall be deemed to have been duly given upon receipt of a legible copy thereof, in each case given or addressed
as aforesaid. All such communications provided for herein by telecopy or electronic mail shall be confirmed in writing promptly after the delivery of such communication (it being understood that non‑receipt of written confirmation of such
communication shall not invalidate such communication).
(a) Expenses. Each Obligor agrees to pay or reimburse (i) the
Administrative Agent and the Lenders for all of their reasonable and documented out of pocket costs and expenses (including the reasonable and documented fees and expenses of Chapman and Cutler LLP, counsel to the Administrative Agent) in
connection with (A) the negotiation, preparation, execution and delivery of the Original Credit Agreement, the Second A&R Credit Agreement, the Third A&R Credit Agreement, the Fourth A&R Credit Agreement, this Agreement and the other
Loan Documents and (B) the discussions regarding, and the negotiation or preparation of, any amendment, modification, supplement or waiver of any of the terms of this Agreement or any of the other Loan Documents (whether or not documented or
consummated, including the reasonable fees and expenses of legal counsel) and (ii) the Administrative Agent and the Lenders for all of their reasonable and documented out of pocket costs and expenses (including the reasonable fees and expenses of
legal counsel) in connection with any enforcement or collection proceedings resulting from the occurrence of an Event of Default.
(b) Indemnification. Each Obligor hereby indemnifies the
Administrative Agent, the Lenders, their respective Affiliates, and their respective directors, officers, employees, attorneys, agents and advisors (each, an “Indemnified Party”) from and against, and
agrees to hold them harmless against, any and all Claims and Losses of any kind (including reasonable fees and disbursements of counsel), joint or several, that is incurred by or asserted or awarded against any Indemnified Party, in each case
arising out of or in connection with or relating to any investigation, litigation or proceeding or the preparation of any defense with respect thereto arising out of or in connection with or relating to this Agreement or any of the other Loan
Documents or the Transactions or any use made or proposed to be made with the proceeds of the Term Loans, whether or not such investigation, litigation or proceeding is brought by an Obligor, any of its shareholders or creditors, an Indemnified
Party or any other Person, or an Indemnified Party is otherwise a party thereto, and whether or not any of the conditions precedent set forth in Article 6 are satisfied or the other Transactions contemplated by this Agreement are consummated,
except to the extent such Claim or Loss is found in a final, non‑appealable judgment by a court of competent jurisdiction to have resulted from any Indemnified Party’s gross negligence or willful misconduct. No Obligor shall assert any Claim
against any Indemnified Party, on any theory of liability, for consequential, indirect, special or punitive damages arising out of or otherwise relating to this Agreement or any of the other Loan Documents or any of the Transactions or the actual
or proposed use of the proceeds of the Term Loans. This Section shall not apply to Taxes other than Taxes relating to a non‑Tax Claim or Loss governed by this Section 13.03(b).
- 112 -
Section 13.04. Amendments, Etc. Except
as otherwise expressly provided in this Agreement, any provision of this Agreement or any other Loan Document (except for the Warrant Certificates, which may be amended, modified, waived or supplemented in accordance with the terms thereof) may be
amended, modified, waived or supplemented only by an instrument in writing signed by the Borrowers, the Administrative Agent and the Majority Lenders; provided that:
(a) no amendment, waiver or consent shall, unless in writing and signed by all of the Lenders, do any of
the following at any time:
(i) change the number of Lenders or the percentage of (A) the Commitments or (B) the aggregate unpaid principal amount of the Term Loans that, in
each case, shall be required for the Lenders or any of them to take any action hereunder (including pursuant to any change to the definition of “Majority Lenders”);
(ii) release one or more Guarantors (or otherwise limit such Guarantors’ liability with respect to the Obligations owing to the Lenders under the
Guarantees) if such release or limitation is in respect of all or substantially all of the value represented by the Guarantees to the Lenders;
(iii) release, or subordinate the Lenders’ Liens in, all or substantially all of the Collateral in any transaction or series of related
transactions (other than in connection with any sale of Collateral permitted herein); or
(iv) amend any provision of this Section 13.04;
(b)no amendment, waiver or consent shall, unless in writing and signed by each Lender specified below for such amendment, waiver or consent:
(i) increase the Commitments of a Lender without the consent of such Lender;
- 113 -
(ii) reduce the principal of, or stated rate of interest on, or any Prepayment Premium payable on, the Term Loans owed to a Lender or any fees or
other amounts stated to be payable hereunder or under the other Loan Documents to such Lender without the consent of such Lender;
(iii) postpone any date scheduled for any payment of principal of, or interest on, the Term Loans, any date scheduled for payment or for any date
fixed for any payment of fees hereunder (excluding the due date of any mandatory prepayment of the Term Loans), in each case payable to a Lender without the consent of such Lender;
(iv) change the order of application of prepayment of the Term Loans from the application thereof set forth in the applicable provisions of
Section 4.01(b) in any manner that adversely affects the Lenders without the consent of holders of a majority of the Commitments or Term Loans outstanding or otherwise change any provision requiring the pro rata distributions hereunder among the
Lenders without all Lenders’ consent; or
(v) modify Section 2.02 without the consent of each Lender directly and adversely affected thereby.
(a) General. The provisions of this Agreement shall be binding upon and inure to the benefit of the
parties hereto and their respective successors and assigns permitted hereby, except that (i) no Obligor may assign or otherwise transfer any of its rights or obligations hereunder without the prior written consent of the Administrative Agent and
each Lender (and any attempted assignment or transfer by such Obligor without such consent shall be null and void) and (ii) no Lender may assign or otherwise transfer its rights or obligations hereunder except in accordance with this Section.
Nothing in this Agreement, expressed or implied, shall be construed to confer upon any Person (other than the parties hereto, their respective successors and assigns permitted hereby, Participants (to the extent provided in paragraph (e) of this
Section) and, to the extent expressly contemplated hereby, the Indemnified Parties of the Lenders) any legal or equitable right, remedy or Claim under or by reason of this Agreement.
(b) Amendments to Loan Documents; Majority Lender Vote. Each of
the Lenders and the Obligors agrees to enter into such amendments to the Loan Documents, and such additional Security Documents and other instruments and agreements, in each case in form and substance reasonably acceptable to the Lenders and the
Obligors, as shall reasonably be necessary to implement and give effect to any assignment made by any Lender (or any direct or indirect assignee thereof) from time to time under this Section 13.05.
- 114 -
(c) Assignments by Lenders.
(i) Subject to the conditions set forth in paragraph (c)(ii) below, any Lender may assign to one or more Persons (other than an Ineligible
Assignee) all or a portion of its rights and obligations under the Loan Documents (including all or a portion of its Commitment and the Term Loans at the time owing to it) (A) with the prior written consent (such consent not to be unreasonably
withheld) of the Administrative Agent and (B) so long as no Default shall have occurred and is continuing, upon notice to the Administrative Borrower; provided that no consent of the Administrative Agent
nor notice to the Administrative Borrower shall be required for an assignment of any Commitment or of all or any portion of the Term Loans to a Lender, an Affiliate of a Lender or an Approved Fund.
(ii) Assignments shall be subject to the following additional conditions:
(A) except in the case of an assignment to a Lender or an Affiliate of a Lender or an assignment of the entire remaining amount of the assigning
Lender’s Commitment or Term Loan, the amount of the Commitment or Term Loan of the assigning Lender subject to each such assignment (determined as of the date the Assignment Agreement with respect to such assignment is delivered to the
Administrative Agent) shall not be less than $500,000, unless the Administrative Agent otherwise consents;
(B) each partial assignment shall be made as an assignment of a proportionate part of all the assigning Lender’s rights and obligations under this
Agreement and the other Loan Documents; and
(C) the parties to each assignment shall execute and deliver to the Administrative Agent an Assignment Agreement in form and substance reasonably
satisfactory to Administrative Agent.
(iii) Subject to acceptance and recording thereof pursuant to paragraph (d) of this Section, from and after the effective date specified in each
Assignment Agreement, the assignee thereunder shall be a party hereto and, to the extent of the interest assigned by such Assignment Agreement, have the rights and obligations of a Lender under the Loan Documents, and the assigning Lender
thereunder shall, to the extent of the interest assigned by such Assignment Agreement, be released from its obligations under the Loan Documents (and, in the case of an Assignment Agreement covering all of the assigning Lender’s rights and
obligations under the Loan Documents, such Lender shall cease to be a party hereto). Any assignment or transfer by a Lender of rights or obligations under the Loan Documents that does not comply with this Section 13.05 shall be treated for
purposes of the Loan Documents as a sale by such Lender of a participation in such rights and obligations in accordance with paragraph (e) of this Section.
- 115 -
(d) Register. The Administrative Agent, acting for this purpose as a non‑fiduciary agent of the Borrowers,
shall maintain at one of its offices a copy of each Assignment Agreement delivered to it and a register for the recordation of the names and addresses of the Lenders, and the Commitment of, and principal amount (and stated interest) of the Term
Loans owing to, each Lender pursuant to the terms hereof from time to time (the “Register”). The entries in the Register shall be conclusive absent manifest error, and the Borrowers, the Administrative
Agent, and the Lenders shall treat each Person whose name is recorded in the Register pursuant to the terms hereof as a Lender hereunder for all purposes of this Agreement, notwithstanding notice to the contrary. The Register shall be available
for inspection by the Borrowers and any Lender, at any reasonable time and from time to time upon reasonable prior notice. No assignment shall be effective for purposes of this Agreement unless (i) it has been recorded in the Register as provided
in this paragraph and (ii) any written consent to such assignment required by paragraph (b) of this Section has been obtained.
(e) Participations. Any Lender may at any time, without the consent of, or notice to, the Borrowers, sell
participations to any Person (a “Participant”), other than a natural person, in all or a portion of such Lender’s rights and obligations under the Loan Documents (including all or a portion of its Commitment
and the Term Loans owing to it); provided that (i) such Lender’s obligations under the Loan Documents shall remain unchanged, (ii) such Lender shall remain solely responsible to the other parties hereto for
the performance of such obligations and (iii) the Borrowers shall continue to deal solely and directly with such Lender in connection therewith.
(f) Any agreement or instrument pursuant to which a Lender sells such a participation shall provide that
such Lender shall retain the sole right to enforce this Agreement and to approve any amendment, modification or waiver of any provision of this Agreement; provided that such agreement or instrument may
provide that such Lender will not, without the consent of the Participant, agree to any amendment, modification or waiver that would (i) increase or extend the term of such Lender’s Commitment, (ii) extend the date fixed for the payment of
principal of or interest on the Term Loans or any portion of any fee hereunder payable to the Participant, (iii) reduce the amount of any such payment of principal, or (iv) reduce the rate at which interest is payable thereon to a level below the
rate at which the Participant is entitled to receive such interest. The Borrowers agree that each Participant shall be entitled to the benefits of Section 5.03 (subject to the requirements and limitations therein, including the requirements under
Section 5.03(f) (it being understood that the documentation required under Section 5.03(f) shall be delivered to the Borrowers and the participating Lender)) to the same extent as if it were a Lender and had acquired its interest by assignment
pursuant to Section 13.05(a), provided that such Participant (A) agrees to be subject to the provisions of Section 5.03(h) as if it were an assignee under Section 13.05(a); and (B) shall not be entitled to
receive any greater payment under Section 5.03, with respect to any participation, than its participating Lender would have been entitled to receive, unless the sale of the participation to such Participant is made with the Administrative
Borrower’s prior written consent. To the extent permitted by Law, each Participant also shall be entitled to the benefits of Section 4.04(a) as though it were a Lender. Each Lender that sells a participation shall, acting solely for this purpose
as a non‑fiduciary agent of the Borrowers, maintain a register on which it enters the name and address of each Participant and the principal amounts (and stated interest) of each Participant’s interest in the Term Loans or other obligations under
the Loan Documents (the “Participant Register”); provided that no Lender shall have any obligation to disclose all or any portion of the Participant Register
(including the identity of any Participant or any information relating to a Participant’s interest in any commitments, loans, letters of credit or its other obligations under any Loan Document) to any Person except to the extent that such
disclosure is necessary to establish that such commitment, loan, letter of credit or other obligation is in registered form under Section 5f.103‑1(c) of the United States Treasury Regulations. The entries in the Participant Register shall be
conclusive absent manifest error, and such Lender shall treat each Person whose name is recorded in the Participant Register as the owner of such participation for all purposes of this Agreement notwithstanding any notice to the contrary.
(g) Certain Pledges. Subject to Section 13.05(c), the Lenders may at any time pledge or assign a security
interest in all or any portion of its rights under this Agreement and any other Loan Document to secure obligations of the Lenders, including any pledge or assignment to secure obligations to a Federal Reserve Bank or another central bank; provided that no such pledge or assignment shall release the Lenders from any of their obligations hereunder or substitute any such pledgee or assignee for the Lenders as a party hereto.
Section 13.06. Survival. The
obligations of the Borrowers under Sections 5.01, 5.02, 5.03, 13.03, 13.05, 13.09, 13.10, 13.11, 13.12, 13.13, 13.14, 13.15 and Article 11 (solely to the extent guaranteeing any of the obligations under the foregoing Sections) shall survive the
repayment of the Obligations and the termination of the Commitments and, in the case of any Lender’s assignment of any interest in the Commitments or the Term Loans hereunder, shall survive, in the case of any event or circumstance that occurred
prior to the effective date of such assignment, the making of such assignment, notwithstanding that such Lenders may cease to be a “Lender” hereunder. In addition, each representation and warranty made, or deemed to be made by a notice of the Term
Loans, herein or pursuant hereto shall survive the making of such representation and warranty.
Section 13.07. Captions. The table of
contents and captions and section headings appearing herein are included solely for convenience of reference and are not intended to affect the interpretation of any provision of this Agreement.
Section 13.08. Counterparts. This
Agreement may be executed in any number of counterparts, all of which taken together shall constitute one and the same instrument and any of the parties hereto may execute this Agreement by signing any such counterpart. Delivery of an executed
signature page of this Agreement by facsimile transmission or electronic transmission (in PDF or DocuSign format) shall be effective as delivery of a manually executed counterpart hereof. The words “execution,” “signed,” “signature,” and words of
like import in this Agreement shall be deemed to include electronic signatures or the keeping of records in electronic form, each of which shall be of the same legal effect, validity or enforceability as a manually executed signature or the use of
a paper-based recordkeeping system, as the case may be, to the extent and as provided for in any applicable Law, including the Federal Electronic Signatures in Global and National Commerce Act, the New York State Electronic Signatures and Records
Act, or any other similar state laws based on the Uniform Electronic Transactions Act.
- 116 -
Section 13.09. GOVERNING LAW. THIS AGREEMENT AND THE OTHER LOAN DOCUMENTS (OTHER THAN THE CANADIAN SECURITY AGREEMENT, IRISH DEBENTURE AND ANY OTHER LOAN DOCUMENTS WHICH ARE SPECIFICALLY GOVERNED BY THE LAWS OF ANOTHER JURISDICTION), THE
RIGHTS AND OBLIGATIONS OF THE PARTIES HEREUNDER AND THEREUNDER, AND ALL CLAIMS, DISPUTES AND MATTERS ARISING HEREUNDER OR THEREUNDER OR RELATED HERETO OR THERETO, SHALL BE GOVERNED BY, AND CONSTRUED IN ACCORDANCE WITH, THE LAWS OF THE STATE OF
NEW YORK APPLICABLE TO CONTRACTS EXECUTED IN AND TO BE PERFORMED ENTIRELY WITHIN THAT STATE, WITHOUT REFERENCE TO CONFLICTS OF LAWS PROVISIONS (OTHER THAN SECTION 5‑1401 OF THE NEW YORK GENERAL OBLIGATIONS LAW).
(a) SUBMISSION TO JURISDICTION. EACH OBLIGOR AGREES THAT ANY
SUIT, ACTION OR PROCEEDING WITH RESPECT TO THIS AGREEMENT OR ANY OTHER LOAN DOCUMENT TO WHICH IT IS A PARTY OR ANY JUDGMENT ENTERED BY ANY COURT IN RESPECT THEREOF SHALL BE BROUGHT IN THE SUPREME COURT OF THE STATE OF NEW YORK OR IN THE UNITED
STATES DISTRICT COURT FOR THE SOUTHERN DISTRICT OF NEW YORK, IN EITHER CASE, SITTING IN NEW YORK COUNTY (EXCEPT, WITH RESPECT TO THE CANADIAN SECURITY AGREEMENT, IRISH DEBENTURE AND ANY OTHER LOAN DOCUMENT, AS OTHERWISE EXPRESSLY PROVIDED
THEREIN) AND IRREVOCABLY SUBMITS TO THE NON-EXCLUSIVE JURISDICTION OF EACH SUCH COURT FOR THE PURPOSE OF ANY SUCH SUIT, ACTION, PROCEEDING OR JUDGMENT
(b) Alternative Process. Each party to this Agreement irrevocably
consents to service of process in the manner provided for notices in Section 13.02. Nothing herein shall in any way be deemed to limit the ability of any party to this Agreement to serve any process in any other manner permitted by applicable Law.
(c) WAIVER OF VENUE, ETC. EACH OBLIGOR
IRREVOCABLY WAIVES TO THE FULLEST EXTENT PERMITTED BY LAW ANY OBJECTION THAT IT MAY NOW OR HEREAFTER HAVE TO THE LAYING OF THE VENUE OF ANY SUIT, ACTION OR PROCEEDING ARISING OUT OF OR RELATING TO THIS AGREEMENT OR ANY OTHER LOAN DOCUMENT IN ANY
COURT PERMITTED BY SECTION 13.10(A) AND HEREBY FURTHER IRREVOCABLY WAIVES TO THE FULLEST EXTENT PERMITTED BY LAW ANY CLAIM THAT ANY SUCH SUIT, ACTION OR PROCEEDING BROUGHT IN ANY SUCH COURT HAS BEEN BROUGHT IN AN INCONVENIENT FORUM. A FINAL
JUDGMENT (IN RESPECT OF WHICH TIME FOR ALL APPEALS HAS ELAPSED) IN ANY SUCH SUIT, ACTION OR PROCEEDING SHALL BE CONCLUSIVE AND MAY BE ENFORCED IN ANY COURT TO THE JURISDICTION OF WHICH SUCH OBLIGOR IS OR MAY BE SUBJECT, BY SUIT UPON JUDGMENT.
- 117 -
Section 13.11. WAIVER OF JURY TRIAL. EACH PARTY HERETO HEREBY IRREVOCABLY WAIVES, TO THE FULLEST EXTENT PERMITTED BY APPLICABLE LAW, ANY AND ALL RIGHT TO TRIAL BY JURY IN ANY SUIT, ACTION OR PROCEEDING ARISING OUT OF OR RELATING TO THIS AGREEMENT,
THE OTHER LOAN DOCUMENTS OR THE TRANSACTIONS CONTEMPLATED HEREBY OR THEREBY.
Section 13.12. WAIVER
OF IMMUNITY. TO THE EXTENT THAT ANY OBLIGOR MAY BE OR BECOME ENTITLED TO CLAIM FOR ITSELF OR ITS PROPERTY OR REVENUE ANY IMMUNITY ON THE GROUND OF SOVEREIGNTY OR THE LIKE FROM SUIT, COURT
JURISDICTION, ATTACHMENT PRIOR TO JUDGMENT, ATTACHMENT IN AID OF EXECUTION OF A JUDGMENT OR EXECUTION OF A JUDGMENT, AND TO THE EXTENT THAT IN ANY SUCH JURISDICTION THERE MAY BE ATTRIBUTED SUCH AN IMMUNITY (WHETHER OR NOT CLAIMED), SUCH OBLIGOR
HEREBY IRREVOCABLY AGREES NOT TO CLAIM AND HEREBY IRREVOCABLY WAIVES SUCH IMMUNITY WITH RESPECT TO ITS OBLIGATIONS UNDER THIS AGREEMENT AND THE OTHER LOAN DOCUMENTS.
Section 13.13. Entire Agreement. This
Agreement and the other Loan Documents constitute the entire agreement among the parties with respect to the subject matter hereof and thereof and supersede any and all previous agreements and understandings, oral or written, relating to the
subject matter hereof. Each Obligor acknowledges, represents and warrants that in deciding to enter into this Agreement and the other Loan Documents or in taking or not taking any action hereunder or thereunder, it has not relied, and will not
rely, on any statement, representation, warranty, covenant, agreement or understanding, whether written or oral, of or with the Lenders other than those expressly set forth in this Agreement and the other Loan Documents.
Section 13.14. Severability. If any
provision hereof is found by a court to be invalid or unenforceable, to the fullest extent permitted by applicable Law the parties agree that such invalidity or unenforceability shall not impair the validity or enforceability of any other provision
hereof.
Section 13.15. No Fiduciary Relationship.
The Administrative Agent, each Lender and their Affiliates (collectively, solely for purposes of this paragraph, the “Lenders”), may have economic interests that conflict with those of the Obligors, their
stockholders or equity holders and/or their Affiliates (collectively, solely for purposes of this paragraph, the “Obligors”). The Obligors acknowledge that the Lenders have no fiduciary relationship with, or
fiduciary duty to, any Obligor arising out of or in connection with this Agreement or the other Loan Documents, and the relationship between each Lender and each Obligor are solely that of creditors and debtors. This Agreement and the other Loan
Documents do not create a joint venture among the parties.
Section 13.16. USA Patriot Act. The
Administrative Agent and the Lenders hereby notify the Obligors that pursuant to the requirements of the USA PATRIOT Act (Title III of Pub. L. 107‑56 (signed into law October 26, 2001)) (the “Act”) and 31 C.F.R. § 1010.230 (the “Beneficial Ownership Regulation”), they are required to obtain, verify and record information that identifies the Obligors, which
information includes the name and address of each Obligor and other information that will allow the Administrative Agent and such Lender to identify each Obligor in accordance with the Act and Beneficial Ownership Regulation, including a beneficial
ownership certification in form and substance acceptable to the Administrative Agent.
- 118 -
Section 13.17. Treatment of Certain
Information; Confidentiality. The Lenders agree to maintain the confidentiality of the Information (as defined below), except that Information may be disclosed to (a) its Affiliates and to its and its Affiliates’ respective partners,
directors, officers, employees, agents, trustees, advisors and representatives (collectively, “Representatives”) (it being understood that the Persons to whom such disclosure is made will be informed of the
confidential nature of such information and instructed to keep such Information confidential), (b) to the extent requested by any regulatory authority purporting to have jurisdiction over it (including any self‑regulatory authority, such as FINRA
or the National Association of Insurance Commissioners) or any exchange, (c) to the extent required by the applicable Laws or by any subpoena or similar legal process, (d) to any other party hereto, (e) in connection with the exercise of any
remedies hereunder or under any other Loan Document or any action or proceeding relating to this Agreement or any other Loan Document or the enforcement of rights hereunder or thereunder, (f) subject to an agreement containing provisions
substantially the same as those in this Section 13.17, to (i) any assignee of or Participant in, or any prospective assignee of or Participant in, any of its rights or obligations under this Agreement or (ii) any actual or prospective counterparty
(or its advisors) to any swap or derivative transaction relating to the Borrowers or any Guarantor and its obligation, (g) with the consent of the Borrowers or (h) to the extent such Information (i) becomes publicly available other than as a result
of a breach of this Section 13.17 or (ii) becomes available to the Lender, or any of its respective Representatives on a nonconfidential basis from a source other than the Borrowers or any other Obligor. For purposes of this Section 13.17, “Information” means all information received from an Obligor relating to such Obligor or its Subsidiary or any of their respective businesses, except that the term “Information” shall not include, and the
Lenders shall not be subject to any confidentiality obligation with respect to any information that (A) is or becomes available to the Lender or any of its Representatives on a nonconfidential basis prior to disclosure by an Obligor or its
Subsidiary, (B) becomes available to a Lender or any of its Representatives after disclosure by an Obligor or its Subsidiary from a source that, to the knowledge of such Lender, is not subject to a confidentiality obligation to such Obligor or
Subsidiary (C) is or becomes publicly available other than as a result of a breach by such Lender, or (D) is developed by a Lender or any of its Representatives. Any Person required to maintain the confidentiality of Information as provided in
this Section 13.17 shall be considered to have complied with its obligation to do so if such Person has exercised the same degree of care to maintain the confidentiality of such Information as such Person would accord to its own confidential
information.
In the case of any Lender that has elected to receive material non‑public information pursuant to Section 8.02, such Lender acknowledges that (x) the Information may include
material non‑public information concerning an Obligor or its Subsidiary, as the case may be, (y) it has developed compliance procedures regarding the use of material non‑public information and (z) it will handle such material non‑public information
in accordance with applicable Law, including United States federal and state securities Laws.
- 119 -
(a) Notwithstanding anything to the contrary contained herein or in any other Loan Document, each Lender
agrees, and the Administrative Agent is hereby irrevocably authorized by each Lender and given a limited power of attorney by each Lender to perform the actions described hereafter in this Section 13.18 (without requirement of notice to or consent
of any Lender except as expressly required by Section 13.04) to take any action reasonably requested by the Borrowers having the effect of releasing any Collateral or Obligations (i) to the extent necessary to permit consummation of any transaction
not prohibited by any Loan Document or that has been consented to by the Lenders or (ii) under the circumstances described in paragraph (b) below.
(b) At such time as the Term Loans and the other Obligations (other than the inchoate indemnity
obligations and Warrant Obligations) under the Loan Documents shall have been paid in full in cash and the Commitments have been terminated, the Collateral shall be released from the Liens created by the Security Documents, and the Security
Documents and all obligations (other than those expressly stated to survive such termination) of the Administrative Agent and each Obligor under the Security Documents shall terminate, all without delivery of any instrument or performance of any
act by any Person.
Section 13.19. Acknowledgement and Consent to
Bail‑In of Affected Financial Institutions. Notwithstanding anything to the contrary in any Loan Document or in any other agreement, arrangement or understanding among any such parties, each party hereto acknowledges that any liability of
any Affected Financial Institution arising under any Loan Document, to the extent such liability is unsecured, may be subject to the Write‑Down and Conversion Powers of the applicable Resolution Authority and agrees and consents to, and
acknowledges and agrees to be bound by:
(a) the application of any Write‑Down and Conversion Powers by the applicable Resolution Authority to any
such liabilities arising hereunder which may be payable to it by any party hereto that is an Affected Financial Institution; and
(b) the effects of any Bail‑In Action on any such liability, including, if applicable:
(i) a reduction in full or in part or cancellation of any such liability;
(ii) a conversion of all, or a portion of, such liability into shares or other instruments of ownership in such Affected Financial Institution,
its parent undertaking, or a bridge institution that may be issued to it or otherwise conferred on it, and that such shares or other instruments of ownership will be accepted by it in lieu of any rights with respect to any such liability under this
Agreement or any other Loan Document; or
(iii) the variation of the terms of such liability in connection with the exercise of the Write‑Down and Conversion Powers of the applicable
Resolution Authority.
- 120 -
(a) The obligations of any Obligor under this Agreement and the other Loan Documents to make payments in
Dollars shall not be discharged or satisfied by any tender or recovery pursuant to any judgment expressed in or converted into any currency other than Dollars, except to the extent that such tender or recovery results in the effective receipt by
the Administrative Agent or Lender of the full amount of Dollars expressed to be payable to the Administrative Agent or such Lender under this Agreement or the other Loan Documents. If, for the purpose of obtaining or enforcing a judgment against
any Obligor in any court or in any jurisdiction, it becomes necessary to convert into or from any currency other than Dollars (such other currency, the “Judgment Currency”) an amount due in Dollars, the
conversion shall be made at the rate of exchange quoted by the Administrative Agent, determined, in each case, as of the Business Day immediately preceding the day on which the judgment is given (such Business Day, the “Judgment Currency Conversion Date”).
(b) If there is a change in the rate of exchange prevailing between the Judgment Currency Conversion Date
and the date of actual payment of the amount due, each Obligor covenants and agrees to pay, or cause to be paid, such additional amounts, if any (but in any event not a lesser amount), as may be necessary to ensure that the amount paid in the
Judgment Currency, when converted at the rate of exchange prevailing on the actual date of payment, will produce the amount of Dollars that could have been purchased with the amount of the Judgment Currency stipulated in the judgment or judicial
award at the rate of exchange prevailing on the Judgment Currency Conversion Date.
(c) For purposes of determining any rate of exchange for this Section 13.20, such amounts shall include
any premium and costs payable in connection with the purchase of Dollars.
Section 13.21. Administrative Borrower. Each
Borrower hereby designates U.S. Holdings as the administrative Borrower (in such capacity, the “Administrative Borrower”) to act as its representative and agent on its behalf, for the purposes of giving
instructions with respect to the disbursement of the proceeds of the Term Loans, giving and receiving all notices and consents hereunder or under any of the other Loan Documents and taking all other actions on behalf of each Borrower under the Loan
Documents. The Administrative Agent and each Lender may regard any notice or other communication pursuant to any Loan Document from U.S. Holdings in its capacity as Administrative Borrower as a notice or communication from each Borrower. Each
warranty, covenant, agreement and undertaking made on behalf of each Borrower by U.S. Holdings in its capacity as Administrative Borrower for the Borrowers shall be deemed for all purposes to have been made by each Borrower and shall be binding
upon and enforceable against each Borrower to the same extent as it if the same had been made directly by each Borrower. Such appointment shall remain in full force and effect unless and until the Administrative Agent shall have received written
notice signed by each Borrower terminating such appointment. Borrowers shall have the right, to appoint another Borrower as the Administrative Borrower with the prior written consent of the Administrative Agent (such consent not to be unreasonably
withheld or delayed). It is understood that the handling of the loan account and Collateral of the Borrowers in a combined fashion, as more fully set forth herein, is done solely as an accommodation to the Borrowers in order to utilize the
collective borrowing powers of the Borrowers in the most efficient and economical manner and at their request, and that neither the Administrative Agent nor the Lenders shall incur liability to the Borrowers as a result hereof. Each Borrower
expects to derive benefit, directly or indirectly, from the handling of the loan account and the Collateral in a combined fashion since the successful operation of each Borrower is dependent on the continued successful performance of the integrated
group. To induce the Administrative Agent and the Lenders to do so, and in consideration thereof, each Borrower hereby jointly and severally agrees to indemnify the Administrative Agent and hold each Indemnified Party harmless against any and all
liability, expense, loss or claim of damage or injury, made against such Indemnified Party by any Borrower or by any third party whosoever, arising from or incurred by reason of (a) the handling of the loan account and Collateral of the Borrowers
as herein provided, (b) the Administrative Agent and the Lenders relying on any instructions of the Administrative Borrower, or (c) any other action taken by the Administrative Agent or any Lender hereunder or under the other Loan Documents.
- 121 -
(a) Each Borrower is accepting joint and several liability hereunder and under the other Loan Documents in
consideration of the financial accommodations to be provided by the Administrative Agent and the Lenders under the Loan Documents, for the mutual benefit, directly and indirectly, of each Borrower and in consideration of the undertakings of the
Borrowers to accept joint and several liability for the Obligations.
(b) Each Borrower, jointly and severally, hereby irrevocably and conditionally accepts, not merely as a
surety but also as a co‑debtor, joint and several liability with the other Borrower, with respect to the payment and performance of all of the Obligations (including any Obligations arising under this Section 13.22), it being the intention of the
parties hereto that all the Obligations shall be the joint and several obligations of each Borrower without preferences or distinction among them.
(c) If and to the extent that any Borrower shall fail to make any payment with respect to any of the
Obligations as and when due or to perform any of the Obligations in accordance with the terms thereof, then in each such event the other Borrower will make such payment with respect to, or perform, such Obligation until such time as all of the
Obligations are paid in full.
(d) The Obligations of each Borrower under the provisions of this Section 13.22 constitute the absolute
and unconditional, full recourse Obligations of each Borrower enforceable against each Borrower to the full extent of its properties and assets, irrespective of the validity, regularity or enforceability of the provisions of this Agreement (other
than this Section 13.22(d)) or any other circumstances whatsoever.
(e) Except as otherwise expressly provided in this Agreement, each Borrower hereby waives notice of
acceptance of its joint and several liability, notice of any Term Loans, notice of the occurrence of any Default, Event of Default, or of any demand for any payment under this Agreement, notice of any action at any time taken or omitted by the
Administrative Agent or the Lenders under or in respect of any of the Obligations, any requirement of diligence or to mitigate damages and, generally, to the extent permitted by applicable law, all demands, notices and other formalities of every
kind in connection with this Agreement (except as otherwise provided in this Agreement). Each Borrower hereby assents to, and waives notice of, any extension or postponement of the time for the payment of any of the Obligations, the acceptance of
any payment of any of the Obligations, the acceptance of any partial payment thereon, any waiver, consent or other action or acquiescence by the Administrative Agent or the Lenders at any time or times in respect of any default by any Borrower in
the performance or satisfaction of any term, covenant, condition or provision of this Agreement, any and all other indulgences whatsoever by the Administrative Agent or the Lenders in respect of any of the Obligations, and the taking, addition,
substitution or release, in whole or in part, at any time or times, of any security for any of the Obligations or the addition, substitution or release, in whole or in part, of any Borrower. Without limiting the generality of the foregoing, each
Borrower assents to any other action or delay in acting or failure to act on the part of the Administrative Agent or a Lender with respect to the failure by any Borrower to comply with any of its respective Obligations, including, without
limitation, any failure strictly or diligently to assert any right or to pursue any remedy or to comply fully with applicable laws or regulations thereunder, which would, but for the provisions of this Section 13.22 afford grounds for terminating,
discharging or relieving any Borrower, in whole or in part, from any of its Obligations under this Section 13.22, it being the intention of each Borrower that, so long as any of the Obligations hereunder remain unsatisfied, the Obligations of each
Borrower under this Section 13.22 shall not be discharged except by performance and then only to the extent of such performance. The Obligations of each Borrower under this Section 13.22 shall not be diminished or rendered unenforceable by any
winding up, reorganization, arrangement, liquidation, reconstruction or similar proceeding with respect to any other Borrower or the Administrative Agent or a Lender.
- 122 -
(f) Each Borrower represents and warrants to the Administrative Agent and the Lenders that such Borrower
is currently informed of the financial condition of the Borrowers and of all other circumstances which a diligent inquiry would reveal and which bear upon the risk of nonpayment of the Obligations. Each Borrower further represents and warrants to
the Administrative Agent and the Lenders that such Borrower has read and understands the terms and conditions of the Loan Documents. Each Borrower hereby covenants that such Borrower will continue to keep informed of the other Borrower’s financial
condition and of all other circumstances which bear upon the risk of nonpayment or nonperformance of the Obligations.
(g) The provisions of this Section 13.22 are made for the benefit of the Administrative Agent and each
Lender, and their successors and assigns, and may be enforced by it or them from time to time against any or all of the Borrowers as often as occasion therefor may arise and without requirement on the part of the Administrative Agent or each
Lender, or any of their successors or assigns first to marshal any of its or their claims or to exercise any of its or their rights against any Borrower or to exhaust any remedies available to it or them against any Borrower or to resort to any
other source or means of obtaining payment of any of the Obligations hereunder or to elect any other remedy. The provisions of this Section 13.22 shall remain in effect until all of the Obligations shall have been paid in full or otherwise fully
satisfied. If at any time, any payment, or any part thereof, made in respect of any of the Obligations, is rescinded or must otherwise be restored or returned by the Administrative Agent or any Lender upon the insolvency, bankruptcy or
reorganization of any Borrower, or otherwise, the provisions of this Section 13.22 will forthwith be reinstated in effect, as though such payment had not been made.
(h) Each Borrower hereby agrees that it will not enforce any of its rights of contribution or subrogation
against the other Borrower with respect to any liability incurred by it hereunder or under any of the other Loan Documents, any payments made by it to the Administrative Agent or the Lenders with respect to any of the Obligations or any collateral
security therefor until such time as all of the Obligations have been paid in full in cash. Any claim which the Administrative Agent or a Lender may have against any Borrower with respect to any payments to the Administrative Agent or any Lender
hereunder are hereby expressly made subordinate and junior in right of payment, without limitation as to any increases in the Obligations arising hereunder or thereunder, to the prior payment in full in cash of the Obligations and, in the event of
any insolvency, bankruptcy, receivership, liquidation, reorganization or other similar proceeding under the laws of any jurisdiction relating to any Borrower, its debts or its assets, whether voluntary or involuntary, all such Obligations shall be
paid in full in cash before any payment or distribution of any character, whether in cash, securities or other property, shall be made to any Borrower therefor.
(i) Each Borrower hereby agrees that after the occurrence and during the continuance of any Default or
Event of Default, such Borrower will not demand, sue for or otherwise attempt to collect any Indebtedness of any other Borrower owing to such Borrower until the Obligations shall have been paid in full in cash. If, notwithstanding the foregoing
sentence, such Borrower shall collect, enforce or receive any amounts in respect of such Indebtedness, such amounts shall be collected, enforced and received by such Borrower as trustee for the Administrative Agent, and such Borrower shall deliver
any such amounts to the Administrative Agent for application to the Obligations in accordance with this Agreement.
- 123 -
Section 13.23. Amendment and Restatement. This
Agreement shall become effective on the Fifth Amendment Restatement Date and amends, restates and replaces in its entirety the Fourth A&R Credit Agreement as of the Fifth Amendment Restatement Date. From and after the Fifth Amendment
Restatement Date all references made to the “Credit Agreement” in any Loan Document or in any other instrument or document shall, without further action, be deemed to refer to this Agreement. All Exhibits and Schedules to the Fourth A&R Credit
Agreement are hereby incorporated by reference and shall be deemed to be Exhibits and Schedules to this Agreement. The Exhibits to the Fourth A&R Credit Agreement are hereby amended by adding Exhibit Q at the conclusion thereof. The Schedules
to the Fourth A&R Credit Agreement are hereby restated or supplemented by the Schedules attached hereto. Each of the parties hereto acknowledges and agrees that this Agreement amends, restates and replaces the Fourth A&R Credit Agreement
and this Agreement does not constitute or operate as a novation or an accord and satisfaction of the Fourth A&R Credit Agreement or the indebtedness, obligations and liabilities of the Obligors evidenced or provided for thereunder. For the
avoidance of doubt, the grant of security interest in the Collateral in favor of the Administrative Agent pursuant to the Security Documents continues in full force and effect.
(a) Each of the Obligors hereby (i) reaffirms its obligations under the Fourth A&R Credit Agreement,
as amended and restated hereby, and each and every other Loan Document to which it is a party (whether those Loan Documents are, or are not, being amended and/or restated in connection herewith), (ii) reaffirms all Liens on the Collateral and all
guaranties which have been granted by it in favor of the Administrative Agent pursuant to any of the Loan Documents and (iii) confirms and agrees that each of the Security Documents continues to secure the payment and performance of the
Obligations.
(b) The parties hereto hereby irrevocably confirm that the security constituted by the Loan Documents or
pursuant thereto prior to the date hereof shall not be impaired, affected or discharged (whether in whole or in part) by or as a result of this Agreement.
(c) The parties hereto acknowledge and agree that all loans, advances and other “Obligations” of any kind
outstanding under the Fourth A&R Credit Agreement immediately prior to the effectiveness of this Agreement shall constitute “Term Loans” and “Obligations” made hereunder.
(d) The parties hereto confirm that this Agreement shall not constitute or effect a novation of the
obligations of each Obligor under the Fourth A&R Credit Agreement and other Loan Documents and in any event, the Administrative Agent and all other parties to this Agreement expressly reserve all guarantees and all other security interests or
other security granted in favor of the Agent pursuant to the Fourth A&R Credit Agreement and other Loan Documents (whether those Loan Documents are, or are not, being amended and/or restated in connection herewith), which guarantees and all
other security interests or other security (whether being amended and/or restated in connection herewith), shall continue to remain in full force and effect.
(e) In addition, unless specifically amended, or amended and restated, hereby or contemporaneously
herewith, each of the “Loan Documents” (as defined in the Existing Credit Agreement) shall continue in full force and effect and that, from and after the Fifth Amendment Restatement Date, (i) all references to loans to, or notes issued by, the
Borrowers therein shall be deemed to refer to the loans to, or notes issued by, the Borrowers hereunder, and (ii) all references to the “Loan Documents” contained therein shall be deemed to refer to the Loan Documents as defined in this Agreement.
[Remainder of the Page Intentionally Left Blank; Signature Pages Follow]
- 124 -
In Witness Whereof, the parties hereto have caused this Agreement to be duly executed and delivered as of the day and year first
above written.
|
|
Borrowers:
Trinity Biotech, Inc.
Clark Laboratories, Inc. (d/b/a Trinity Biotech (USA))
Biopool U.S., Inc. (d/b/a Trinity Biotech
Distribution)
Primus Corporation
MarDx Diagnostics, Inc.
IMMCO Diagnostics, Inc.
TRIB Biosensors Inc.
|
| By: _____________________ |
|
|
Name: John Gillard
Title: Treasurer
|
[Signature Page to Fifth Amended and Restated Credit Agreement and Guaranty]
|
|
Guarantors:
Trinity Biotech plc
By: /s/ John Gillard
Name: John Gillard
Title: Director
Trinity Research Limited
By: /s/ John Gillard
Name: John Gillard
Title: Director
Trinity Biotech Financial Services Limited
By: /s/ John Gillard
Name: John Gillard
Title: Director
Trinity Biotech Manufacturing Limited
By: /s/ John Gillard
Name: John Gillard
Title: Director
Trinity Biotech Manufacturing Services Limited
By: /s/ John Gillard
Name: John Gillard
Title: Director
Trinity Biotech (Joint Venture) Limited
By: /s/ John Gillard
Name: John Gillard
Title: Director
|
[Signature Page to Fifth Amended and Restated Credit Agreement and Guaranty]
|
|
Phoenix Bio-tech Corp.
By: /s/ Ronan O’Caoimh
Name: Ronan O’Caoimh
Title: Director
Immco Diagnostics (Canada) Inc.
By: /s/ Ronan O’Caoimh
Name: Ronan O’Caoimh
Title: CEO
Nova Century Scientific Inc.
By: /s/ Ronan O’Caoimh
Name: Ronan O’Caoimh
Title: CEO
Konamite Limited
By: /s/ John Gillard
Name: John Gillard
Title: Director
Metabolomic Diagnostics Limited
By: /s/ Gary Keating
Name: Gary Keating
Title: Director
|
[Signature Page to Fifth Amended and Restated Credit Agreement and Guaranty]
Perceptive Credit Holdings III, LP
as Administrative Agent and Lender
By: Perceptive Credit Opportunities GP, LLC,
its general partner
By: /s/ Sandeep Dixit
Name: Sandeep Dixit
Title: Chief Credit Officer
Name: Sandeep Dixit
Title: Chief Credit Officer
By: /s/ Sam Chawla
Name: Sam Chawla
Title: Portfolio Manager
Name: Sam Chawla
Title: Portfolio Manager
[Signature Page to Fifth Amended and Restated Credit Agreement and Guaranty]
Fifth Amendment Term Loan Commitments
|
Lender
|
Fifth Amendment Term Loan
Commitment
|
|
Perceptive Credit Holdings III, LP
|
$2,000,000
|
Warrant Shares
|
Lender
|
Number of Warrant American Depositary Shares (represented by American Depositary Receipts) granted under the Existing Warrant Certificate
|
Number of Warrant American Depositary Shares (represented by American Depositary Receipts) granted under the Effective Date Warrant Certificate
|
Number of Warrant American Depositary Shares (represented by American Depositary Receipts) granted under the Third Amendment Warrant Certificate
|
|
Perceptive Credit
Holdings III, LP
|
500,000*
|
500,000*
|
1,000,000
|
|
∗
|
Reflects the revised ADS Ratio effective as of February 23, 2024, such that the Existing Warrant Certificate for 2,500,000 ADSs is now a warrant for 500,000 ADSs.
|
|
∗
|
Reflects the revised ADS Ratio effective as of February 23, 2024, such that the Effective Date Warrant Certificate for 2,500,000 ADSs is now a warrant for 500,000 ADSs.
|
Exhibit 99.2
Press Release dated May 15, 2025
|
Contact: Trinity Biotech plc
Susan O’Connor
(353)-1-2769800
|
LifeSci Partners, LLC
Eric Ribner
(1)-646-751-4363
investorrelations@trinitybiotech.com
|
|
RedChip Companies Inc.
Dave Gentry, CEO
(1)-407-644-4256
TRIB@redchip.com
|
Trinity Biotech Publishes Fourth Quarter and Fiscal Year 2024
Financial Results & Provides a Business Update
DUBLIN, Ireland (May 15, 2025)…. Trinity Biotech plc (Nasdaq: TRIB) a commercial stage biotechnology company focused on diabetes management solutions and
human diagnostics, including wearable biosensors, today announced results for the quarter ended December 31, 2024 and the fiscal year then ended.
Key Highlights and Developments
| • |
Management continues to make significant progress on the execution of the profitability focused initiatives announced in 2024 as part of its Comprehensive Transformation Plan, many of which are now completed or at the final stages of
execution and expected to deliver near term profitability improvements:
|
| o |
Consolidation & Offshore Manufacturing:
|
| ◾ |
We obtained World Health Organisation (“WHO”) approval in December 2024 to permit the later-stage manufacturing process of TrinScreen HIV and Uni-Gold HIV at our outsourced provider. This offshore manufacturing structure is now active,
with an initial focus on Uni-Gold HIV.
|
| ◾ |
As previously announced, we planned to transfer some of the more technical aspects of production of both of our rapid HIV tests to our offshore partner. This transfer has been successfully completed We have applied for WHO approval for
this extended offshore production process for TrinScreen HIV and expect approval in Quarter 3 2025. We expect to apply for WHO approval for Uni-Gold HIV for the extended process shortly, with approval expected in late Quarter 3 2025. Once
in place we expect these initiatives to be gross margin accretive.
|
| ◾ |
We continued to make significant progress in consolidating our main haemoglobin manufacturing activities that have historically been carried out at our Kansas City plant into two of our other sites. We have successfully transferred two
of the major manufacturing processes to other Group sites and have significantly reduced headcount at our Kansas facility. The Kansas facility’s main manufacturing activities are now in wind-down which we expect to be fully completed by the
end of 2025. However, in light of the uncertainty regarding international tariffs, these plans remain subject to change.
|
| ◾ |
As previously announced, we intended to consolidate the main manufacturing activities of our autoimmune test manufacturing site in Buffalo, New York into our Jamestown, New York site. We have successfully completed that site
consolidation with a resulting significant reduction in headcount.
|
| o |
Centralisation & Offshore Corporate Services:
|
| ◾ |
We have added additional functions to our new centralised corporate services site, with the resultant reduction in headcount in other locations.
|
| • |
Due to the significant aforementioned changes, Quarter 1 2025 was a transitional quarter as we focussed on delivering structural changes to drive long term profitability for the business. As a result, we deferred manufacturing of certain
products while we changed manufacturing locations, with a resultant impact on Quarter 1 2025 revenue. In addition, given the uncertainty regarding demand for our rapid HIV tests as a result of the U.S. Executive Order on Reevaluating and
Realigning United States Foreign Aid, we further pulled back HIV test production in Quarter 1 2025. Primarily as a result of these changes, we expect our Quarter 1 revenue for 2025 to be within the range of US$7.0 million to US$8.0 million,
which is substantially below the Quarter 1 2024 revenue. As our new more efficient manufacturing structure ramps up, and much of the uncertainty regarding the demand for our rapid HIV tests has dissipated with us seeing strong demand for
future orders, we expect our revenues to increase back up to a comparable level to 2024 over the course of late Quarter 2 to Quarter 3 2025, but with much improved profitability compared to the prior year.
|
Diabetes CGM Developments
| o |
We continue to progress the development of our next generation continuous glucose monitoring (“CGM”) solution for diabetes management.
|
| o |
We have recently completed a further round of pre-pivotal testing on our updated CGM sensor. We are currently analysing the results from that trial and expect to announce the results from that trial in due course.
|
Fourth Quarter Results
Total revenues for Q4, 2024 were $15.9m which compares to $13.4m in Q4, 2023, an increase of 18.1% and which were broken down as follows:
|
2024
Quarter 4
|
2023
Quarter 4
|
Increase/
(Decrease)
|
|
|
US$’000
|
US$’000
|
%
|
|
|
Clinical laboratory
|
10,313
|
11,279
|
(8.6%)
|
|
Point-of-Care
|
5,544
|
2,149
|
158.0%
|
|
Total
|
15,857
|
13,428
|
18.1%
|
Our Point-of-Care (‘PoC’) portfolio generated revenue of $5.5m for Q4 2024, compared to $2.1m in Q4 2023, an increase of 158.0%. Sales of our HIV screening test, TrinScreen HIV were $3.2m in the
quarter ($0.4m in Q4 2023).
Our clinical laboratory revenue was $10.3m in Q4 2024, a decrease of $1.0m or 8.6% compared to $11.3m in Q4 2023. This decrease was driven by a fall in revenues in Infectious Diseases by 34.3%
($0.6m) and a drop in Immco lab revenues of 9.4% ($0.3m). This decrease was offset by an increase in our haemoglobins business, which was 4.0% higher year-over-year, albeit revenues were down $0.1m compared to Q3 2024 in line with expectations as
we commercially reposition our instrument offering in line with our new improved diabetes column system which is now being rolled out.
Gross profit for the quarter was $4.9m and gross margin for Q4 2024 was 30.8%, a decrease year-over-year from the gross margin of 34.0% in Q4 2023.
Net loss for the quarter was $17.0m, which increased from $5.5m in Q4 2023. This was driven by restructuring, impairment and once- off costs in the quarter totalling $4.7m compared to $0.3m in Q4
2023. There was also an increase in selling, general and administrative expenses from $7.0m in Q4 2023 to $8.4m, and an increase in net financing expense from $1.7m to $4.3m. The basic and diluted loss per
ADS for Q4 2024 was $1.28 compared to $0.72 in Q4 2023.
Liquidity
The Group’s cash balance increased to $5.2m at the end of Q4 2024 from $3.7m at the end of Q4 2023.
Cash generated by operating activities for Q4 2024 was $3.6m (Q4 2023: $0.3m). During Q4 2024 the Company had investing cash
outflows of $2.7m (Q4 2023: $0.9m), the largest element of this pertained to the capitalization of the development costs of our CGM device.
At the Market Program
On July 12, 2024, the Company entered into an At the Market Offering Agreement with Craig-Hallum Capital Group LLC, as sales agent. As of December 31, 2024, the Company had sold 4,081,403 ADSs
under the ATM Program, for aggregate gross proceeds of $8.3 million and aggregate net proceeds of approximately $7.6 million, after deducting commissions and fees.
Fiscal Year 2024 Results
Total revenues for continuing operations for fiscal year 2024 were $61.6m compared to $56.8m in 2023, an increase of 8.3% year on year and were broken down as follows:
|
Full Year
2024
|
Full Year
2023
|
Increase/
(Decrease)
|
|
|
US$’000
|
US$’000
|
%
|
|
|
Clinical laboratory
|
44,122
|
47,741
|
(7.6%)
|
|
Point-of-Care
|
17,433
|
9,091
|
91.8%
|
|
Total
|
61,555
|
56,832
|
8.3%
|
Clinical laboratory revenues decreased by $3.6m from $47.7m for the year ended December 31, 2023 to $44.1m for year ended December
31, 2024, which represents a decrease of 7.6%. This decrease in clinical laboratory revenues was driven by: i) lower autoimmune lab services revenue of $0.7m, primarily due to the full year impact following the loss of our transplant testing
service contract with a local healthcare provider which ended in Q1, 2023; and ii) lower revenues for our Infectious Diseases related products of $0.7m year on year, and iii) declines in our haemoglobin business of $1.1m, with revenues 5.2% lower
year on year.
Point-of-Care revenues for the year 2024 grew strongly (+91.8%) compared to 2023. Sales of our HIV screening test, TrinScreen HIV were $10.0m for the year ($0.4m in 2023) as we continued to see
strong demand following our initial shipments in late 2023. This was partially offset by a decrease of 14.3% in other Point-of-Care revenues, primarily driven by decreased sales in our UniGold HIV range.
Gross profit for 2024 amounted to $21.4m, representing a gross margin of 34.8% compared to 34.2% in 2023.
Total loss for 2024 amounted to $31.8m, an increase in the total loss compared to the 2023 loss of $24.0m. This is primarily driven by the gain of $12.7m on the divesture of Fitzgerald Industries
included in the profit from discontinued operations in 2023. Impairment charges decreased from $11.1m for 2023 to $1.4m for 2024, however there were restructuring and other once off costs in 2024 totalling $6.1m ($nil in 2023).
Research and development expenses increased from $4.4m in 2023 to US$4.5m for 2024 mainly due to lower capitalisation of payroll costs into product development intangible assets
Selling, general and administrative expenses decreased for 2024 by $2.3m to $28.8m compared to 2023 as a result of a $1.9m decrease in salaries and related personnel costs, reflecting the impact of
organisational realignment measures undertaken as part of the restructuring program, alongside lower non-cash share-based payments expense of $0.8m.
Net financing expense at $9.6m represented a decrease from 2023 at $9.9m.
Further Amended Credit Agreement with Perceptive to Enhance Liquidity and Drive Comprehensive Transformation Plan
On May 14, 2025, the Company entered into an amended credit agreement with its primary lender, Perceptive Advisors. This amendment provides additional
liquidity, further enhancing the Company’s near-term financial position as it advances its Comprehensive Transformation Plan and continues development of its innovative CGM technology.
Under the terms of the agreement, further additional liquidity in the amount of approximately $4.5 million has been provided to the Company through a
combination of cash and payment-in-kind interest, strengthening liquidity during this pivotal period of transformation. In addition, the amended credit agreement extends the maturity date of the loan by six months to July 27, 2026.
This summary of the amended credit agreement is qualified in its entirety by reference to the full agreement filed as an exhibit to the Company’s Form 6-K filed with the SEC on May 15, 2025.
Forward-Looking Statements
This release includes statements that constitute “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995 (the “Reform Act”), including but not
limited to statements related to Trinity Biotech’s cash position, financial resources and potential for future growth, market acceptance and penetration of new or planned product offerings, and future recurring revenues and results of operations.
Trinity Biotech claims the protection of the safe harbor for forward-looking statements contained in the Reform Act. These forward-looking statements are often characterized by the terms “may,” “believes,” “projects,” “expects,” “anticipates,” or
words of similar import, and do not reflect historical facts. Specific forward-looking statements contained in this release may be affected by risks and uncertainties, including, but not limited to, our ability to capitalize on the Waveform
transaction and of our recent acquisitions, our continued listing on the Nasdaq Stock Market, our ability to achieve profitable operations in the future, the impact of tariffs on the Company’s revenues and raw materials purchases, the impact of the
spread of COVID-19 and its variants, potential excess inventory levels and inventory imbalances at the company’s distributors, losses or system failures with respect to Trinity Biotech’s facilities or manufacturing operations, the effect of
exchange rate fluctuations on international operations, fluctuations in quarterly operating results, dependence on suppliers, the market acceptance of Trinity Biotech’s products and services, the continuing development of its products, required
government approvals, risks associated with manufacturing and distributing its products on a commercial scale free of defects, risks related to the introduction of new instruments manufactured by third parties, risks associated with competing in
the human diagnostic market, risks related to the protection of Trinity Biotech’s intellectual property or claims of infringement of intellectual property asserted by third parties and risks related to condition of the United States economy and
other risks detailed under “Risk Factors” in Trinity Biotech’s annual report on Form 20-F for the fiscal year ended December 31, 2024 and Trinity Biotech’s other periodic reports filed from time to time with the United States Securities and
Exchange Commission. Forward-looking statements speak only as of the date the statements were made. Trinity Biotech does not undertake and specifically disclaims any obligation to update any forward-looking statements.
About Trinity Biotech
Trinity Biotech is a commercial stage biotechnology company focused on diabetes management solutions and human diagnostics, including wearable biosensors. The Company develops, acquires,
manufactures and markets diagnostic systems, including both reagents and instrumentation, for the point-of-care and clinical laboratory segments of the diagnostic market and has recently entered the wearable biosensor industry, with the acquisition
of the biosensor assets of Waveform Technologies Inc. and intends to develop a range of biosensor devices and related services, starting with a continuous glucose monitoring product. Our products are used to detect infectious diseases and to
quantify the level of Haemoglobin A1c and other chemistry parameters in serum, plasma and whole blood. Trinity Biotech sells direct in the United States and through a network of international distributors and strategic partners in over 75 countries
worldwide. For further information, please see the Company's website: www.trinitybiotech.com.
Trinity Biotech plc
Consolidated Income Statements
|
(US$000’s except share data)
|
Three Months Ended
December 31, 2024
(unaudited)
|
Three Months Ended
December 31, 2023
(unaudited)
|
Twelve Months Ended
December 31, 2024
(unaudited)
|
Twelve Months Ended
December 31, 2023
|
||||||||||||
|
Revenues
|
15,857
|
13,428
|
61,555
|
56,832
|
||||||||||||
|
Cost of sales
|
(10,980
|
)
|
(8,861
|
)
|
(40,114
|
)
|
(37,382
|
)
|
||||||||
|
Gross profit
|
4,877
|
4,567
|
21,441
|
19,450
|
||||||||||||
|
Gross margin %
|
30.8
|
%
|
34.0
|
%
|
34.8
|
%
|
34.2
|
%
|
||||||||
|
Other operating income
|
(1,829
|
)
|
-
|
(1,787
|
)
|
141
|
||||||||||
|
Research & development expenses
|
(1,453
|
)
|
(1,117
|
)
|
(4,543
|
)
|
(4,379
|
)
|
||||||||
|
Selling, general and administrative expenses
|
(8,371
|
)
|
(6,939
|
)
|
(28,815
|
)
|
(31,152
|
)
|
||||||||
|
Selling, general and administrative expenses – Restructuring costs
|
(1,903
|
)
|
-
|
(4,181
|
)
|
-
|
||||||||||
|
Once off items
|
(1,872
|
)
|
(1,872
|
)
|
||||||||||||
|
Impairment charges
|
(962
|
)
|
(290
|
)
|
(1,408
|
)
|
(11,105
|
)
|
||||||||
|
Operating Loss
|
(11,513
|
)
|
(3,779
|
)
|
(21,165
|
)
|
(27,045
|
)
|
||||||||
|
Financial income
|
(903
|
)
|
611
|
-
|
1,171
|
|||||||||||
|
Financial expenses
|
(3,381
|
)
|
(2,337
|
)
|
(9,565
|
)
|
(11,053
|
)
|
||||||||
|
Net financing expense
|
(4,284
|
)
|
(1,726
|
)
|
(9,565
|
)
|
(9,882
|
)
|
||||||||
|
Loss before tax
|
(15,797
|
)
|
(5,505
|
)
|
(30,730
|
)
|
(36,927
|
)
|
||||||||
|
Income tax credit
|
(585
|
)
|
3
|
(486
|
)
|
59
|
||||||||||
|
Loss for the period on continuing operations
|
(16,382
|
)
|
(5,502
|
)
|
(31,216
|
)
|
(36,868
|
)
|
||||||||
|
Profit/(Loss) for the period on discontinued operations
|
(573
|
)
|
-
|
(573
|
)
|
12,850
|
||||||||||
|
Loss for the period (all attributable to owners of the parent)
|
(16,955
|
)
|
(5,502
|
)
|
(31,788
|
)
|
(24,018
|
)
|
||||||||
|
Loss per ADS (US cents)
|
(127.9
|
)
|
(71.8
|
)
|
(177.0
|
)
|
(313.8
|
)
|
||||||||
|
Diluted loss per ADS (US cents)
|
(127.9
|
)
|
(71.8
|
)
|
(177.0
|
)
|
(313.8
|
)
|
||||||||
|
Weighted average no. of ADSs used in computing basic earnings per ADS*
|
13,259,461
|
7,665,514
|
17,959,674
|
7,654,970
|
||||||||||||
|
Weighted average no. of ADSs used in computing diluted earnings per ADS*
|
13,259,461
|
7,665,514
|
17,959,674
|
7,654,970
|
||||||||||||
*As of February 23, 2024, Trinity Biotech changed the ratio of its American Depositary Shares (“ADS”) from one (1) ADS representing four (4) ‘A’ ordinary shares to one (1) ADS representing twenty (20) ‘A’ ordinary
shares. The above loss per ADS calculations reflects this change.
Trinity Biotech plc
Consolidated Balance Sheets
|
December 31,
2024
US$ ‘000
(unaudited)
|
December 31,
2023
US$ ‘000
|
|||||||
|
ASSETS
|
||||||||
|
Non-current assets
|
||||||||
|
Property, plant and equipment
|
4,621
|
1,892
|
||||||
|
Goodwill and intangible assets
|
51,343
|
16,270
|
||||||
|
Financial assets
|
2,455
|
-
|
||||||
|
Deferred tax assets
|
3,553
|
1,975
|
||||||
|
Derivative financial asset
|
166
|
178
|
||||||
|
Other assets
|
28
|
79
|
||||||
|
Total non-current assets
|
62,166
|
20,394
|
||||||
|
Current assets
|
||||||||
|
Inventories
|
19,374
|
19,933
|
||||||
|
Trade and other receivables
|
16,065
|
13,901
|
||||||
|
Income tax receivable
|
518
|
1,516
|
||||||
|
Cash, cash equivalents and deposits
|
5,167
|
3,691
|
||||||
|
Total current assets
|
41,124
|
39,041
|
||||||
|
TOTAL ASSETS
|
103,290
|
59,435
|
||||||
|
EQUITY AND LIABILITIES
|
||||||||
|
Equity attributable to the equity holders of the parent
|
||||||||
|
Share capital
|
4,190
|
1,972
|
||||||
|
Share premium
|
63,397
|
46,619
|
||||||
|
Treasury shares
|
(24,922
|
)
|
(24,922
|
)
|
||||
|
Accumulated deficit
|
(79,117
|
)
|
(48,644
|
)
|
||||
|
Translation reserve
|
(5,461
|
)
|
(5,706
|
)
|
||||
|
Equity component of convertible note
|
6,709
|
6,709
|
||||||
|
Other reserves
|
23
|
23
|
||||||
|
Total deficit
|
(35,181
|
)
|
(23,949
|
)
|
||||
|
Current liabilities
|
||||||||
|
Income tax payable
|
364
|
279
|
||||||
|
Trade and other payables
|
26,782
|
12,802
|
||||||
|
Exchangeable senior note payable
|
210
|
210
|
||||||
|
Provisions
|
2,454
|
50
|
||||||
|
Lease liabilities
|
2,285
|
1,694
|
||||||
|
Total current liabilities
|
32,095
|
15,035
|
||||||
|
Non-current liabilities
|
||||||||
|
Senior secured term loan
|
72,391
|
40,109
|
||||||
|
Derivative financial liability
|
1,658
|
526
|
||||||
|
Convertible note
|
15,401
|
14,542
|
||||||
|
Lease liabilities
|
10,477
|
10,872
|
||||||
|
Contingent consideration
|
1,813
|
-
|
||||||
|
Provisions
|
75
|
-
|
||||||
|
Deferred tax liabilities
|
4,561
|
2,300
|
||||||
|
Total non-current liabilities
|
106,376
|
68,349
|
||||||
|
TOTAL LIABILITIES
|
138,471
|
83,384
|
||||||
|
TOTAL EQUITY AND LIABILITIES
|
103,290
|
59,435
|
||||||
Trinity Biotech plc
Consolidated Statements of Cash Flows
|
|
Three
Months
Ended
December 31, 2024
US$ ‘000
(unaudited)
|
Three Months Ended
December 31, 2023
US$ ‘000
(unaudited)
|
Twelve Months Ended
December 31, 2024
US$ ‘000
(unaudited)
|
Twelve Months Ended
December 31, 2023
US$ ‘000
|
||||||||||||
|
Cash flows from operating activities
|
||||||||||||||||
|
Loss for the period
|
(16,955
|
)
|
(5,502
|
)
|
(31,789
|
)
|
(24,018
|
)
|
||||||||
|
Adjustments to reconcile loss to cash generated by/(used in) operating activities:
|
||||||||||||||||
|
Depreciation
|
317
|
2
|
675
|
831
|
||||||||||||
|
Amortisation
|
109
|
460
|
1,190
|
946
|
||||||||||||
|
Income tax credit
|
585
|
(3
|
)
|
486
|
(59
|
)
|
||||||||||
|
Financial income
|
-
|
(611
|
)
|
-
|
(1,171
|
)
|
||||||||||
|
Financial expense
|
4,284
|
2,337
|
9,565
|
11,053
|
||||||||||||
|
Share-based payments
|
140
|
(1,009
|
)
|
1,316
|
2,069
|
|||||||||||
|
Foreign exchange gains on operating cash flows
|
708
|
385
|
1,010
|
238
|
||||||||||||
|
Impairment charge
|
962
|
290
|
1,408
|
11,105
|
||||||||||||
|
Gain on sale of business
|
-
|
-
|
-
|
(12,718
|
)
|
|||||||||||
|
Other non-cash items
|
7,010
|
2,602
|
6,863
|
2,548
|
||||||||||||
|
|
||||||||||||||||
|
Operating cash inflows/(outflows) before changes in working capital
|
(2,840
|
)
|
(1,049
|
)
|
(9,276
|
)
|
(9,176
|
)
|
||||||||
|
Net movement on working capital
|
6,423
|
1,359
|
4,075
|
(2,693
|
)
|
|||||||||||
|
|
||||||||||||||||
|
Cash generated by/(used in) operations
|
3,583
|
310
|
(5,201
|
)
|
(11,869
|
)
|
||||||||||
|
Income taxes (paid)/received
|
(233
|
)
|
(65
|
)
|
1,010
|
312
|
||||||||||
|
|
||||||||||||||||
|
Net cash generated by/(used in) operating activities
|
3,350
|
245
|
(4,191
|
)
|
(11,557
|
)
|
||||||||||
|
|
||||||||||||||||
|
Cash flows from investing activities
|
||||||||||||||||
|
Payments to acquire intangible assets
|
(2,579
|
)
|
(641
|
)
|
(9,659
|
)
|
(1,901
|
)
|
||||||||
|
Acquisition of property, plant and equipment
|
(157
|
)
|
(250
|
)
|
(405
|
)
|
(803
|
)
|
||||||||
|
Payments to acquire financial asset
|
-
|
-
|
-
|
(700
|
)
|
|||||||||||
|
Proceeds from sale of business (net of transaction costs)
|
-
|
-
|
(12,904
|
)
|
28,160
|
|||||||||||
|
|
||||||||||||||||
|
Net cash generated by/(used in) investing activities
|
(2,736
|
)
|
(891
|
)
|
22,968
|
24,756
|
||||||||||
|
|
||||||||||||||||
|
Cash flows from financing activities
|
||||||||||||||||
|
Issue of ordinary share capital including share premium (net of issuance costs)
|
545
|
-
|
7,391
|
-
|
||||||||||||
|
Net proceeds from new senior secured term loan
|
2,000
|
-
|
30,176
|
5,000
|
||||||||||||
|
Expenses paid in connection with debt financing
|
-
|
-
|
-
|
(147
|
)
|
|||||||||||
|
Repayment of senior secured term loan
|
-
|
-
|
-
|
(10,050
|
)
|
|||||||||||
|
Penalty for early settlement of term loan
|
-
|
-
|
-
|
(905
|
)
|
|||||||||||
|
Interest paid on senior secured term loan
|
-
|
(1,129
|
)
|
(5,946
|
)
|
(7,314
|
)
|
|||||||||
|
Interest paid on convertible note
|
(75
|
)
|
(75
|
)
|
(300
|
)
|
(300
|
)
|
||||||||
|
Interest paid on exchangeable notes
|
-
|
(4
|
)
|
(8
|
)
|
(8
|
)
|
|||||||||
|
Payment of lease liabilities
|
(665
|
)
|
(558
|
)
|
(2,503
|
)
|
(2,318
|
)
|
||||||||
|
|
||||||||||||||||
|
Net cash used in financing activities
|
1,805
|
(1,766
|
)
|
28,810
|
(16,042
|
)
|
||||||||||
|
|
||||||||||||||||
|
Decrease in cash and cash equivalents
|
2,419
|
(2,412
|
)
|
1,651
|
(2,843
|
)
|
||||||||||
|
Effects of exchange rate movements on cash held
|
(92
|
)
|
(158
|
)
|
(175
|
)
|
(44
|
)
|
||||||||
|
Cash and cash equivalents at beginning of period
|
2,840
|
6,261
|
3,691
|
6,578
|
||||||||||||
|
|
||||||||||||||||
|
Cash and cash equivalents at end of period
|
5,167
|
3,691
|
5,167
|
3,691
|
||||||||||||